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ABSTRACT 
 
Jin Kyung Lee: Role of Hepatic Transport Proteins in Drug Disposition and 
Drug-induced Liver Injury 
(Under the direction of Kim L. R. Brouwer) 
 
Transport proteins in the liver play a crucial role in hepatic uptake and biliary 
excretion of drugs/metabolites. Understanding how altered hepatic transport (due to 
sex, genetic polymorphisms, disease states, drug interactions) influences systemic 
and hepatic exposure of drugs/metabolites is important from both a therapeutic and 
toxicologic standpoint. The objective of this dissertation research was to investigate 
the role of hepatic transport proteins in the hepatobiliary disposition of 
drugs/generated metabolites and drug-induced liver injury. 
 Initial studies in perfused livers from male and female wild-type (WT) and 
breast cancer resistance protein (Bcrp)-deficient mice revealed that acetaminophen 
sulfate and glucuronide hepatobiliary disposition was influenced by sex-dependent 
Bcrp expression as well as other factors relating to conjugate formation and 
basolateral transport. In a second set of studies, sandwich-cultured hepatocytes 
(SCH), coupled with pharmacokinetic modeling/Monte Carlo simulations, were used 
to examine the impact of impaired biliary excretion on the hepatobiliary disposition of 
troglitazone (TGZ) and metabolites. Consistent with in vivo data, TGZ was 
extensively metabolized to TGZ-sulfate, and to a lesser extent to TGZ-glucuronide 
and TGZ-quinone, in both rat and human SCH.  Modeling/simulation revealed that 
hepatocyte accumulation of metabolites was extensive when biliary excretion 
 iv
pathways were impaired; medium concentrations (analogous to systemic 
concentrations in vivo) may not reflect changes in hepatic exposure.  Subsequent 
studies focused on two hepatotoxic drugs (trabectedin and sulindac) and the 
potential role of altered hepatic transport in drug-induced liver injury.  Trabectedin-
mediated cytotoxicity was significantly decreased in dexamethasone-pretreated WT 
rat SCH and in Mrp2-deficient TR-
 
rat SCH, compared to control WT rat SCH. These 
data emphasize the importance of Mrp2 and Mrp3 in hepato-protection from 
trabectedin-mediated cytotoxicity. Sulindac and metabolites inhibited multiple 
hepatic transport proteins in rat and human hepatocytes; potent inhibition of the 
hepatic transport of bile acids and/or drugs by sulindac sulfide and sulfone may play 
a previously unrecognized role in sulindac-mediated hepatotoxicity. Collectively, this 
dissertation research demonstrated the impact of sex-dependent transporter 
expression on the hepatobiliary disposition of phase II conjugates, illustrated use of 
an in vitro approach coupled with modeling/simulation to predict altered 
drug/metabolite hepatobiliary disposition, and defined the involvement of multiple 
transport proteins in drug-induced liver injury. 
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CHAPTER 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
This work has been published in part in Drug Transport in Liver. You, G., and Morris, 
M.E. (eds), In: Drug Transporters. Wiley Publishers, 2007: 359-410. 
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Transport of xenobiotics by the liver is supported by the polarized nature of 
hepatocytes; the basolateral (sinusoidal and lateral) membrane domain represents 
the interface with sinusoidal blood, while the canalicular (apical) membrane domain 
faces the bile duct lumen. Basolateral transport proteins mediate the movement of 
compounds to and from the blood, while canalicular transport proteins mediate flux 
of compounds from hepatocytes to bile.  Nomenclature for the human hepatic 
transport proteins, example substrates and relevant references are provided in Table 
1.1 (uptake transport proteins) and Table 1.2 (efflux transport proteins). 
 
Hepatic Uptake Transport Proteins 
 The Na+-taurocholate cotransporting polypeptide [NTCP, (SLC10A1)] 
mediates the basolateral uptake of both conjugated and unconjugated bile acids in a 
sodium-dependent manner with a 2:1 sodium-to-taurocholate stoichiometry. An 
inwardly directed Na+ gradient maintained by the activity of Na+/K+ ATPase serves 
as the driving force for NTCP (Meier and Stieger, 2002). Besides serving as the 
primary uptake mechanism for conjugated and unconjugated bile acids, NTCP also 
transports sulfated bile acids (e.g. chenodeoxycholate-3-sulfate, taurolithocholate-3-
sulfate) and steroid sulfates, as well as certain drugs (e.g. rosuvastatin, 
cholorambucil-taurocholate) (Trauner and Boyer, 2003; Ho et al., 2006). Ho et al. 
recently demonstrated ethnicity-dependent polymorphisms in the human NTCP gene 
resulting in decreased transport function of bile acid (Ho et al., 2004).  
 The family of organic anion transporting polypeptides [OATPs, (SLCO)] is 
responsible for the sodium independent uptake of a large variety of amphipathic 
 3
compounds including bile acids, hormones, eicosanoids, and various drugs 
(Hagenbuch and Meier, 2004). Although a number of studies have revealed the 
substrate specificity of OATPs, the driving force behind OATP-mediated transport 
remains controversial. Bi-directional transport of substrates and anions (e.g. GSH 
and HCO3-) has been demonstrated for Oatp1a1 (Li et al., 1998; Li et al., 2000). In 
contrast, Briz et al. demonstrated cis-stimulation of taurocholate uptake by GSH in 
oocytes expressing OATP1B3, suggesting co-transport of GSH and bile acids (Briz 
et al., 2006). Mahagita et al. proposed that OATP1B3 functions as a bidirectional 
facilitated diffusion transporter rather than a bidirectional exchanger or cotransporter 
(Mahagita et al., 2007). Because some rodent Oatps are not orthologs of human 
OATP proteins, the prediction of human OATP-mediated transport from animal 
models is challenging (Hagenbuch and Meier, 2003). Among 11 human OATP 
isoforms identified, the human liver expresses OATP1A2 (previously named OATP-
A), OATP1B1 (previously named OATP-C), OATP1B3 (previously named OATP-8), 
and OATP2B1 (previously named OATP-B). OATP1A2 and OATP2B1 are widely 
expressed in several tissues, whereas OATP1B1 and OATP1B3 are selectively 
expressed in the liver (Konig et al., 2000a; Konig et al., 2000b). Despite distinct 
substrate affinity profiles, there are overlapping substrates for OATP1A2, 1B1 and 
1B3, such as bile acids, bromosulfophthalein (BSP), dehydroepiandrosterone sulfate 
(DHEAS) and estrone-3-sulfate. As detailed in Table 1.1, the substrate specificity for 
OATP2B1 is selective, while the other three liver-expressed OATPs transport 
diverse compounds including organic anions, bulky cations, and neutral steroids.  
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 In addition to NTCP and OATPs, organic anion transporter 2 [OAT2, 
(SLC22A7)] and organic cation transporter 1 and 3 [OCT, (SLC22A1 and SLC22A3, 
respectively)] also are expressed in the human liver and function as ion exchangers 
(Sun et al., 2001; Choi and Song, 2008).  OAT2 is responsible for the hepatic uptake 
of negatively charged compounds such as methotrexate, zidovudine and taxol. 
While OATPs mediate transport of bulky type II cations, small cations (previously 
type I) are transported by OCTs.  OCT1, which is expressed exclusively in liver, 
mediates transport of several therapeutic drugs including imatinib, metformin, and 
famotidine, whereas OCT3 is selective towards endogenous substrates (Table 1.1).  
  
Canalicular Efflux Transport Proteins  
All canalicular xenobiotic transport proteins, except the recently-identified 
MATE1 organic cation-H+ exchanger (Terada and Inui, 2008), belong to the ATP-
binding cassette (ABC) family of proteins which mediate ATP-dependent transfer of 
solutes.  The canalicular efflux transport system includes the multidrug resistance 
protein 1 [MDR1, (ABCB1)], MDR 3 (ABCB4), the bile salt export pump [BSEP, 
(ABCB11)], the multidrug resistance associated protein 2 [MRP2, (ABCC2)] and the 
ABC half-transporter protein breast cancer resistance protein [BCRP, (ABCG2)]. 
MDR1 (ABCB 1), generally referred to as P-glycoprotein, was first identified 
over two decades ago in multidrug resistant (MDR) tumor cells (Juliano and Ling, 
1976);  MDR1 represents the most widely studied ABC transport protein. MDR1 is 
responsible for biliary excretion of bulky hydrophobic and cationic substrates such as 
chemotherapeutic agents (e.g., daunorubicin, doxorubicin, etoposide, paclitaxel, 
 5
vinblastine, vincristine), cardiac glycosides (e.g., digoxin), rhodamine 123, 
cyclosporine A, and HIV-1 protease inhibitors (e.g., amprenavir, inidnavir, nelfinavir, 
ritonavir, saquinavir). MDR1 modulators have been evaluated for their ability to 
increase drug sensitivity during chemotherapy because overexpression of MDR1 on 
the surface of tumor cells causes multidrug resistance (Honma et al., 2002).  MDR3 
(ABCB4) is a phospholipid flippase and is involved in the biliary secretion of 
phospholipids and cholephilic compounds.  Thus, MDR3 plays a crucial role in basic 
liver physiology in human and rats because phospholipids and cholesterol are 
responsible for the formation of micelles that solubilize bile acids in the lumen of the 
bile canaliculus (Carrella and Roda, 1999).  Mutations in the MDR3 gene lead to 
progressive familial intrahepatic cholestasis type 3 (PFIC3), a disease that is 
characterized by increased γ-glutamyltranspeptidase levels, ductular proliferation, 
and inflammatory infiltrate which can progress to biliary cirrhosis.  MDR3 is reported 
to have substrate specificity similar to MDR1, but the rate of transport of substrate is 
lower than for MDR1 (Evers et al., 2000).   
The bile salt export pump [BSEP, (ABCB11)] is the predominant bile acid 
efflux transport protein, and mediates excretion of conjugated and unconjugated bile 
acids into bile.  It was reported that BSEP might also participate in transport of non-
bile acid substrates such as pravastatin (Kullak-Ublick et al., 2000; Hirano et al., 
2005b).  Patients with progressive familial intrahepatic cholestasis type 2 (PFIC2) 
have a mutation in the ABCB11 gene and absence of BSEP protein expression, 
which leads to hepatocellular injury and necrosis caused by the increased 
intracellular concentration of detergent-like bile acids (Kullak-Ublick et al., 2004).  
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Inhibition of BSEP by several drugs such as troglitazone, bosentan, cyclosporine A 
and rifampicin has been suggested as one mechanism of drug-induced liver injury 
(Fattinger et al., 2001; Funk et al., 2001a; Mita et al., 2006).   
MRP2 (ABCC2) is a major xenobiotic efflux pump at the canalicular 
membrane.  MRP2 plays a key role in the biliary excretion of organic anions 
including bilirubin-diglucuronide, glutathione conjugates, sulfated bile acids, and 
divalent bile acid conjugates as well as numerous drugs such as sulfopyrazone, 
indomethacin, penicillin, vinblastine, methotrexate and telmisartan (Table 1.2).  
Patients with Dubin-Jonson syndrome suffer from defective hepatic biliary excretion 
due to absence of MRP2.  Animals with hereditary conjugated hyperbilirubinemia 
(Mrp2-deficient rats (GY/TR(-)) and Eisai hyperbilirubinemic rats (EHBR)) exhibit 
elevated MRP3 expression. This phenomenon has been explained as a 
compensatory mechanism to extrude MRP2 substrates into the systemic circulation 
under cholestatic conditions in order to reduce the burden on the liver (Konig et al., 
1999b; Kuroda et al., 2004).  
Breast cancer resistance protein [BCRP, (ABCG2)] is highly expressed in the 
canalicular membrane of the liver as well as in the intestine, breast, and placenta.  
BCRP is a member of the ABC half-transporter protein family and forms a functional 
homodimer.  It mediates transport of estrone-3-sulfate and various sulfated steroid 
compounds.  It is also known to be involved in development of resistance to a variety 
of anticancer agents such as SN-38, mitoxantrone, topotecan and doxorubicin. 
Coadministration of topotecan in combination with GF120918, a potent BCRP and 
MDR1 inhibitor, significantly increased topotecan oral bioavailability in mice, 
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probably due to the inhibition of biliary clearance and enhanced intestinal absorption 
(Kruijtzer et al., 2002). 
Recently, several mammalian orthologues of the bacterial multidrug and 
toxin extrusion (MATE)-type transporters have been identified. In humans, the 
isoform MATE1 is localized to the bile canalicular membrane in the liver (Otsuka et 
al., 2005b).  The driving force for organic cation extrusion by MATE1 is the inwardly 
directed H+ gradient (Otsuka et al., 2005b). Several organic cations (e.g. metformin, 
cimetidine and tetraethyl ammonium) have been identified as substrates for MATE1 
(Table 1.2). The role of MATE1 in hepatobiliary disposition of drugs remains to be 
elucidated.  
Basolateral Efflux Transport Proteins 
The organic anion transporting polypeptides [OATPs, (SLCO)] represent the 
major family of basolateral uptake transport proteins for organic anions and have 
been hypothesized to also function as basolateral efflux transport proteins under 
certain conditions.  However, the in vivo role of these transport proteins for 
basolateral egress of drugs from the hepatocyte warrants further studies (Durr et al., 
2000).   
The ATP-dependent multidrug resistance-associated protein [MRP, (ABCC)] 
subfamily is a major class of efflux transport proteins on the hepatic basolateral 
membrane.  MRP1, 3, 5, and 6 are involved in cellular transport of both hydrophobic 
uncharged molecules and hydrophilic anionic compounds.  MRP1 (ABCC1) is 
responsible for efflux of various organic anions including glucuronide-, glutathione-, 
and sulfate-conjugated drugs.  The expression of MRP1 (ABCC1) is very low on the 
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basolateral membrane in healthy liver, but MRP1 is highly inducible during severe 
liver injury and this induction is believed to play a role in liver protection (Wilson et al., 
2003).  MRP3 (ABCC3) is involved in the hepatic excretion of glucuronide 
conjugates (e.g., acetaminophen glucuronide), methotrexate, and estradiol-17β-
glucuronide (E217G).  The expression level of MRP3 is markedly increased under 
cholestatic conditions (Hirohashi et al., 1999).  MRP4 (ABCC4) and MRP5 (ABCC5) 
transport cyclic nucleotides such as cAMP and cGMP, as well as the purine analogs 
6-mercaptopurine and 6-thioguanine (Zhou et al., 2001).  MRP4 has been implicated 
in the transport of nucleoside-like drugs such as zidovudine, lamivudine, and 
stavudine, as well as non-nucleotide substrates (e.g., methotrexate), and the reverse 
transcriptase inhibitor azidothymidine.  MRP4 also is involved in the transport of 
sulfate conjugates of bile acids and steroids (Zelcer et al., 2003).  While the 
expression level of MRP5 in healthy liver is relatively low, treatment with 
lipopolysaccharide (LPS) results in down-regulation of MRP2 and induction of MRP5, 
suggesting that MRP5 may participate in the hepatic response to cholestasis 
(Donner et al., 2004).  MRP6 is localized at the lateral side and canalicular 
membrane. MRP6 transports glutathione conjugates and the endothelin receptor 
antagonist, BQ-123 (Madon et al., 2000).  Mutation of the MRP6 gene causes 
pseudoxanthoma elasticum (PXE), an inheritable systemic connective tissue 
disorder affecting the skin, eyes and blood vessels (Perdu and Germain, 2001).  
Clarification of the role of MRP6 in canalicular membrane transport awaits further 
investigation.   
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Table 1.1: Human Hepatic Uptake Transport Proteins 
Protein/ 
Gene symbol 
Substrates References 
NTCP/ 
SLC10A1 
BSP; cholate; estrone-3-sulfate; glycocholate; 
taurochenodeoxycholate; tauroursodeoxycholate; 
taurocholate 
Rosuvastatin 
(Meier et al., 1997) 
 
 
(Ho et al., 2006) 
OATP1A2/ 
SLCO1A2 
 
Bile acids; BQ-123; Bromosulfophthalein (BSP);DHEAS; 
[D-penicillamine2,5]enkephalin (DPDPE); Estradiol-17β-
glucuronide (E217G); estrone-3-sulfate; n-methyl quinine; 
ouabain; prostaglandin E2; thyroid hormones (T3, T4) 
Deltorphin II 
Fexofenadine 
Levofloxacin 
Methotrexate 
Microcystin-LR 
Pitavastatin 
Saquinavir 
(Kullak-Ublick et al., 2001) 
 
 
 
(Gao et al., 2000) 
(Cvetkovic et al., 1999) 
(Maeda et al., 2007) 
(Badagnani et al., 2006) 
(Fischer et al., 2005) 
(Fujino et al., 2005) 
(Su et al., 2004) 
OATP1B1/ 
SLCO1B1 
 
Arsenic (arsenite, arsenate) 
Atrasentan 
Atorvastatin; Simvastatin 
 
Benzylpenicillin 
Bile acids; BQ-123; BSP; DHEAS; DPDPE; E217G; 
estrone-3-sulfate; T3, T4;leukotriene C4(LTC4); 
prostaglandin E2 
Bilirubin, bilirubin glucuronides 
Bosentan 
Caspofungin 
Cerivastatin; Pravastatin 
Fluvastatin 
Irinotecan metabolite (SN-38) 
Methotrexate 
Microcystin-LR 
Olmesartan 
 
Pitavastatin 
Pravastatin 
Repaglinide 
Rifampin 
Rosuvastatin 
Troglitazone-sulfate 
Valsartan 
(Lu et al., 2006) 
(Katz et al., 2006) 
(Kameyama et al., 2005; 
Lau et al., 2006) 
(Tamai et al., 2000) 
(Kullak-Ublick et al., 2001) 
 
 
(Cui et al., 2001) 
(Treiber et al., 2007) 
(Sandhu et al., 2005) 
(Kameyama et al., 2005) 
(Kopplow et al., 2005) 
(Nozawa et al., 2004b) 
(Abe et al., 1999) 
(Fischer et al., 2005) 
(Nakagomi-Hagihara et al., 
2006) 
(Fujino et al., 2004) 
(Hsiang et al., 1999) 
(Kajosaari et al., 2005) 
(Vavricka et al., 2002) 
(Ho et al., 2006) 
(Nozawa et al., 2004b) 
(Yamashiro et al., 2006) 
OATP1B3/ 
SLCO1B3 
Amanitin 
Bile acids; BQ-123; BSP; Deltorphin-II; DHEAS; digoxin; 
DPDPE; E217G; estrone-3-sulfate; LTC4; ouabain; T3; 
T4 
Bosentan 
CCK-8 
Digoxin 
Docetaxel 
Enalapril 
Fexofenadine 
(Letschert et al., 2006) 
(Kullak-Ublick et al., 2001) 
 
(Treiber et al., 2007) 
(Ismair et al., 2001) 
(Kullak-Ublick et al., 2001) 
(Smith et al., 2005a) 
(Liu et al., 2006) 
(Shimizu et al., 2006) 
(Kopplow et al., 2005) 
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Table 1.2: Human Hepatic Efflux Transport Proteins 
Protein/ 
Gene symbol 
Substrates References 
MRP1/ 
ABCC1 
 
Daunorubicin; Doxorubicin; etoposide; vindcristine 
Glutathione 
Methotrexate (MTX) 
(Cole et al., 1994) 
(Madon et al., 2000) 
(Zeng et al., 2001) 
MRP3/ 
ABCC3 
Acetaminophen glucuronide 
E217G; monovalent and sulfated bile salts; MTX 
 
Etoposide 
(Xiong et al., 2000) 
(Hirohashi et al., 1999; Zeng 
et al., 2001) 
(Madon et al., 2000) 
Fluvastatin 
Methotrexate 
Microcystin-LR 
Monoglucuronosyl bilirubin 
Olmesartan 
 
Paclitaxel 
Pitavastatin 
Rifampin 
Rosuvastatin 
Telmisartan 
Valsartan 
(Abe et al., 2001) 
(Fischer et al., 2005) 
(Cui et al., 2001) 
(Nakagomi-Hagihara et al., 
2006) 
(Smith et al., 2005a) 
(Fujino et al., 2004) 
(Vavricka et al., 2002) 
(Ho et al., 2006) 
(Ishiguro et al., 2006) 
(Yamashiro et al., 2006) 
OATP2B1/ 
SLCO2B1 
 
Atorvastatin 
Benzylpenicillin 
Bosentan 
BSP; DHEAS; estrone-3-sulfate 
Glibenclamide 
Fluvastatin 
Pravastatin 
Pitavastatin 
Rosuvastatin 
(Grube et al., 2006) 
(Tamai et al., 2000) 
(Treiber et al., 2007) 
(Kullak-Ublick et al., 2001) 
(Satoh et al., 2005) 
(Kopplow et al., 2005) 
(Nozawa et al., 2004a) 
(Hirano et al., 2006) 
(Ho et al., 2006) 
OAT2/ 
SLC22A7 
5-Fluorouracil; Allopurinol; L-ascorbic acid; Bumetanide; 
DHEAS; estrone-3-sulfate; glutarate; prostaglandin E2 
Erythromycin; theophylline 
Methotrexate 
Prostaglandin F2α 
Ranitidine 
Tetracycline 
Zidovudine 
(Kobayashi et al., 2005a) 
 
(Kobayashi et al., 2005b) 
(Sun et al., 2001) 
(Enomoto et al., 2002) 
(Tahara et al., 2005) 
(Babu et al., 2002) 
(Takeda et al., 2002) 
OCT1/ 
SLC22A1 
Acyclovir, ganciclovir 
Azidoprocainamide methoiodide; n-methyl-quinidine; n-
methyl-quinine; tributylmethylammonium 
Choline 
Imatinib 
Metformin 
Famotidine, ranitidine 
Prostaglandin E2, Prostaglandin F2α 
(Takeda et al., 2002) 
(van Montfoort et al., 2001) 
 
(Grundemann et al., 1999) 
(Thomas et al., 2004) 
(Kimura et al., 2005) 
(Bourdet et al., 2005) 
(Kimura et al., 2002) 
OCT3/ 
SLC22A3 
Adrenaline, noradrenaline, tyramine 
Agmatine, MPP+; tetraethylammonium 
Atropine, etilefrine 
Cimetidine 
(Grundemann et al., 1998) 
(Hayer-Zillgen et al., 2002) 
(Muller et al., 2005) 
(Grundemann et al., 1999) 
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Fexofenadine (Matsushima et al., 2008) 
MRP4/ 
ABCC4 
Azidothymidine 
cAMP; cGMP; PMEA 
 
 
MTX 
Prostaglandin E1; Prostaglandin E2  
(Schuetz et al., 1999) 
(Jedlitschky et al., 2000; 
Chen et al., 2001; Reid et 
al., 2003a) 
(Chen et al., 2002) 
(Reid et al., 2003a) 
MRP5/ 
ABCC5 
cAMP; cGMP 
Adefovir 
(Jedlitschky et al., 2000) 
(Reid et al., 2003a) 
MRP6/ 
ABCC6 
BQ-123 (Madon et al., 2000) 
BSEP/ 
ABCB11 
Conjugated and unconjugated bile salts; TC 
Fexofenadine 
Pravastatin 
(Gerloff et al., 1998) 
(Matsushima et al., 2008) 
(Hirano et al., 2005a) 
MRP2/ 
ABCC2 
Acetaminophen glucuronide; carboxydichlorofluorescein 
Camptothecin; doxorubicin 
Cerivastatin; estron-3-sulfate 
Cisplatin; vincristine 
Etoposide 
Glibenclamide; indomethacin; rifampin 
Glucuronide, glutathione, and sulfate conjugates; LTC4 
MTX 
Pitavastatin 
Pravastatin 
Rosuvastatin 
(Xiong et al., 2000) 
(Koike et al., 1997) 
(Hirano et al., 2005b) 
(Kawabe et al., 1999) 
(Konig et al., 1999b) 
(Payen et al., 2000) 
(Konig et al., 1999b) 
(Hooijberg et al., 1999) 
(Hirano et al., 2005b) 
(Sasaki et al., 2002) 
(Kitamura et al., 2008) 
MDR1/ 
ABCB1 
Amprenavir; indinavir; nelfinavir; ritonavir; saquinavir 
 
Atorvastatin 
Aldosterone; corticosterone; dexamethasone; digoxin 
Cyclosporin A; mitoxantrone (MX) 
Debrisoquine; erythromycin; lovastatin; terfenadine 
Digoxin; quinidine 
Doxorubicin; paclitaxel; rhodamine 123 
 
Etoposide 
Fexofenadine 
Levofloxacin; Grapafloxacin 
Losartan; vinblastine 
Pitavastatin 
Rosuvastatin 
Tacrolimus 
Talinolol 
 
Verapamil; Norverapamil 
(Kim et al., 1998; Polli et al., 
1999) 
(Bogman et al., 2001) 
(Ueda et al., 1992) 
(Marie et al., 1992) 
(Kim et al., 1999) 
(Fromm et al., 1999) 
(van der Sandt et al., 2000; 
Advani et al., 2001) 
(Lum et al., 1993) 
(Cvetkovic et al., 1999) 
(Yamaguchi et al., 2000) 
(Soldner et al., 1999) 
(Hirano et al., 2005b) 
(Kitamura et al., 2008) 
(Floren et al., 1997) 
(Spahn-Langguth et al., 
1998) 
(Pauli-Magnus et al., 2000) 
MDR3/ 
ABCB4 
Phospholipids (Evers et al., 2000) 
BCRP/ 
ABCG2 
Albendazole sulfoxide; Oxfendazole 
Daunorubicin; doxorubicin; MX; sulfated conjugates 
Ciprofloxacin; Ofloxacin; Norfloxacin 
Cerivastatin 
Dirithromycin; Erythromycin; Rifampicin 
Genistein 
Epirubicin 
Irinotecan; Topotecan 
Imatinib 
(Merino et al., 2005a) 
(Doyle et al., 1998) 
(Merino et al., 2006) 
(Matsushima et al., 2005) 
(Janvilisri et al., 2005) 
(Imai et al., 2004) 
(Robey et al., 2003) 
(Maliepaard et al., 2001) 
(Burger et al., 2004) 
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Lamivudine 
Methotrexate 
Nitrofurantoin 
Pitavastatin 
Prazosin; rhodamine 123 
Rosuvastatin 
Sulfasalazine 
 
SN-38; SN-38 glucuronide 
Testosterone; tamoxifen; estradiol 
Zidovudine 
(Wang et al., 2003) 
(Volk et al., 2002) 
(Wang and Morris, 2007) 
(Hirano et al., 2005b) 
(Ozvegy et al., 2001) 
(Kitamura et al., 2008) 
(van der Heijden et al., 
2004) 
(Yoshikawa et al., 2004) 
(Janvilisri et al., 2003) 
(Wang et al., 2004) 
MATE1/ 
SLC47A1 
Tetraethylammonium (TEA) 
Cimetidine; metformin; procainamide; topotecan; 
(Otsuka et al., 2005a) 
(Tanihara et al., 2007) 
 
Potential Role of Hepatic Transport Proteins in Drug-Induced Liver Injury  
Drug-induced liver injury has emerged as the most common reason for the 
withdrawal of FDA-approved drugs from the market (FDA, 2000).  Drug-induced 
hepatotoxicity may be classified as intrinsic or idiosyncratic.  Intrinsic hepatotoxicity 
is generally predictable, dose-dependent, and characteristic for a particular drug.  In 
contrast, idiosyncratic toxicity is unpredictable, not dose-related, and displays no 
clear underlying mechanism.  Drug-induced liver injury can be evaluated by 
measuring the activity of alanine aminotransferase (ALT) and alkaline phosphatase 
(ALP) in the plasma (Benichou, 1990); liver injury is designated hepatocellular injury 
if the ALT level is greater than 2 times the upper limit of normal (ULN), or if a ratio of 
ALT/ULN and ALP/ULN is greater than 5; cholestatic injury can be characterized by 
elevations in ALP greater than 2 times the ULN or by a ratio of ALT/ULN and 
ALP/ULN that is less than 2; mixed patterns of liver injury are defined as a ratio of 
ALT/ULN and ALP/ULN that is greater than 2 but less than 5.  
Age, gender, genetic and environmental factors may affect susceptibility to 
drug-induced liver injury.  Early studies focused on bioactivation, covalent adduct 
formation, immunotoxicity, and disruptions in cellular bioenergetics as mechanisms 
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underlying hepatotoxicity, but more recent data suggest that alterations in hepatic 
transport may be an important mechanism of toxic endpoints. Inhibition of 
canalicular Bsep has been reported as one mechanism of drug-induced liver injury 
because impaired Bsep function leads to elevated hepatic concentrations of 
detergent-like bile acids, which can disrupt key membrane-associated cellular 
functions  (Spivey et al., 1993; Funk et al., 2001a).  Troglitazone (Rezulin) was the 
first thiazolidinedione approved for the treatment of type 2 diabetes prior to its 
withdrawal from the market in 2000 due to idiosyncratic liver injury (Herrine and 
Choudhary, 1999).  Several mechanisms underlying troglitazone-induced 
hepatotoxicity have been proposed (Smith, 2003), including Bsep inhibition by both 
troglitazone (KI, apparent = 1.3 µM) and its primary metabolite, troglitazone sulfate (KI, 
apparent = 0.23 µM) (Funk et al., 2001b).  Troglitazone causes intrahepatic 
accumulation of bile acids, which can lead to hepatocellular necrosis and severe 
liver damage (Gores et al., 1998).  Following troglitazone administration, Mrp2-
deficient rats exhibited a marked delay in the biliary excretion and enhanced urinary 
excretion of troglitazone sulfate leading to elevated serum bile acid concentrations 
relative to wild-type rats (Kostrubsky et al., 2001). Although troglitazone has been 
one of the most studied examples of hepatotoxicity resulting from Bsep inhibition, 
other drugs, including bosentan, glibenclamide, cyclosporin, and rifampin also impair 
Bsep function (Stieger et al., 2000; Fattinger et al., 2001). In addition to cis-inhibition 
of Bsep, estradiol-17-β-glucuronide trans-inhibits Bsep following biliary excretion by 
Mrp2 (Stieger et al., 2000). In the absence of Mrp2, estradiol-17-β-glucuronide-
induced cholestasis is not observed (Sano et al., 1993; Stieger et al., 2000). 
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Hepatic transport proteins may provide a protective role against drug-induced 
hepatotoxicity through changes in transporter expression (Ananthanarayanan et al., 
1994).  Intrahepatic and obstructive cholestasis in humans and rats result in down-
regulation of Oatp/Ntcp isoforms and up-regulation of Mrp isoforms (Gartung et al., 
1996; Donner and Keppler, 2001; Wagner et al., 2003). In patients with hepatitis or 
chronic cholestasis, up-regulation of major hepatic efflux transporters such as MDR1, 
MRP1 and MRP3 have been reported (Wilson et al., 2003).  Similarly, during liver 
injury caused by acetaminophen and carbon tetrachloride which are both well-known 
hepatic toxicants, expression of hepatic transport proteins in mice was modulated 
(Aleksunes et al., 2005; Moffit et al., 2006): Mrp2 protein expression was slightly 
increased; Mrp3 and Mrp4 expression was increased by 3.6-fold and 16-fold, 
respectively; Oatps and Ntcp were down-regulated. Collectively, hepatocytes may 
prevent accumulation of potentially toxic chemicals and protect against subsequent 
liver injury by limiting influx and enabling efficient efflux of harmful toxicants following 
down-regulation of uptake transporters and up-regulation of efflux transporters.   
In certain cases, impaired hepatic transport may provide protection against 
drug-induced liver injury.  Many electrophiles that form covalent adducts with 
intracellular macromolecules are detoxified by conjugation with glutathione.  Mrp2-
deficient rats do not excrete glutathione into bile, resulting in a ~2-3-fold increase in 
hepatic glutathione concentrations (Dietrich et al., 2001).  Acetaminophen, a 
commonly used antipyretic and analgesic agent, induces severe liver injury at high 
doses when acetaminophen sulfation and glucuronidation become saturated and 
oxidation to N-acetyl-p-benzoquinoneimine, a potent electrophile, becomes a 
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significant metabolic pathway (Galinsky and Levy, 1981).  N-acetyl-p-
benzoquinoneimine may be detoxified by conjugation with glutathione, but as this 
co-factor becomes depleted, the electrophilic metabolite forms covalent adducts, 
which can lead to cellular necrosis (Dahlin et al., 1984).  Administration of toxic 
acetaminophen doses (1 g/kg) induced the expected hepatotoxicity in wild-type rats, 
but had no apparent adverse effects in Mrp2-deficient rat livers (Silva et al., 2005).  
Elevated glutathione concentrations in Mrp2-deficient rats appear to play a 
protective role in acetaminophen-induced hepatotoxicity; a similar effect also would 
be expected for other electrophiles in Mrp2-deficient rats (Silva et al., 2005).  
In this dissertation project, the role of hepatic transport proteins in drug-
induced liver injury was assessed using troglitazone, trabectedin, and sulindac as 
model hepatotoxic compounds. As mentioned above, Bsep inhibition by troglitazone 
and troglitazone sulfate has been proposed as one mechanism for troglitazone-
mediated liver injury. In rats and humans, troglitazone is extensively metabolized to 
troglitazone sulfate (TS) which is transported by BCRP (Enokizono et al., 2007). 
Patients who have impaired functional activity of BCRP (e.g. due to a polymorphism 
or drug-drug interaction) may have increased potential for troglitazone-mediated 
hepatotoxicity due to higher accumulation of TS in the liver. Trabectedin is a 
promising anticancer agent which is currently under phase II evaluation (Schoffski et 
al., 2008). During phase I/II clinical trials, the most prevalent adverse effect was 
hepatotoxicity with elevated ALP and/or bilirubin levels (Beumer et al., 2005b). Little 
is known about the metabolic profiles of trabectedin in rats and humans, but multiple 
cytochrome P450 enzymes (3A4, 2C9, 2C19, 2D6, and 2E1) appear to be involved 
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in trabectedin metabolism. Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), 
has been consistently associated with liver injury among NSAIDs (Aithal and Day, 
2007). Sulindac is metabolized to sulindac sulfide, which has anti-inflammatory 
properties, and is also transformed to sulindac sulfone, which has antiproliferative 
effects against colon cancer (Davies and Watson, 1997). Several investigators have 
demonstrated a linear correlation between sulindac sulfide concentrations and 
hepatotoxicity (Duggan et al., 1978; Laffi et al., 1986). Although hepatocellular and 
mixed patterns of sulindac-mediated hepatotoxicity have been reported, cholestatic 
patterns of liver injury were most commonly observed (Tarazi et al., 1993).  
 
Modulation of Hepatic Transport Proteins by Drugs and Patient-Specific Factors 
As discussed above, hepatic transport proteins play an important role in the 
uptake and excretion of endogenous and exogenous compounds. Altered hepatic 
transport function (e.g., inhibition, induction, or altered translocation) may have a 
significant impact on the hepatobiliary disposition of drugs. 
Inhibition of cytochrome P450 (CYP) enzymes is an important mechanism of 
many toxic drug interactions, but accumulating data suggest that some interactions 
may be mediated, at least in part, by transport proteins. Numerous transport 
interactions occur at the level of hepatic uptake. Cyclosporine A increased the AUC 
of atovastatin, lovastatin and simvastatin ~7.4-fold, 5-fold and ~2.5-fold, respectively; 
these statins are transported into the hepatocyte by OATPs, and are cleared by 
CYP3A4-mediated metabolism and P-gp-mediated biliary excretion (Shitara and 
Sugiyama, 2006). The observed interaction between some statins (atorvastatin, 
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simvastatin, and lovastatin) and cyclosporine A may be caused by the combined 
effects on drug metabolizing enzymes and transport proteins; cyclosporine A not 
only inhibits CYP3A4-mediated metabolism, but also affects OATP-mediated hepatic 
uptake and P-gp-mediated biliary excretion.  Cyclosporine A also increased the AUC 
of rosuvastatin ~7.1-fold (Simonson et al., 2004). This interaction may be due to 
impaired OATP-mediated hepatic uptake of rosuvastatin, since rosuvastain is neither 
a P-gp nor a CYP3A4 substrate or inhibitor (Martin et al., 2002; Cooper et al., 2003),. 
The interaction between atorvastatin or rosuvastatin and cyclosporine A is consistent 
with pharmacokinetic alterations of these statins observed in subjects with genetic 
polymorphisms in OATP1B1; the AUC of atorvastatin and rosuvastatin in subjects 
with the SLCO1B1 c.521CC genotype was 144% and 65% higher than in subjects 
with the SLCO1B1 c.521TT genotype (Pasanen et al., 2007).  
Undoubtedly, interactions in biliary excretion or basolateral efflux also occur.  
Although there is accumulating evidence of potential drug-drug interactions 
mediated by inhibition of these hepatic efflux transport proteins based on in vitro 
screening, clinical trials examining hepatic efflux transporter-mediated drug 
interactions often demonstrate an undetectable or weak interaction in humans. 
Impaired function of hepatic efflux transport proteins may increase hepatocelluar 
exposure without affecting the plasma pharmacokinetics. Drug interactions at the 
level of hepatic efflux can be assessed in human only via imaging techniques or 
quantifying biliary clearance. Alternatively, the application of a modeling/simulation 
approach coupled with in vitro data may address these issues as demonstrated in 
Chapter 3 based on Monte Carlo simulations.  
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In addition to acute inhibition, long term administration of xenobiotics can 
modulate transport function by affecting transcriptional, translational and 
posttranslational events (Hong and You, 2007). The transcriptional regulation of 
transporter gene expression in hepatocytes is mediated by a large variety of orphan 
nuclear receptors [e.g., pregnane X receptor (PXR), liver X receptor (LXR), 
constitutive androstane receptor (CAR) and farnesoid X receptor (FXR)] coupled 
with a heterodimeric partner (e.g., retinoic acid X receptor).  Although many 
investigations have focused on the identification of regulatory mechanism(s) 
responsible for the induction of transport proteins (Rizzo et al., 2005; Urquhart et al., 
2007), the overlapping gene targets and ligand specificity for orphan nuclear 
receptors make it difficult to determine how regulatory processes ultimately affect the 
functional pharmacokinetic outcomes of transport protein induction. Other than 
orphan nuclear receptors, some signaling events also can modulate transport 
protein expression. For example, an estrogen response element has been identified 
in the BCRP promoter region, and BCRP expression appears to be influenced by 
estrogen (E1) and/or estradiol (E2) in cancer cell lines when the E1 receptor (ER) is 
present (Ee et al., 2004; Imai et al., 2005). However, whether these hormones 
increase or inhibit BCRP expression is controversial; BCRP expression was 
increased by E2-mediated transcriptional up-regulation in ER-α-positive MCF-7 
breast cancer cells (Zhang et al., 2006b), while another group demonstrated 
posttranscriptional BCRP down-regulation by E2 in the same cell line (Imai et al., 
2005). In addition, BCRP expression is regulated by the phophoinositol-3 kinase 
(PI3K)-Akt signaling pathway via posttranscriptional/translational mechanisms in 
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BCRP-overexpressing K562 cells (Nakanishi et al., 2006). Interestingly, imatinib, a 
potent tyrosine kinase inhibitor, decreased BCRP expression by modulating PI3K-
Akt signaling pathway in the same cell line (Nakanishi et al., 2006). However, the 
effect of these signaling pathways on BCRP regulation in BCRP-expressing cancer 
or non-polarized cell lines may not be reflected in hepatocytes, or in vivo.  
 Hepatic transport protein function can be modulated by altered 
translocation of transport protein(s) between the plasma membrane and 
intracellular vesicles. The mechanisms of intracellular trafficking of some hepatic 
proteins to the correct plasma membrane domain have been examined previously 
(Wakabayashi et al., 2006). Newly synthesized canalicular transport proteins in 
the Golgi apparatus may be directly trafficked to the apical membrane (e.g., P-gp), 
or may be stored transiently in intracellular compartments before apical delivery to 
the membrane (e.g., Bsep) (Kipp et al., 2001; Kipp et al., 2003); some stimuli such 
as taurocholate or dibutyryl (DB) cAMP are involved in Bsep and P-gp trafficking. 
Trafficking of Mrp2 to the apical membrane is mediated by a protein kinase C-
dependent mechanism (Beuers et al., 2001).  Some xenobiotics interacting with 
these stimuli may affect the intracellular trafficking of canalicular transport proteins, 
thus resulting in changes in biliary excretion. Although limited information is 
available for the mechanism(s) of basolateral transport protein trafficking, the 
cysteine residues of extracellular loop IX-X, responsible for disulfide linkages, 
appear to be involved in the targeting of OATP to the basolateral membrane 
(Hanggi et al., 2006). The current understanding of the mechanism(s) of 
intracellular translocation of xenobiotics is rudimentary. Interestingly, a recent 
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investigation by Munteanu et al. demonstrated the presence of functional P-gp in 
the Golgi and the mitochondrial membrane of doxorubicin-resistant K562 leukemia 
cells; doxorubicin was transported by P-gp into the mitochondria (Munteanu et al., 
2006). This finding suggests that xenobiotics may accumulate within intracellular 
organelles via transport proteins prior to hepatic basolateral and canalicular 
excretion. 
Sex-related variations in the expression and activity of drug transport 
proteins may contribute to sex-related differences in therapeutic response or 
toxicity. P-glycoprotein has been reported to be higher in livers of men compared 
with women, but phenotyping with fexofenadine did not demonstrate sex 
differences in clearance (Schuetz et al., 1995; Kim et al., 2001). Sex-dependent 
expression of Bcrp/BCRP have been demonstrated in mice and humans; men 
have 2-3 fold higher BCRP expression than women (Merino et al., 2005b).  
 
Experimental Tools for Studying Hepatic Transport  
1) Membrane Vesicles Prepared From Transfected Systems: Uptake of substrates 
into membrane vesicles prepared from purified basolateral and canalicular liver 
plasma membranes is an established technique for elucidating the kinetics of 
membrane transport proteins (Moseley et al., 1990; Wolters et al., 1991).  
Theoretically, liver plasma membrane vesicles include every transport protein that 
resides on the hepatocyte plasma membrane, and these can be used to assess the 
overall contribution of all transport proteins to the uptake and efflux of substrates.  
Utilization of recombinant expression systems enables the preparation of membrane 
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vesicles from cells over-expressing a single transport protein; this system has been 
used to determine whether a compound is an inhibitor and/or substrate for a specific 
transport protein.  Membrane vesicles prepared from transfected cells that over-
express the target transport protein have been used with either a radio-labeled 
compound to directly measure the uptake, or unlabeled compound to evaluate the 
ability of the compound to inhibit the transport of a radio-labeled probe substrate for 
the transport protein (Leslie et al., 2003; El-Sheikh et al., 2007).  Active transport in 
membrane vesicles should be energy-dependent, temperature-dependent and 
saturable (Leier et al., 1994; Allen et al., 2002).  Membrane vesicles also are a 
useful model system to characterize mechanisms of transport.  For example, the 
dependence of MRP1-mediated vincristine transport on reduced glutathione (GSH) 
has been characterized using membrane vesicles (Allen et al., 2002).  However, the 
utility of membrane vesicles is somewhat limited because of labor intensive, time-
consuming processes of vesicle preparation. 
2) Freshly-Isolated Suspended Hepatocytes: Freshly-isolated hepatocytes in 
suspension are preferable to cultured hepatocytes for characterization of the 
mechanisms of hepatic uptake due to the technical ease of determining initial rates 
of uptake. To characterize uptake mechanism(s), various conditions have been 
applied in experiments using suspended hepatocytes, such as addition of inhibitor(s) 
for uptake pathways, substitution of sodium with choline, depletion of ATP and low 
temperature (Brock and Vore, 1984). One major disadvantage of suspended 
hepatocytes is that cells should be used within 6-8 h due to a rapid decrease in 
activity of both metabolic and transport proteins. In addition, during cell isolation, 
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hepatocytes lose polarity, and canalicular transport proteins such as P-gp and Mrp2 
are internalized. Thus, use of suspended hepatocytes to determine biliary clearance 
is limited (Roelofsen et al., 1998; Bow et al., 2008).  
3) Sandwich Cultured Hepatocytes: Hepatocytes cultured between two layers of 
gelled collagen in a sandwich configuration re-create the three-dimensional in vivo 
cellular environment and re-establish cell polarity forming canalicular membrane 
domains bounded by junctional complexes and bile canalicular networks (Liu et al., 
1998; Liu et al., 1999c).  In sandwich-cultured hepatocytes (SCH), transport proteins 
are expressed on the appropriate membrane domains (Hoffmaster et al., 2004a).  
For example, confocal microscopy revealed the co-expression of P-gp and Mrp2 on 
the canalicular domain, and biliary excretion of [D-penicillamine2,5]enkephalin (3H-
DPDPE) and 5 (and 6)-carboxy-2',7'-dichlorofluorescein (CDF) confirmed P-gp and 
Mrp2 function, respectively.  Expression and appropriate localization of transport 
proteins in SCH enables the utilization of this model to investigate drug-drug 
interactions mediated by inhibition of hepatobiliary excretion, and to elucidate the 
consequences of protein induction (Annaert et al., 2001; Zamek-Gliszczynski et al., 
2003; Turncliff et al., 2004).  SCH exhibit down-regulation of NTCP and up-
regulation of MRP3; these changes may be due to the somewhat cholestatic nature 
of the canalicular networks that lack normal bile drainage via the common bile duct 
in vivo. 
4) Isolated Perfused Liver Model: The isolated perfused rat liver system was first 
reported by Claude Bernard in 1855 and has been used to investigate the 
physiology and pathophysiology of the rat liver for many years (Wolkoff et al., 1979).  
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Although it is labor intensive and time- and animal-consuming, the isolated perfused 
liver system has been used widely to investigate hepatobiliary transport of drugs 
since it maintains intact hepatic architecture, remains viable for ~ 3 hr and allows for 
collection of perfusate and bile.  This system is applicable for use with chemical 
modulators (e.g., inducers or inhibitors), and livers from rodents with transport 
protein(s) knocked out may be perfused to determine the contribution of specific 
proteins to hepatobiliary disposition.  For example, in situ isolated perfused mouse 
livers have been used to identify the role of P-gp and Bcrp in the biliary excretion of 
4-methylumbelliferyl sulfate (4-MUS) using P-gp- and Bcrp-deficient mice (Zamek-
Gliszczynski et al., 2006a); the biliary excretion of 4-MUS was obliterated in Bcrp-
deficient mice while 4-MUS biliary excretion was comparable between wild-type and 
P-gp-deficient mice, showing the exclusive role of Bcrp in 4-MUS biliary excretion.  
The use of 10 µM GF120918 in isolated perfused livers from wild-type mice showed 
significantly reduced biliary excretion of 4-MUS, which was comparable to that in 
livers from Bcrp-deficient mice.  
5) Animal Knockout Models: Genetic models of transport protein deficiencies also 
have been used in in vivo pharmacokinetic and pharmacodynamic studies to assess 
the role of a particular transport protein in drug disposition.  Animal models with 
transport protein deficiencies are a valuable tool to study hepatobiliary drug transport 
due to intact liver physiology and preserved hepatic metabolic activity and transport 
processes.  However, the potential disadvantage of the knockout animal is the 
compensatory up-regulation of other metabolic enzymes and/or transport proteins as 
a result of the loss of a transport system.  For example, the mutational disruption of 
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mdr1 genes led to over-expression of CYP3A, 2B, and 1A proteins and increased 
the catalytic activity of CYP enzymes (Schuetz et al., 2000).  Interestingly, this up-
regulation of CYP enzymes was observed only in P-gp deficient mice housed in 
Amsterdam, but not in P-gp deficient mice housed in the United States, suggesting 
that both the genetic deficiency and environmental factors regulated P450 
expression in P-gp-deficient mice. Another example is the increased expression of 
basolateral Mrp3 in rodents with hereditary conjugated hyperbilirubinemia [Mrp2-
deficient rats (GY/TR-) and Eisai hyperbilirubinemic rats (EHBR)] (Kuroda et al., 
2004).  This compensatory up-regulation of MRP3 also is observed in patients with 
Dubin-Johnson syndrome who suffer from impaired biliary excretion of organic anion 
due to the absence of MRP2 (Tsujii et al., 1999).  Another limitation of using 
knockout animal models is the lack of predictability of these models to humans. For 
example, it has been documented previously that substrate specificity between the 
human MDR1 and mouse Mdr1a was markedly different, suggesting species 
differences in P-gp-mediated transport (Yamazaki et al., 2001). Species differences 
in the biliary excretion of phase II conjugates between rats and mice have been 
demonstrated recently (Zamek-Gliszczynski et al., 2008); Bcrp1 was involved 
exclusively in the biliary excretion of sulfate metabolites in mice, whereas both Mrp2 
and Bcrp1 were responsible for canalicular transport of sulfate metabolites in rats.  
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Specific Aims 
The goal of this dissertation project was to investigate the role of hepatic 
transport proteins in drug disposition and drug-induced liver injury. Transport 
proteins, individually and/or in concert, play a crucial role in hepatic uptake and 
excretion of drugs and metabolites. Thus, altered hepatic transport protein 
function (due to disease state, genetic polymorphism or drug-drug interactions) 
may influence systemic and/or hepatic concentrations, thereby altering therapeutic 
efficacy and/or toxicity. A multiexperimental approach was employed to address 
these key issues regarding hepatic transport mechanisms: 1) sex-related 
differences in the hepatobiliary disposition of phase II conjugates; 2) in vitro tools 
to assess altered transport function; 3) the role of transport proteins in drug-
induced liver injury. 
 
AIM #1. Elucidate the Mechanism of Differences in the Hepatobiliary 
Disposition of Acetaminophen and Metabolites in Male and Female Mice. 
Hypothesis: Sex-dependent hepatic Bcrp expression (male > female) results in sex-
dependent hepatobiliary disposition of phase II conjugates. This hypothesis was 
tested using an in situ mouse liver perfusion approach to compare the disposition of 
acetaminophen and metabolites in male and female wild-type and Bcrp-deficient 
mice.  
1.a. Characterize the impact of sex-dependent expression of Bcrp on the 
hepatobiliary disposition of acetaminophen and generated metabolites 
[glucuronide (AG); sulfate (AS)] in male and female wild-type and Bcrp-
deficient mice. 
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1.b. Use a pharmacokinetic modeling approach to estimate pharmacokinetic 
parameters and evaluate mechanisms by which the hepatobiliary disposition 
of Bcrp substrates was altered. 
1.c. Compare protein expression levels of the major biliary and basolateral 
transport proteins among male and female wild-type and Bcrp-deficient mice.  
AIM #2. Assess the Utility of an Integrated in vitro Approach [Sandwich-
cultured Hepatocytes (SCH) and Modeling/Simulation] in Predicting 
Alterations in the Hepatobiliary Disposition of Troglitazone (TGZ) and 
Metabolites. 
Hypothesis: Rat and Human SCH can be used to mimic the in vivo disposition of 
TGZ and generated metabolites in rats and humans.  Compartmental 
pharmacokinetic modeling and Monte Carlo simulation approaches can be applied to 
data from SCH to examine the consequences of canalicular transport protein 
modulation resulting from drug interactions or disease states, on hepatic exposure in 
hypothetical “populations” of hepatocytes.  
 2.a. Assess the metabolism of TGZ, which is governed primarily by phase II 
conjugation, and the hepatobiliary disposition of TGZ and generated metabolites 
in rat and human SCH. 
 2.b. Use pharmacokinetic modeling and Monte Carlo simulation approaches to 
predict alterations in  hepatic exposure and routes of excretion of TGZ and 
generated metabolites.  
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AIM #3. Examine the Potential Role of Hepatic Transport Proteins in Liver 
Injury Mediated by Trabectedin and Sulindac. 
Hypothesis 1: Mrp2 as well as CYP3A1/2 play a role in the previously reported 
hepato-protective effect of DEX against trabectedin-mediated hepatotoxicity in rats 
and humans. SCH, which closely mimic the metabolic and transport capabilities of 
the intact liver, can predict this DEX-mediated hepato-protection.   
3.a. Assess the effect of DEX and BSO on trabectedin-mediated hepatotoxicity 
in SCH from WT and Mrp2-deficient TR- rats.  
3.b. Examine the effect of DEX and BSO on the expression levels of transport 
proteins in WT SCH. 
3.c. Determine the role of Mrp2 in the hepatobiliary disposition of trabectedin in 
the rat isolated perfused liver (IPL) using WT and Mrp2-deficient TR- rats. 
 
Hypothesis 2: Interaction of sulindac and metabolites with hepatic transport 
proteins disrupts the hepatobiliary disposition of bile acids, bile acid conjugates 
and/or therapeutic drugs, thereby resulting in sulindac-mediated liver injury.   
4.a. Examine the impact of acute exposure of sulindac, sulindac sulfone and 
sulindac sulfide on  hepatobiliary disposition of nitrofurantoin (NF), taurocholate 
(TC) and estradiol-17-β-glucuronide (E217G) in rat SCH.  
 4.b. Determine the inhibitory potency of sulindac sulfone and sulindac sulfide on 
TC and E217G initial uptake in freshly-isolated rat hepatocytes.  
 4.c. Elucidate altered hepatobiliary disposition of TC by sulindac, sulindac 
sulfone and sulindac sulfide in human SCH, and subsequently determine the 
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inhibitory potency of sulindac metabolites on TC initial uptake in freshly-isolated 
human hepatocytes.  
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ABSTRACT   
Breast cancer resistance protein (BCRP; ABCG2) is expressed in the hepatic 
canalicular membrane and mediates biliary excretion of xenobiotics including sulfate 
and glucuronide metabolites of some compounds. Hepatic Bcrp expression is sex-
dependent, with higher expression in male mice. The hypothesis that sex-dependent 
Bcrp expression influences the hepatobiliary disposition of phase II metabolites was 
tested in the present study using acetaminophen (APAP), and the generated APAP 
glucuronide (AG) and sulfate (AS) metabolites in single-pass in situ perfused livers 
from male and female wild-type and Abcg2(-/-) (Bcrp-deficient) mice. 
Pharmacokinetic modeling was utilized to estimate parameters governing the 
hepatobiliary disposition of APAP, AG and AS. In wild-type mice, the biliary excretion 
rate constant was 2.5- and 7-fold higher in males compared to females for AS and 
AG, respectively, reflecting male-predominant Bcrp expression. Sex-dependent 
differences in AG biliary excretion were not observed in Bcrp-deficient mice and AS 
biliary excretion was negligible. Interestingly, sex-dependent basolateral excretion of 
AG (higher in males) and AS (higher in females) was noted in wild-type mice with a 
similar trend in Bcrp-deficient mouse livers, reflecting an increased rate constant for 
AG formation in male and AS formation in female mouse livers. In addition, the rate 
constant for AS basolateral excretion was increased significantly in female 
compared to male mouse livers. Interestingly, Mrp4 protein was higher in female 
compared to male mouse livers. In conclusion, sex-dependent differences in 
conjugation and transporter expression result in profound differences in the 
hepatobiliary disposition of AG and AS in male and female mouse livers. 
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INTRODUCTION 
The breast cancer resistance protein (BCRP) belongs to the ATP-binding 
cassette transporter G family and was first cloned in 1998 from mitoxantrone-
resistant cell lines (Doyle et al., 1998).  BCRP is highly expressed in the canalicular 
membrane of the hepatocyte as well as in the intestinal epithelia, blood-brain barrier, 
and placenta (Robey et al., 2008).  BCRP has wide substrate specificity, including 
organic anions, cations, and zwitterions.  BCRP mediates the transport of sulfated 
hormone metabolites, SN-38, mitoxantrone, topotecan, doxorubicin, flavopiridol, 
nitrofurantoin, various flavonoids and the cholorophyll metabolite pheophorbide A 
(Robey et al., 2001; Jonker et al., 2002; Nakagawa et al., 2002; Bates et al., 2004; 
Imai et al., 2004; Jonker et al., 2005; Merino et al., 2005a).   
Male-predominant expression of Bcrp has been reported in mouse liver 
(Merino et al., 2005b; Tanaka et al., 2005).  Bcrp is influenced by sex hormones; 
estradiol suppresses and testosterone induces Bcrp expression (Tanaka et al., 
2005).  Sex-dependent differences in Bcrp expression have been shown to influence 
the pharmacokinetics of drugs (Merino et al., 2005b).  For example, the area under 
the plasma concentration-time curve of nitrofurantoin in female wild-type mice was 
~2-fold higher than in male mice after oral administration; the cumulative biliary 
excretion of nitrofurantoin was 9-fold higher in male compared to female mice.  In 
contrast, no significant sex differences in plasma concentrations or the hepatobiliary 
excretion of nitrofurantoin were observed in Bcrp-deficient mice, indicating that 
hepatic Bcrp protein contributes to sex differences in wild-type mice (Merino et al., 
2005b).   
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The role of various transport proteins in the biliary excretion of phase II 
metabolites has been examined using several compounds including acetaminophen, 
4-methylumbelliferone and harmol, which are metabolized primarily to glucuronide 
and sulfate conjugates in mice (Zamek-Gliszczynski et al., 2006c).  In situ single-
pass liver perfusion in male mice demonstrated that Bcrp plays a predominant role in 
the biliary excretion of sulfate conjugates, whereas the biliary excretion of 
glucuronide conjugates was mediated by both Bcrp and, to a lesser extent, Mrp2.  
Glucuronide and sulfate conjugates of acetaminophen (AG and AS, respectively) are 
transported from the hepatocytes into sinusoidal blood by basolateral transport 
proteins; Mrp3 mediates basolateral excretion of AG whereas Mrp3, Mrp4, and other 
transport proteins may be involved in the basolateral excretion of AS in mice (Xiong 
et al., 2002; Manautou et al., 2005; Zamek-Gliszczynski et al., 2006b).  In the liver, 
mRNA levels of Mrp4 were higher in female than in male C57BL/6 mice, but Mrp2 
and Mrp3 mRNA levels did not differ based upon gender (Maher et al., 2005).  Sex-
dependent differences in the disposition of some phase II conjugates might be 
anticipated, considering the important role of transport proteins in the biliary and 
basolateral excretion of phase II conjugates.  In addition, these sex-dependent 
differences in hepatobiliary disposition may be of potential clinical relevance, as 
some sulfate conjugates are important from a physiologic [e.g., 
dehydroepiandrosterone sulfate (DHEAS) and estrone-sulfate] or pharmacologic 
(e.g., minoxidil sulfate) standpoint. 
 The purpose of this study was to examine the influence of Bcrp and sex on 
the hepatobiliary disposition of phase II metabolites, using APAP as a model 
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substrate.  In situ single-pass liver perfusion in male and female wild-type and Bcrp-
deficient mice was utilized to examine the hepatobiliary disposition of AG and AS.  
Compartmental pharmacokinetic modeling was performed to recover relevant 
parameters governing hepatobiliary disposition of AG and AS.  In light of the 
physiologic and pharmacologic roles that some conjugates play in vivo, it is 
important to investigate the potential for significant sex-dependent differences in 
hepatobiliary disposition of sulfate and glucuronide metabolites.  
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METHODS 
Materials. APAP, AG, AS, cimetidine, taurocholate and Krebs-Henseleit buffer 
packets were purchased from Sigma-Aldrich (St. Louis, MO).  All other reagents 
were of analytical grade and were available commercially.  
Mice. Male and female C57BL/6 (wild-type) and Abcg2(-/-) (Bcrp-deficient) (created 
by Deltagen Inc., San Mateo, CA) mice (23–30 g) were a gift from Eli Lilly and 
Company.  Further information regarding background and breeding of these mice 
has been detailed previously (Nezasa et al., 2006).  All animal procedures were 
approved by The Institutional Animal Care and Use Committee at the University of 
North Carolina at Chapel Hill. 
In Situ Single-pass Liver Perfusion. The abdominal cavity of each mouse was 
opened to expose the intestines, liver, and gallbladder. The common bile duct above 
the duodenum was ligated and the gallbladder was cannulated with PE-10 tubing 
(BD Biosciences, Franklin Lakes, NJ). A loose suture was placed around the inferior 
vena cava below the liver.  The portal vein was cannulated with a 20-gauge catheter 
(B. Braun Medical, Inc., Bethlehem, PA) and the liver was perfused with oxygenated 
drug-free Krebs-Henseleit buffer containing 5 µM taurocholate at a flow rate of 5 
ml/min. The inferior vena cava below the liver was severed immediately by an 
incision below the loose suture.  Thereafter, the inferior vena cava above the liver 
was cannulated with a 20-gauge catheter.  The inferior vena cava below the liver 
was ligated to direct all perfusate outflow to the inferior vena cava above the liver.  
After a 15-min pre-perfusion period to equilibrate liver temperature and stabilize bile 
flow, the liver was perfused with buffer containing 500 nM APAP for 40 min. Liver 
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perfusion was continued for an additional 30 min after APAP infusion with drug-free 
buffer. Perfusate outflow was collected at designated time points throughout the 70-
min experiment. Bile was collected in toto at 10-min intervals.  At the end of the 
perfusion, livers were isolated and snap frozen. 
Analytical Methods. Perfusate, bile and liver homogenate samples were diluted 1:5, 
1:250 and 1:10, respectively, to obtain a final sample aliquot of 500 µl.  Samples 
were protein-precipitated by the addition of 390 µl ice-cold methanol containing the 
internal standard cimetidine.  After the removal of protein by centrifugation at 3,000g 
for 15 min at 4ºC, the supernatants were analyzed by liquid chromatography with 
detection by tandem mass spectrometry (Applied Biosystems API 4000 triple 
quadrupole with TurboIonSpray interface; Foster City, CA).  AS, AG and the internal 
standard (cimetidine) were eluted from an Aquasil C18 column (2.1 x 50 mm, dp = 5 
µm; Thermo Electron Corporation, San Jose, CA) using a mobile phase gradient (A, 
0.1% formic acid in water; B, 0.1% formic acid in methanol; 0–0.75 min hold at 5% B; 
0.75–2.5 min linear gradient to 70% B; 2.5–3.5 min hold at 70% B, 3.5–3.6 min linear 
gradient to 5% B, 3.6–4 min hold at 5% B; flow rate, 0.75 ml/min; 0.8–4 min directed 
to mass spectrometer) and were detected in negative ion mode using multiple 
reaction monitoring: AS, 230 150 m/z; AG, 326 150 m/z; cimetidine, 251 157 
m/z. Concentrations of APAP and the internal standard (cimetidine) were quantified 
using the chromatographic conditions detailed above, but were detected in positive 
ion mode using multiple reaction monitoring: acetaminophen, 152 110 m/z; 
cimetidine, 253 117 m/z. Care was taken to confirm that no in-source 
fragmentation of the conjugates back to APAP occurred.  Standard curves of each 
 56
analyte (0.5-1000 nM) were prepared in the appropriate matrices; inter- and intra-
day CVs were <15%.   
Western Blot Analysis. Mouse livers, perfused with phosphate-buffered saline 
solution, were removed promptly and frozen. Livers were homogenized with 3 
volumes of Tris-HCl solution (pH 7.4) containing complete protease inhibitor cocktail 
(Roche Diagnostics, Mannheim, Germany). The homogenates were centrifuged at 
1500×g for 10 min, and the supernatant was ultracentrifuged at 100,000×g for 30 
min. The resulting pellet was suspended in Tris-HCl solution (pH 7.4) containing 
complete protease inhibitor cocktail, 1% sodium dodecyl sulfate, and 1 mM ethylene 
diamine tetraacetic acid. The protein concentration of the solution was determined 
with the BCA protein assay reagent kit (Pierce Biotechnology, Inc., Rockford, IL). 
Bcrp expression was determined using the anti-BCRP primary monoclonal antibody 
(BXP-53; Alexis Biochemicals, Carlsbad, CA) at a 1:1000 dilution.  Anti-MRP4 (M4I-
10; Alexis Biochemicals) was used at a 1:1000 dilution to determine the expression 
of Mrp4.  Protein loading was normalized to β-actin, which was detected using a β-
actin antibody at a dilution of 1:5000 (C4; Chemicon, San Fransisco, CA).  
Immunoreactive protein bands were detected by chemilumiscence using a Bio-Rad 
VersaDoc imaging system and densitometry analysis was achieved using the 
Quantity One software package v.4.1 (Bio-Rad Laboratories, Hercules, CA).   
Pharmacokinetic Modeling. A compartmental modeling approach was utilized to 
describe the hepatobiliary disposition of APAP and metabolites in perfused livers 
from male and female wild-type and Bcrp-deficient mice, and to recover estimates of 
key pharmacokinetic parameters. AG and AS outflow perfusate and biliary excretion 
 57
rates were calculated as the product of flow (perfusate or bile) and outflow perfusate 
or biliary concentrations, respectively, during each collection period, and then were 
normalized to liver weight. Several structurally-distinct models were evaluated; 
standard model selection criteria including residual distribution and Akaike’s 
information criterion were used to identify the optimal structure. The compartmental 
model that best described the data is shown in Figure 2.1. Differential equations 
derived from the model scheme in Figure 2.1 were as follows: 
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The final model included compartments representing hepatocellular spaces for 
APAP, AG and AS.  To describe the prolonged biliary excretion of AG and AS after 
 58
APAP washout relative to basolateral excretion of AG and AS, an intervening 
compartment between the site of conjugate formation and the bile compartment was 
included in the model.  This intervening compartment was required in order to 
describe disposition of AG in all livers, and of AS in wild-type but not in Bcrp-
deficient mouse livers (AS biliary concentrations measured in Bcrp-deficient mouse 
livers were below the limit of quantitation of the assay).  Differential equations 
describing substrate flux in each compartment were fit simultaneously to the 
perfusate and biliary excretion rate data by nonlinear least-squares regression 
(WinNonlin Pro version 4.2; Pharsight, Mountain View, CA) with a weighting scheme 
of 1/(Y predicted).  The precision of parameter estimates was maximized with 
stepwise nonlinear least-squares regression.  AG perfusate and biliary excretion rate 
data from male and female wild-type and Bcrp-deficient mouse livers were used to 
estimate Kperf, AG, Kg1 and Kbile,AG, while Clup, Kperf, APAP, Kgluc and Ksulf were held 
constant at the estimated values.  Likewise, AS perfusate and biliary excretion rate 
data were used to estimate Kperf,AS, Ks1 and Kbile,AS while Clup, Kperf, APAP, Kgluc and Ksulf 
were held constant at the estimated values.  
Data Analysis. All data are expressed as mean ± SD unless otherwise indicated. 
The effects of Bcrp expression (wild-type or Bcrp-deficient) and sex (male or female) 
were assessed using a two-way analysis of variance.  Data shown in Table 2.1, 
Figure 2.3 and 2.4 were analyzed further with Bonferroni’s post-hoc test, but no 
further analysis was performed for pharmacokinetic parameter estimates shown in 
Table 2.2, as an interaction between Bcrp expression and sex was observed for one 
of the estimates in the two-way analysis of variance.  An unpaired Student’s t-test 
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was used to determine the statistical significance of differences in AS biliary 
excretion from male and female mouse livers because AS biliary excretion was 
negligible in Bcrp-deficient mice.  Differences were considered to be statistically 
significant when p < 05.  
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RESULTS 
Statistically significant differences were observed in body weights among 
male and female wild-type mice, but mouse liver weights normalized for body weight 
were comparable between wild-type and Bcrp-deficient male and female mice (Table 
2.1).  Outflow perfusate concentrations of APAP reached a plateau within 20 min of 
continuous perfusion (Figure 2.2).  The hepatic extraction ratios of APAP, calculated 
from inflow and outflow APAP perfusate concentrations between 30 and 40 min of 
perfusion, ranged from 24.8 to 35.4% among mouse groups (Table 2.1).  Since 
APAP, AG and AS concentrations in liver homogenates after the 30-min washout 
phase were negligible, total recovery (% of dose) was calculated by adding 
recovered APAP, AG and AS in outflow perfusate and bile; in all cases, total 
recovery was comparable among all mouse groups (Table 2.1). 
Biliary excretion of AG in livers from male wild-type mice was ~2.5-fold higher 
than in female wild-type mouse livers, but AG biliary excretion between male and 
female Bcrp-deficient mice was comparable (Figure 2.3A).  Relative to the 
corresponding wild-type mouse livers, biliary excretion of AG was decreased ~73% 
and ~54% in male and female Bcrp-deficient mouse livers, respectively.  Cumulative 
AG excretion in outflow perfusate from male wild-type and Bcrp-deficient livers was 
~1.6-fold higher compared to female wild-type and Bcrp-deficient livers (Figure 2.3B).   
Biliary excretion of AS in livers from male wild-type mice was ~2.2-fold higher 
than in female wild-type livers (Figure 2.4A).  In Bcrp-deficient mice, AS biliary 
recovery was negligible. AS basolateral excretion in female wild-type and Bcrp-
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deficient mouse livers was ~3.1-fold and ~2.4-fold higher, respectively, than in livers 
from their male counterparts (Figure 2.4B).  
Immunoblot analysis was performed with crude membrane fractions of liver 
homogenates from male and female wild-type and Bcrp-deficient mice to compare 
the levels of Bcrp and Mrp4 protein (Figure 2.5).  As previously reported (Tanaka et 
al., 2005), densitometry analysis revealed that hepatic Bcrp protein, normalized to 
the β-actin signal, was 3-fold higher in male wild-type mice than in female wild-type 
mice.  Interestingly, there was a trend toward increased hepatic Mrp4 protein in 
females; Mrp4 protein, normalized to β-actin signal, in female wild-type and Bcrp-
deficient mouse livers was 3.5- and 1.6-fold higher than male mouse livers from wild-
type and Bcrp-deficient mice, respectively.  
The model scheme presented in Figure 2.1 best described the current 
experimental data.  Representative fits of the model to APAP, AG and AS biliary and 
basolateral excretion rate vs. time data are shown in Figure 2.6. Pharmacokinetic 
parameter estimates obtained by resolving the differential equations representing 
biliary and basolateral excretion rate vs. time data for APAP, AG and AS are 
presented in Table 2.2.  The uptake clearance (CLup) was comparable to the 
perfusate flow rate (Q; 5 ml/min). The rate constant for APAP basolateral excretion 
(Kperf, APAP) was comparable among male and female wild-type and Bcrp-deficient 
mouse livers.  Sex-dependent differences in metabolite formation rate constants 
were observed; the rate constant for AG formation (Kgluc) was ~2-fold higher in male 
mouse livers, and the rate constant for AS formation (Ksulf) was ~2-4-fold higher in 
female mouse livers.  The basolateral excretion rate constant of AS (Kperf,AS), but not 
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AG (Kperf,AG), differed based on sex; the AS basolateral excretion rate constant was 
~2-fold higher in female vs. male mouse livers.  The AG biliary excretion rate 
constant (Kbile,AG) was higher in male than in female wild-type mouse livers (0.014 
min-1 vs. 0.002 min-1), but was similar between male and female Bcrp-deficient 
mouse livers.  The rate constant for movement of AS from hepatic compartment 1 to 
2 (Ks1) was higher in male compared to female wild-type mouse livers.  Likewise, the 
rate constant for AS biliary excretion (Kbile,AS) in male vs. female wild-type mouse 
livers was higher (0.107 min-1 vs. 0.043 min-1).   
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DISCUSSION  
 The current studies support the hypothesis that sex-dependent hepatic Bcrp 
expression influences the hepatobiliary disposition of sulfate and glucuronide 
conjugates of the model substrate APAP during in situ single-pass mouse liver 
perfusion.  Male-predominant Bcrp protein expression in wild-type mouse livers is 
consistent with ~2.5-fold higher biliary excretion of AG and AS in male compared to 
female wild-type mouse livers.  Sex-dependent differences in biliary excretion of AG 
were not observed in Bcrp-deficient mice.  Pharmacokinetic modeling revealed that 
the rate constants governing AG and AS biliary excretion were significantly higher in 
male compared with female wild-type mouse livers.  AS biliary excretion was 
negligible and AG biliary excretion rates were markedly reduced in Bcrp-deficient 
mice, consistent with recent findings demonstrating an important role of Bcrp in AG 
and AS biliary excretion in male mice (Zamek-Gliszczynski et al., 2006c).  Both Bcrp 
and Mrp2 appear to be involved in AS biliary excretion in rats (Zamek-Gliszczynski 
et al., 2005), however, AS biliary excretion was not decreased in Mrp2-deficient mice 
(Zamek-Gliszczynski et al., 2006c).  This apparent discrepancy in the mechanisms 
of AS biliary excretion may be due to species-specific differences in the affinity of 
multiple hepatic efflux proteins for AS.  
 Interestingly, sex differences were observed for basolateral excretion of AG 
and AS, with more extensive basolateral excretion of AG in male and more 
extensive AS basolateral excretion in female mouse livers (Figure 2.3B, 2.4B). One 
explanation for these findings may be that the rate constant governing AG formation 
(Kgluc) was greater in male mouse livers, whereas the rate constant for AS formation 
 64
(Ksulf) was greater in female mouse livers, suggesting sex-dependent differences in 
formation of AG and AS. Although the primary isoforms of UDP-
glucuronosyltransferases (Ugt) and sulfotransferases (Sult) responsible for AG and 
AS formation in mice remain to be elucidated, previously published data 
demonstrate male-predominant mRNA expression of Ugt1a5 and female-
predominant mRNA expression of Sult1a1 and Sult2a1/2 in mouse livers (Alnouti 
and Klaassen, 2006; Buckley and Klaassen, 2007).  In human liver microsomes, 
protein expression of UGT1A6, a major isoform responsible for AG formation, was 
50% higher in males compared to females (Court et al., 2001).  
Sex-dependent basolateral excretion of AG and AS also may be due to 
differences in the expression of transport protein(s) responsible for AG and AS 
basolateral excretion.  As previously reported, Mrp3 plays a significant role in 
basolateral excretion of AG, whereas both Mrp3 and Mrp4, as well as other 
unidentified mechanisms, may be involved in AS basolateral excretion (Xiong et al., 
2002; Manautou et al., 2005; Zamek-Gliszczynski et al., 2006b). Previous studies 
showed moderate expression of Mrp3 mRNA in mouse livers, but no differences in 
Mrp3 mRNA were noted between male and female mouse livers (Maher et al., 2005). 
In the current study, pharmacokinetic modeling revealed that the rate constants for 
AG basolateral excretion between male and female mouse livers were not different. 
Thus, greater AG basolateral excretion in male vs. female mouse livers appears to 
be due primarily to more extensive glucuronidation in male mouse livers. In contrast, 
the rate constant governing AS basolateral excretion (Kperf,AS) was significantly 
higher in female vs. male mouse livers; this finding cannot be explained by 
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increased AS formation in female mice.  Interestingly, Western blot analysis 
demonstrated greater Mrp4 protein in crude membrane fractions from female 
compared to male mouse livers, consistent with previous findings that hepatic Mrp4 
mRNA was increased in female compared to male wild-type mice (Maher et al., 
2005). This sex-dependent increase in Mrp4 protein levels, coupled with more 
extensive sulfation in female mouse livers, may explain, in part, the higher AS 
basolateral excretion in female mouse livers since Mrp4 has been implicated in the 
basolateral excretion of AS (Lickteig et al., 2007).  
The pharmacokinetic model included an intervening compartment between 
the sites of conjugate formation and excretion into bile.  This additional compartment 
was required to describe the prolonged biliary excretion of AG and AS during the 
washout phase (Figure 2.1).  Movement of AG and AS from the site of conjugate 
formation to the site of biliary excretion was best described as a unidirectional rather 
than bidirectional process, based on markedly lower coefficients of variation (CV%) 
associated with this model fit.  Similarly, pharmacokinetic modeling of the in vivo 
disposition of APAP and AG in rats has suggested the existence of a discrete 
cytosolic compartment prior to AG biliary excretion (Studenberg and Brouwer, 1993).  
In a study of hepatic intracellular distribution of several compounds, the presence of 
a cytosolic link between metabolite formation and subsequent biliary excretion also 
was proposed (Levine and Singer, 1972). Arias and coworkers demonstrated that 
newly synthesized canalicular transport proteins (e.g., P-gp) may be directly 
trafficked from the Golgi apparatus to the apical membrane, or may be stored 
transiently in intracellular compartments before apical delivery to the membrane (e.g., 
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Bsep)(Kipp et al., 2001); taurocholate or dibutyryl cAMP can stimulate trafficking of 
Bsep and P-gp.  Immunohistochemical studies clearly revealed BCRP subcellular 
localization in folate-deprived MCF cells. In contrast, intense BCRP localization was 
noted at cell-to-cell contacts in parental MCF cells cultured in medium containing 
high concentrations of folic acid (Ifergan et al., 2005).  Although subcellular 
localization of BCRP in hepatocytes remains to be elucidated, substrate binding or 
association with subcellularly-localized Bcrp protein prior to substrate biliary 
excretion may explain the observation of unidirectional flux of AG and AS (Kg1 and 
Ks1) suggested by the current pharmacokinetic model. 
In conclusion, the present study demonstrated sex-dependent hepatobiliary 
disposition of glucuronide and sulfate conjugates of APAP in mice due to differences 
in hepatic transport protein expression and conjugation.  In light of the extensive use 
of the mouse as a model species to examine hepatobiliary drug disposition and 
drug-induced liver injury, such sex-dependent differences in transport proteins and 
phase II conjugation may explain different outcomes between male and female mice 
during preclinical drug development. 
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Table 2.1. Mouse body weights, liver weights normalized to body weight, 
acetaminophen (APAP) extraction ratio and total recovery at 70 min in in situ single-
pass perfused livers from male and female wild-type and Bcrp-deficient mice.a  
 Wild-type Bcrp-deficient 
 Male Female Male Female 
Body weight (g)  28.4 ± 0.8b 25.8 ± 1.8b 25.9 ± 1.7 24.5 ± 1.7 
Liver weight/Body 
weight (%) 4.7 ± 0.2 4.8 ± 0.5 4.3 ± 0.2 4.4 ± 0.7 
Extraction ratio (%) 35.4 ± 4.8 29.6 ± 7.1 30.8 ± 6.1 24.8 ± 1.2 
Total recovery  
(% of dose) 98.4 ± 5.2 91.7 ± 8.5 93.6 ± 3.7 98.2 ± 4.8 
Livers were perfused with Krebs-Henseleit buffer containing 500 nM APAP for 40 
min followed by an additional 30-min infusion with drug-free buffer.  
a mean ± SD (n = 3-4 per group) 
b
 p < 0.05 
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Table 2.2. Mean pharmacokinetic parameter estimates governing APAP, AG and AS 
disposition in in situ single-pass perfused livers from wild-type and Bcrp-deficient 
male and female mice.a  
Parameter Wild-type Bcrp-deficient Mean estimates (CV%) 
Clup (ml/min)   
  Male 5.63 (12.1) 5.60 (13.2) 
  Female 5.79 (4.9) 5.55 (8.8) 
Kperf,APAP (min-1)    
  Male 0.468 (16.5) 0.588 (44.7) 
  Female 0.525 (31.1) 0.564 (36.3) 
Kgluc (min-1)c   
  Male 0.183 (36.9) 0.199 (17.3) 
  Female 0.121 (16.5) 0.119 (8.2) 
Ksulf (min-1)c   
  Male 0.007 (13.1) 0.009 (50.6) 
  Female 0.026 (8.8) 0.018 (44.6) 
Kperf, AG (min-1)   
  Male 0.168 (45.4) 0.247 (22.5) 
  Female 0.217 (49.3) 0.214 (77.3) 
Kg1 (min-1)   
  Male 0.044 (89.3) 0.104 (36.7) 
  Female 0.093 (49.4) 0.092 (55.3) 
Kbile, AG (min-1)b,c   
  Male 0.014 (45.4) 0.001 (66.4) 
  Female 0.002 (68.1) 0.001 (72.1) 
Kperf, AS (min-1)c   
  Male 0.379 (38.6) 0.271 (11.7) 
  Female 0.663 (17.6) 0.634 (9.6) 
Ks1 (min-1)c   
  Male 0.048 (25.3) N/A 
  Female 0.017 (39.5) N/A 
Kbile, AS (min-1)c   
  Male                      0.107 (8.0) N/A 
  Female 0.043 (72.6) N/A 
a n = 3-4 per group; N/A, not available; CV, coefficients of variation 
b
 p < 0.05, Wild-type vs. Bcrp-deficient mice 
c
 p < 0.05, Male vs. Female 
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Figure 2.1. Model scheme depicting the hepatic disposition of APAP, AG and AS in 
the single-pass perfused mouse liver. Q, flow rate; Cin, concentration of APAP in 
inflow perfusate; Cout, concentration of APAP in outflow perfusate; XAPAP, amount of 
APAP in liver compartment; XAG-1 and XAG-2, amount of AG in liver compartments 1 
and 2, respectively; XAS-1 and XAS-2, amount of AS in liver compartments 1 and 2, 
respectively; CLup, uptake clearance into the liver; Kperf,APAP, first-order rate constant 
for basolateral excretion of APAP; Kperf,AG, first-order rate constant for basolateral 
excretion of AG; Kperf,AS, first-order rate constant for basolateral excretion of AS; Kgluc 
and Ksulf, first-order rate constant for formation of AG and AS, respectively; Kg1, first-
order rate constant for movement of AG from hepatic compartment 1 to 2; Ks1, first-
order rate constant for movement of AS from hepatic compartment 1 to 2; Kbile,AG 
and Kbile,AS, first-order rate constants for biliary excretion of AG and AS, respectively.  
AS biliary excretion was lower than the limit of quantitation in Bcrp-deficient mouse 
livers. 
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Figure 2.2. APAP concentrations (nM) in outflow perfusate from male wild-type (●) 
and Bcrp-deficient (○), and female wild-type (▼) and Bcrp-deficient (∆) mouse liver 
perfusions. Livers were perfused with Krebs-Henseleit buffer containing 500 nM 
APAP for 40 min followed by an additional 30-min infusion with drug-free buffer (n = 
3-4/group).  
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Figure 2.3. Cumulative biliary excretion and basolateral excretion of AG (A and B, 
respectively; nmol/g liver) in male and female wild-type and Bcrp-deficient perfused 
mouse livers through 70 min as described in Figure 2.2 legend (n = 3-4/group; p < 
0.05).  
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Figure 2.4. Cumulative biliary excretion and basolateral excretion of AS (A and B, 
respectively; nmol/g liver) in male and female wild-type and Bcrp-deficient perfused 
mouse livers through 70 min as described in Figure 2.2 legend (n = 3-4/group; 
N.D.:not detected; p < 0.05).  
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Figure. 2.5. Representative immunoblot of Bcrp, Mrp4 and actin in crude membrane 
fractions from male and female wild-type and Bcrp-deficient mouse liver 
homogenates from three independent experiments (30 µg protein/well).  
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Wild-type Bcrp-deficient 
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Mrp4 
Actin 
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Figure. 2.6. Representative outflow perfusate rate (pmol/min/g liver) of AG (●) and 
AS (■), and biliary excretion rate (pmol/min/g liver) of AG (○) and AS (□) in male and 
female wild-type (solid symbols) and Bcrp-deficient (open symbols) mouse livers.  
Livers were perfused with Krebs-Henseleit buffer containing 500 nM APAP for 40 
min followed by an additional 30-min infusion with drug-free buffer. Curves represent 
the best fit of the model scheme depicted in Figure 2.1 to the data.  
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CHAPTER 3 
 
Hepatobiliary Disposition of Troglitazone (TGZ) and Metabolites in Rat and 
Human Sandwich-Cultured Hepatocytes: Use of Monte Carlo Simulations to 
Assess Impact of Changes in Biliary Excretion on Substrate Accumulation 
 in Cells versus Culture Medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter will be submitted to Pharmaceutical Research.  
 79
ABSTRACT 
This study examined the hepatobiliary disposition of troglitazone (TGZ) and 
its derived metabolites [TGZ sulfate (TS), TGZ glucuronide (TG), and TGZ quinone 
(TQ)] over time in rat and human sandwich-cultured hepatocytes (SCH).  To 
determine the disposition of TGZ and its metabolites generated in rat and human 
SCH, cells were incubated with 10 µM TGZ for 120 min. Rat and human SCH 
mimicked the in vivo disposition of TGZ/metabolites; TGZ was metabolized primarily 
to TS, and to a lesser extent to TG and TQ, in both human and rat SCH. In human 
SCH, the biliary excretion index (BEI) was negligible for TGZ and TQ, ~16% for TS, 
and ~43% for TG over the duration of the 120 min incubation; in rat SCH, BEI for TS 
and TG was 13% and 41%, respectively. Pharmacokinetic modeling and Monte 
Carlo simulations were employed to evaluate the impact of modulating the biliary 
excretion rate constant (Kbile) for TS or TG on metabolite accumulation in medium 
and hepatocytes. The required number of observations to discern statistically 
significant alterations in response to changes in Kbile was greater in medium than in 
hepatocytes, suggesting that cellular concentrations (analogous to tissue 
accumulation in vivo) is a more sensitive metric than medium concentrations 
(analogous to systemic concentrations in vivo). Simulations supported the 
hypothesis that altered hepatobiliary transport may not always be evident based on 
medium concentrations in rat SCH. Pharmacokinetic modeling/simulation coupled 
with data from SCH is a useful in vitro approach to predict alterations in 
drug/metabolite hepatobiliary disposition in humans.  
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INTRODUCTION 
Troglitazone (TGZ), a peroxisome proliferator-activated receptor gamma 
(PPARγ) agonist, was withdrawn from the market in 2000 due to severe idiosyncratic 
liver injury (Graham et al., 2003; Smith, 2003). Hepatotoxicity associated with TGZ 
has been classified as hepatocellular liver injury (Chan et al., 2002). Several 
mechanisms for TGZ’s hepatotoxicity have been proposed (Smith, 2003; Masubuchi, 
2006), including inhibition of the bile salt export pump (BSEP, ABCB11), the hepatic 
transport protein primarily responsible for biliary excretion of bile acids, by TGZ and 
TGZ sulfate (TS) (Funk et al., 2001a). BSEP inhibition may cause hepatic 
accumulation of detergent-like bile acids, thereby resulting in hepatocellular injury. 
Interestingly, TS is a more potent inhibitor of BSEP (IC50 = 0.4-0.6 µM) than TGZ 
(IC50 = 3.9 µM)(Funk et al., 2001a), emphasizing the importance of metabolite-
mediated hepatotoxicity, in addition to that of the parent drug.  
TGZ is metabolized extensively by the liver in humans as well as in rats; the 
in vivo metabolic profile and disposition of TGZ in rats are similar to that in humans. 
In humans, TGZ is metabolized extensively in the liver primarily to a sulfate 
conjugate mostly via sulfotransferase (SULT) 1A3 (Honma et al., 2002), and also to 
a glucuronide conjugate mostly via UDP-glucuronosyltransferase (UGT) 1A1 
(Watanabe et al., 2002; Nakagomi-Hagihara et al., 2006); TGZ also is oxidized to a 
quinone derivative by cytochrome P450 isozymes CYP3A4 and CYP2C8 (Yamazaki 
et al., 1999). After oral administration of TGZ for 7 days in humans, the area under 
the plasma concentration vs. time curve at steady state (AUCss) for TS was ~7-10-
fold higher than that of TGZ; the plasma AUCss for TQ was comparable to that of 
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TGZ, but the AUCss for TG was only 20-40% of that for TGZ (Loi et al., 1999). 
Similarly, after oral administration of [14C]TGZ to male rats, the AUC of TS 
accounted for 89% of the AUC of total plasma radioactivity, while the AUC of TGZ 
and TG was only 5% and 1% of the AUC of total plasma radioactivity, respectively 
(Kawai et al., 1997). After intravenous administration of [14C]TGZ to male rats, the 
biliary excretion of TS and TG was 61% and 2% of the dose, respectively; TGZ and 
TQ recovery in bile accounted for less than 0.1% of the dose (Kawai et al., 1997). 
Since TGZ is extensively metabolized and little parent compound is excreted 
unchanged into urine or bile (Kawai et al., 1997), the total body clearance of TGZ is 
governed by its metabolic clearance (Izumi et al., 1996). 
Sensitive and rapid in vitro screening tools to predict hepatotoxicity are 
needed in the pharmaceutical industry. Primary hepatocytes remain an important 
tool for studying the metabolism and hepatotoxic potential of xenobiotics. 
Hepatocytes cultured in a single layer of collagen are suitable for cytotoxicity assays, 
but the use of this tool is limited due to loss of metabolic activity and short survival 
periods (Hewitt et al., 2007).  Hepatocytes cultured in sandwich configuration 
between layers of extracellular matrix have overcome many of the limitations of 
conventional hepatocyte culture because the cells repolarize, regain their proper 
morphology, and maintain liver-specific metabolic activity, including stable 
expression of cytochrome P450 enzymes over longer times (Liu et al., 1998; Liu et 
al., 1999b; Liu et al., 1999d; Liu et al., 1999e; Hamilton et al., 2001; Hewitt et al., 
2007; Mingoia et al., 2007). Furthermore, sandwich-cultured hepatocytes develop 
functional networks of bile canalicular structures between cells that are sealed by 
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tight junctions (LeCluyse et al., 1994). Measurements of biliary excretion of drugs 
and metabolites in humans are often indirect or require invasive procedures, but 
cells and canalicular networks of sandwich-cultured hepatocytes are directly 
accessible, allowing the quantitation of substrates and metabolites excreted into the 
medium, retained within the cell, or excreted into the bile (Hoffmaster et al., 2004b; 
Turncliff et al., 2006).  
The present study utilized rat and human SCH to examine the metabolism of 
TGZ, governed primarily by phase II conjugation, and the hepatobiliary disposition of 
TGZ and its generated metabolites. Moreover, the ability of this in vitro system to 
estimate the in vivo disposition of TGZ and metabolites previously reported in rats 
and humans was assessed. A pharmacokinetic model was developed to estimate 
key parameters governing the hepatic metabolism and disposition of TGZ and 
metabolites in rat SCH. Monte Carlo simulations were utilized to predict the influence 
of hepatic transport modulation on the hepatobiliary disposition of TGZ and 
metabolites in a hypothetical “population” of hepatocytes.  
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MATERIALS AND METHODS 
Chemicals. Penicillin-streptomycin solution, dexamethasone (DEX), Hanks’ 
balanced salts (HBSS), HBSS modified (HBSS without Ca2+ and Mg+), collagenase 
(type IV), and Triton X-100 were purchased from Sigma-Aldrich, Inc (St. Louis, MO). 
Dulbecco’s modified Eagle’s medium (DMEM) and MEM non-essential amino acids 
were purchased from Invitrogen (Carlsbad, CA). Insulin/transferrin/selenium culture 
supplement (ITSTM), BioCoatTM culture plates and MatrigelTM extracellular matrix 
were purchased from BD Biosciences Discovery Labware (Bedford, MA). TGZ was 
purchased from Toronto Research Chemicals Inc. (Ontario, Canada). TS, TG, and 
TQ were kindly provided by Daiichi-Sankyo Co., Ltd (Tokyo, Japan). All other 
chemicals and reagents were of analytical grade and were readily available from 
commercial sources.  
Hepatocyte Culture. Male Wistar rats (220-300 g; Charles River Laboratories, Inc., 
Raleigh, NC) were maintained on a 12-hr light/dark cycle with free access to water 
and rodent chow. The Institutional Animal Care and Use Committee of the University 
of North Carolina at Chapel Hill approved all procedures. Rat hepatocytes were 
isolated using a two-step collagenase perfusion method as described previously (Liu 
et al., 1999c). Hepatocytes were plated at a density of 1.75 x 106 cells/well on 6-well 
BioCoatTM plates in Dulbecco’s modified Eagle’s medium (DMEM; 1.5 ml) containing 
5% fetal bovine serum, 10 µM insulin, 1 µM DEX, 2 mM L-glutamine, 1% MEM non-
essential amino acids, 100 units penicillin G sodium and 100 µg streptomycin sulfate. 
Hepatocytes were allowed to attach ~2 hr, and the medium was changed to remove 
unattached cells. Cells were overlaid ~24 hr later with BD MatrigelTM at a 
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concentration of 0.25 mg/ml in 2 ml/well ice-cold DMEM supplemented with 0.1 mM 
MEM non-essential amino acids, 2 mM L-glutamine, 100 units penicillin G sodium, 
100 µg streptomycin, 1% ITSTM and 0.1 µM DEX. CellzDirect (Durham, NC) kindly 
provided human hepatocytes cultured in 6-well plates, seeded at a density of 1.5 x 
106 cells/well, and overlaid with MatrigelTM. Table 3.1 shows demographics of human 
liver donors. Human cells were cultured in the same medium as rat hepatocytes. 
Both rat and human hepatocytes were cultured at 37°C i n a humidified incubator 
with 95% O2/5% CO2. Medium was changed daily until the experiments were 
conducted.  
Metabolism of TGZ and Accumulation of Parent and Metabolites in Medium, 
Cells, and Bile in Rat and Human SCH. Modulation of Ca2+ in the incubation buffer 
was used to manipulate the tight junctions sealing the canalicular networks between 
cells. In Ca2+-containing standard buffer (HBSS with 0.35 g/L sodium bicarbonate), 
tight junction integrity is preserved and substrates are excreted into the bile 
canaliculi; incubation of cells in Ca2+-free buffer (HBSS modified, with 0.35 g/L 
sodium bicarbonate and 0.38 g/L EGTA) disrupts the tight junctions, opens the 
canalicular spaces, and canalicular contents are released into the incubation 
medium (Liu et al., 1999e). Subtracting the amount of substrate accumulated in cells 
after a pre-incubation in Ca2+-free buffer from the accumulated amount in cells + bile 
after pre-incubation with Ca2+-containing buffer yields the amount of substrate 
excreted into the canalicular networks.  
To evaluate metabolism of TGZ, day-4 cells (rat; n=3 livers) and day-8 or day-10 
cells (human; n=2 livers) were incubated at 37 °C for 10, 20, 30, 60, 90, and 120 min 
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for rat SCH, and for 30, 60, and 120 min for human SCH, with 10 µM TGZ in culture 
medium. Aliquots of medium were removed at each timepoint, and samples were 
diluted with methanol (1:2 v/v). At the designated time, cells were washed twice and 
incubated at 37 °C for 5 min with HBSS with Ca 2+ (cells + bile) or without Ca2+ (cells). 
After incubation, buffer was aspirated and cells were lysed with 1 ml of 70%:30% 
(v/v) methanol:water, and sonicated for 20 sec with a sonic dismembrator (model 
100, Fisher Scientific, Pittsburgh, PA). Medium, and cells or cells + bile lysate 
samples were stored at <-70 °C until analysis.  
Transport of TGZ, and Preformed TS and TG Metabolites in Rat SCH. To 
confirm transport of TGZ and its preformed metabolites in rat SCH, media was 
aspirated from cells on culture day 4 and cells were rinsed twice and then pre-
incubated for 10 min at 37°C with 2 ml of warmed HBS S+Ca2+ buffer (cells + bile) or 
Ca2+-free HBSS buffer (cells). Medium was aspirated and cells were treated with 5 
µM TGZ, TS, or TG in 1.5 ml HBSS +Ca2+ buffer for 10 min. After incubation, the 
dosing medium was removed, cells were washed 3x with 2 ml of ice-cold HBSS 
+Ca2+ buffer. The wash buffer was aspirated, cells were lysed by adding 1 ml of 
70%:30% (v/v) methanol:water, and samples were sonicated for 20 sec with a sonic 
dismembrator (model 100, Fisher Scientific, Pittsburgh, PA). Cells and cells + bile 
lysate samples were stored at <-70°C until analysis. Tre atments were performed in 
triplicate in n=1 experiment (TGZ) or n=3 experiments (TS and TG).  
Sample Analysis. Substrate accumulation was corrected for nonspecific binding to 
the extracellular matrix by subtracting accumulation in MatrigelTM-coated BioCoatTM 
plates without cells. The BCA protein assay (Pierce Biotechnology, Inc., Rockford, 
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IL) was used to quantify total protein concentration in cell lysate samples using 
bovine serum albumin as the reference standard, and accumulation was normalized 
to protein concentration. To account for the incompatibility of the protein assay with 
methanol, the average protein concentration for standard HBSS or Ca2+-free HBSS 
incubations in a representative plate from the same liver preparation was used to 
normalize accumulation. The medium and cell or cell + bile lysate samples were 
centrifuged at 12,000×g for 2 min at 4 °C, and the su pernatant was diluted 1:6 (v/v) 
with 79%:21% (v/v) methanol:water containing an internal standard (ethyl warfarin). 
A Shimadzu solvent delivery system (Columbia, MD) and a Leap HTC Pal 
thermostated autosampler (Carrboro, NC) connected to an Applied Biosystems API 
4000 triple quadruple mass spectrometer with a TurboSpray ion source (Applied 
Biosystems, Foster City, CA) were used for analysis. Tuning, operation, integration 
and data analysis were performed in negative ionization mode using multiple 
reaction monitoring (Analyst software v.1.4.1, Applied Biosystems). Separation was 
accomplished using an Aquasil C18, 50×2.1 mm column, with a 5 µm particle size 
(ThermoElectron, San Jose, CA). Analysis required 15 µL of sample and a solvent 
flow of 0.75 mL/min. Initial gradient conditions (80% 10 mM ammonium acetate 
aqueous solution and 20% methanol) were held for 0.8 min. From 0.8 to 1.5 min, the 
mobile phase composition increased linearly to 60% methanol, and the eluent was 
directed to the mass spectrometer. From 1.5 to 4 min, the mobile phase composition 
increased linearly to 65% methanol. At 4.1 min, the methanol composition was 
increased to 90%. The flow was held at 90% methanol until 4.3 min. At 4.4 min, the 
column was equilibrated with 80% 10 mM ammonium acetate aqueous solution. The 
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total run time, including equilibration, was 5 min per injection. Eight point calibration 
curves (5-5000 nM) were constructed as composites of TGZ (440.0→397.1), TS 
(520.2→440.1), TG (616.2→440.1), and TQ (456.1→413.1) using peak area ratios 
of analyte and ethyl warfarin (320.8→160.9). All points on the curves back-
calculated to within ± 15% of the nominal value.  
 B-CLEAR® technology (Qualyst, Inc., Raleigh, NC) was used to calculate the 
biliary excretion index (BEI), which represents the percentage of accumulated 
substrate that is excreted into bile, using the following equation (Liu et al., 1999c): 
100
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Pharmacokinetic Modeling. The average rat SCH accumulation data for TGZ and 
metabolites, including TS, TG and TQ, were utilized in pharmacokinetic modeling 
analysis. Several structurally-distinct models were evaluated, and standard model 
selection criteria, including Akaike’s information criterion, residual distribution, and 
the distribution of the residual error, were used to identify the optimal structure. The 
model scheme shown in Figure 3.1 best described the disposition of TGZ and 
generated metabolites in rat SCH over 120 min in the medium (M), hepatocytes (C) 
and bile canaliculi (B). Differential equations derived from the model scheme in 
Figure 3.1 (see legend for definition of parameters) were as follows: 
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Differential equations describing the accumulation of TGZ and generated 
metabolites in medium, hepatocytes and bile canaliculi were fit simultaneously by 
nonlinear least-squares regression (WinNonlin Pro version 5.0.1; Pharsight, 
Mountain View,CA) using a weighting scheme of 1/(Y predicted).  
Monte Carlo Simulations. Parameter estimates with associated variance 
(recovered by nonlinear least-squares regression of the flux data shown above) and 
uncontrolled error (experimental or analytical error; 15%) served as input for Monte 
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Carlo simulations. To explore hepatic TS and TG disposition in response to impaired 
transport in a hypothetical “population” of hepatocytes, simulations were performed 
by modulating the rate constant for TS or TG biliary excretion. In order to estimate 
the number of observations (sample size) necessary to detect a statistically 
significant difference in TS or TG accumulation in cells or medium due to changes in 
the TS or TG biliary excretion rate constant (Kbile, TS or Kbile, TG), data from Monte 
Carlo simulations at designated time points (10, 20, 30, 60, 90 and 120 min) were 
analyzed using one-way ANOVA. Based on the effect size (the square root of the 
ratio of the between-group to within-group variance) calculated by Cohen’s f2 (Cohen, 
1988), a sample size for each time point was calculated to achieve a power of 0.80 
(p<0.05)(2008). The relative power to detect a statistically significant difference in 
medium vs. cell at each time point was calculated as a ratio of the number of 
observations (sample size) necessary to detect a statistically significant difference in 
accumulation in medium to the number of observations necessary for accumulation 
in cells. 
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RESULTS 
Hepatobiliary disposition of TGZ and generated metabolites in human SCH.  
The disposition of TGZ and the generated metabolites in the medium and 
hepatocytes at 30, 60, and 120 min is shown in Table 3.2; cumulative recovery of 
TGZ and generated metabolites (medium + hepatocytes + bile) was 109-117%. At 
120 min, TGZ in the medium accounted for 64% of the dose. TS was the 
predominant metabolite of TGZ in the medium (30% of dose) as well as hepatocytes 
(5.6% of dose) during the 120-min incubation; TG and TQ were recovered 
predominantly in the medium (3% and 2.4% of dose, respectively) with negligible 
cellular accumulation (less than 1% of dose). Accumulation of TGZ and TQ in bile 
canaliculi was negligible. The BEI values of TS (15-17 %) and TG (41-46 %) were 
comparable at 30, 60, and 120 min in human SCH (Table 3.2).  
Hepatobiliary disposition of TGZ and metabolites in rat SCH. 
 Initial experiments confirmed that TGZ and preformed metabolites of TGZ, TS 
and TG,  were taken up into rat SCH (Figure 3.2). Following a 10-min accumulation, 
average cell + bile accumulation of TGZ was only slightly greater than cellular 
accumulation (1600s. 1560 pmol/mg protein), consistent with a negligible BEI for 
TGZ of 2.3%. Average cell + bile accumulation was slightly greater than cellular 
accumulation for TS (2280 vs. 1940 pmol/mg protein) and TG (908 vs. 605 pmol/mg 
protein), consistent with more extensive BEI values of 15% and 34% for TS and TG, 
respectively.  
The disposition of TGZ and its generated metabolites in medium, hepatocytes, 
and bile are plotted in Figure 3.3, 3.4, and 3.5, respectively. Cumulative recovery of 
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TGZ and its metabolites from medium, hepatocytes and bile was comparable 
throughout the 120-min incubation period (90-104%) (Table 3.3). At 120 min, 35% of 
the dose remained in the medium as TGZ (Table 3.3). Among metabolites present in 
the medium, TS was predominant (38% of dose), followed by TG (7% of dose) and 
TQ (1% of dose) at 120 min. Figure 3.4. depicts the hepatocyte accumulation of TGZ 
and its generated metabolites over the 120-min incubation period. TS formation was 
rapid and extensive; cellular accumulation of TS exceeded TGZ even at 10 min 
(5.4% vs. 1.5% of the dose, respectively; Table 3.3). The cellular accumulation of 
TG was <0.4% of the dose over the 120-min incubation. TQ in the hepatocytes was 
negligible. The average BEI of TS and TG was 13% and 41% over the 120-min 
incubation time; accumulation of TGZ and TQ in bile was negligible (Figure 3.5; 
Table 3.3).  
Pharmacokinetic modeling of the hepatobiliary disposition of TGZ and its 
generated metabolites in rat SCH.  
Because data were collected at more time points in rat SCH, a compartmental 
pharmacokinetic model was developed using data from rat SCH. The model scheme 
depicted in Figure 3.1 best described the disposition of TGZ, TS, TG and TQ in rat 
SCH during the 120-min incubation. Representative descriptions of the best fit of the 
pharmacokinetic model to the TGZ/generated metabolite vs. time data are shown in 
Figures 3.3-3.5. Pharmacokinetic parameter estimates obtained by resolving the 
differential equations describing hepatocellular disposition of TGZ, TS, TG and TQ 
vs. time data are included in Table 3.4. The first-order rate constant for TS formation 
(0.382 min-1)
 
was ~6-fold greater than that for TG formation (0.061 min-1). The 
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pharmacokinetic model incorporated a formation process for TQ from TGZ in the 
incubation medium, instead of cellular TQ formation, because accumulation of TQ in 
hepatocytes was negligible while TQ in the medium represented ~1% of the dose at 
120 min. In order to explain the decreased accumulation of TS and TG in bile 
canaliculi after 20 min, first-order rate constants for TS and TG flux from the bile 
canaliculi to the incubation medium were incorporated into the pharmacokinetic 
model. Consistent with data from the uptake study with preformed TGZ metabolites, 
TS and TG (Figure 3.2), the first-order rate constant for TS uptake (Kuptake, TS; 0.005 
min-1)
 
was greater than for the TG uptake rate constant (Kuptake, TG; 0.001 min-1). The 
first-order rate constant for biliary excretion of TG (0.061 min-1) was ~3-fold higher 
for TS (0.023 min-1). The first-order rate constant for basolateral efflux of TG (0.160 
min-1) was ~5-fold greater than for TS (0.031 min-1). 
Monte Carlo simulations  
Monte Carlo simulations were performed to assess the impact of modulation 
of the first-order rate constant for biliary excretion of TS (Kbile, TS) and TG (Kbile, TG) on 
the hepatobiliary disposition of TS and TG, respectively (Figure 3.6). Overall, 
measurements of cellular accumulation were more sensitive to changes in kinetic 
parameters than were measurements of substrate concentrations in medium. 
Cellular accumulation measurements were 1.4- to 270-times more sensitive than 
medium accumulation measurements for TG; cellular accumulation measurements 
were 2.2- to 10.2-times more sensitive than medium accumulation measurements 
for TS (Table 3.5).  
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DISCUSSION 
The present study examined the hepatobiliary disposition of TGZ and its 
metabolites in the SCH system; results confirmed that functional activity of phase II 
conjugation enzymes is preserved in rat and human SCH. In addition, 
pharmacokinetic modeling and simulation studies were employed to examine the 
impact of impaired biliary excretion on hepatobiliary disposition of TS and TG in rat 
SCH.  
In human SCH, TS was most abundant, and TQ was more abundant than TG, 
in the medium at 30 min; amounts of both TQ and TG were similar at 60 and 120 
min in the medium. Amounts of TQ and TG in cells were also similar at all time 
points, but no TGZ and TQ was found in the bile at any time. Kostrubsky and 
colleagues treated conventionally-cultured human hepatocytes with 10 µM TGZ; at 1 
hour, concentrations of TS and TQ were the highest in medium (depending on 
donor), followed by parent TGZ, and TG (Kostrubsky et al., 2000). Our data show 
that in human SCH at 1 hour, unconjugated TGZ is most abundant in the medium 
(88.84% of dose), followed by TS (13.37% of dose), TQ (2.23% of dose), and lastly 
TG (1.56% of dose). 
Transport of TGZ and its preformed metabolites was confirmed in rat SCH. 
While TGZ, TS, and TG were taken up into rat hepatocytes, it appears that TS was 
taken up into cells more efficiently compared to TGZ even though TS is more 
hydrophilic than TGZ. These data are consistent with the observation that TS is a 
higher affinity substrate than TGZ or TG for the uptake transporter OATP1B1, 
(Nozawa et al., 2004b). Further experiments revealed that in rat SCH, TS was the 
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major metabolite found in the medium, cells, and bile at all timepoints. TG was the 
next most abundant metabolite found in the medium and bile at all time points, while 
TQ was only detected in lesser amounts in the medium, but not in cells or bile. This 
observation may be explained by photooxidation of TGZ to TQ; thus, subsequent 
pharmacokinetic modeling incorporated conversion of TGZ to TQ in medium (Fu et 
al., 1996).  
Additionally, in rat and human SCH, TS and TG were transported into the bile 
canaliculi, while transport of TGZ into the bile canaliculi was negligible. These 
findings in SCH are consistent with published in vivo reports showing that little 
parent TGZ is recovered in rat bile, while TS  and TG (68.0% and 11.6% of dose, 
respectively, after oral dosing of TGZ) are excreted into bile in rats (Izumi et al., 
1996; Kawai et al., 1997). These medium and biliary excretion profiles resembled 
the plasma profiles (TS > TG) and biliary excretion (TS > TG), respectively, after oral 
dosing of TGZ to rats in vivo (Izumi et al., 1997; Kawai et al., 1997). The greater 
amount of TS compared to TG in rat SCH, and the greater value of Kf, TS compared 
to Kf,TG correspond to data by Izumi et al. showing that the sulfate formation 
clearance was 6-fold higher than glucuronide formation clearance in rats (Izumi et al., 
1997).  
 The accumulation of TS and TG in bile remained constant or decreased 
during the incubation time after 20 min in both human and rat SCH (Table 3.2 and 
Table 3.3). To account for this decrease, the pharmacokinetic model incorporated a 
rate constant for flux of TS and TG from the bile into the medium (Figure 3.1). The 
flux of other compounds from bile into the medium of SCH has been noted 
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previously. The first-order rate constant for flux of taurocholate (TC) and [D-
penicillamine2,5] enkephalin (DPDPE) from bile was reported to be 0.85 min-1 (Liu et 
al., 1999e) and 1.6 min-1 (Hoffmaster et al., 2005), respectively, but only 0.05 min-1 
for 5 (and 6)-carboxy-2',7'-dichlorofluorescein (CDF) [Abe, unpublished data]. The 
greater rate constant for flux of TC and DPDPE compared to CDF, TS (0.17 min-1; 
Table 3.4) and TG (0.094 min-1; Table 3.4) may be attributed to different culture 
conditions: 2×106cells/60-mm dish overlaid with rat tail type 1 collagen for studies 
conducted with TC and DPDPE vs. 1.75×106 cells/6-well plates overlaid with 
MatrigelTM for studies conducted with CDF and TGZ.  
The accumulation of TS and TG in the medium in rat SCH (38% and 7% of 
the dose, respectively) was comparable to values obtained in human SCH (30% and 
3% of the dose, respectively). Transport proteins responsible for the basolateral 
excretion of TS and TG remain to be identified. It has been documented previously 
that Mrp3 plays a predominant role in the basolateral excretion of glucuronide 
conjugates, while both Mrp3 and Mrp4 are involved in the basolateral excretion of 
sulfate conjugates along with additional yet-to-be-identified mechanism(s) (Zamek-
Gliszczynski et al., 2006b). Pharmacokinetic modeling revealed a ~5-fold higher first-
order rate constant for TG than for TS basolateral efflux. This observation may 
reflect more efficient basolateral efflux of TG, presumably by Mrp3; Mrp3 expression 
was increased over time in culture in rat SCH (unpublished observation). 
Monte Carlo simulations revealed that cellular accumulation is a more 
sensitive measure of changes in the rate constant for biliary excretion of TS or TG 
(Kbile,TS or Kbile,TG) than medium accumulation. In practice, the number of 
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observations necessary to observe a statistically significant difference in the medium 
was too high (19-7271 for TG; 13-144 for TS), while the number of observations 
necessary to observe a statistically significant difference in hepatocytes was more 
reasonable (14-27 for TG; 4-27 for TS) (Table 3.5). SCH data coupled with modeling 
and simulation are capable of estimating the impact of altered transport function on 
hepatic (reflected in hepatocyte accumulation) and systemic (reflected in medium 
accumulation) exposure. Peak plasma concentrations or AUCplasma often have been 
used to examine the effect of modulation of canalicular transport proteins on drug 
disposition, but results of this simulation suggest that those parameters may not 
always reflect changes in hepatic exposure due to modulation of biliary excretory 
pathways. Physiologically-based pharmacokinetic modeling of pravastatin 
distribution also suggested that plasma concentrations are not sensitive enough to 
detect changes in canalicular efflux; altered canalicular efflux of pravastatin changed 
liver concentrations markedly, but had minimal effect on plasma concentrations 
(Watanabe et al., 2009).  
 The failure of preclinical testing to predict the hepatotoxicity of TGZ 
emphasizes the importance of understanding the metabolism and hepatobiliary 
disposition of drugs in development, in both humans and in species commonly used 
for animal testing. One of the most efficient ways to study species differences in 
metabolism and hepatobiliary disposition is with the use of in vitro models. In vitro 
models are also an important tool for the prediction of the pharmacokinetics and 
pharmacodynamics of drugs in humans. One benefit of using sandwich-cultured 
hepatocytes is that concentrations of parent drug and metabolites in medium can be 
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measured, in addition to discriminating between accumulation within hepatocytes 
and bile. Efflux into medium may be analogous to efflux from the hepatocytes into 
plasma in vivo, while efflux into the bile may approximates biliary excretion in vivo. 
Because data in humans regarding intracellular concentrations in the liver of TGZ 
and its metabolites is lacking, as is data about efflux of parent or metabolites into 
bile, the sandwich-cultured model may be a useful in vitro tool to predict human in 
vivo hepatobiliary disposition. Herein we have shown that the sandwich-cultured 
hepatocyte model can be used to elucidate the hepatobiliary disposition of TGZ and 
metabolites in both humans and rats. 
In conclusion, phase II metabolites of TGZ were detected in both rat and 
human SCH, indicating the preservation of functional activity of sulfotransferase and 
UDP-glucuronosyltransferase in the SCH system. The remarkable similarity in TGZ 
metabolism and hepatobiliary disposition between rats and humans in vivo also was 
observed in rat and human SCH, respectively, suggesting that the SCH model is a 
useful in vitro tool to predict in vivo hepatobiliary disposition in rats and humans. 
Pharmacokinetic modeling and simulation, coupled with data obtained from the SCH 
model, may be used as an in vitro approach to determine likely alterations in 
drug/metabolite hepatobiliary disposition in humans.  
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Table 3.1. Demographics of human liver donors  
Donor Age Gender Ethnicity Co-medications 
1 36 Female Caucasian Oral contraceptive, HCTZ 
2 64 Female Caucasian 
Atorvastatin, Amlodipine, 
Benazepril, Alendronate 
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Table 3.2. Disposition of TGZ and generated metabolites in human SCH 
TGZ, TS, TG and TQ (expressed as % of dose) in medium, cells and bile at 30, 60 
and 120 min after incubation in medium initially containing 10 µM TGZ.  BEI of TS 
and TG was calculated as described in Materials and Methods Data represent mean 
of a single determination in n=2 livers (N.D, not-detectable). 
  TGZ TS 
Time Medium Cells Bile Medium Cells Bile BEI 
(min) (% of dose) (% of dose) (%) 
30 93.94 3.5 N.D 3.69 6.27 1.29 17 
60 88.84 2.8 N.D 13.37 6.61 1.22 17 
120 64.24 2.04 N.D 30.29 5.64 0.99 15 
  TQ TG 
Time Medium Cells Bile Medium Cells Bile BEI 
(min) (% of dose) (% of dose) (%) 
30 2.28 0.07 N.D 0.63 0.06 0.05 46 
60 2.23 0.07 N.D 1.56 0.06 0.04 41 
120 2.41 0.07 N.D 2.98 0.05 0.04 43 
Time Recovery       
(min) (%)       
30 112       
60 117       
120 109       
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Table 3.3. Disposition of TGZ and its generated metabolites in rat SCH 
TGZ, TS, TG and TQ (expressed as % of dose) in medium, cells and bile at 10, 20, 
30, 60, 90 and 120 min after incubation in medium initially containing 10 µM TGZ.  
BEI
 
of TS and TG was calculated as described in Materials and Methods after 
incubation of TGZ (10 µM) in rat SCH. Data represent mean ± S.E.M (n=3 livers; 
N.D, non-detectable).  
  TGZ TS 
Time Medium Cells Bile Medium Cells  Bile BEI 
(min) (% of dose) (% of dose) (%) 
10 94.28 ± 9.29 1.50 ± 0.31 N.D 0.48 ± 0.06 5.46 ± 0.72 0.92 ± 0.47 12 ± 6 
20 86.38 ± 3.42 1.97 ± 0.21 N.D 2.97 ± 0.58 7.15 ± 1.50 1.56 ± 0.15 19 ± 2 
30 81.10 ± 3.68 1.57 ± 0.06 N.D 6.14 ± 0.57 7.92 ± 2.17 1.35 ± 0.26 17 ± 5 
60 63.55 ± 4.98 1.38 ± 0.45 N.D 18.61 ± 2.02 9.20 ± 1.73 1.16 ± 0.45 12 ± 4 
90 46.90 ± 3.07 0.73 ± 0.24 N.D 29.93 ± 2.64 8.64 ± 1.74 1.27 ± 0.34 14 ± 4 
120 35.30 ± 2.87 0.30 ± 0.13 N.D 37.80 ± 2.70 7.88 ± 1.67 0.75 ± 0.13 10 ± 4 
  TQ TG 
Time Medium Cells  Bile Medium Cells  Bile BEI 
(min) (% of dose) (% of dose) (%) 
10 1.00 ± 0.07 N.D N.D 0.19 ± 0.02 0.39 ± 0.01 0.19 ± 0.02 33 ± 2 
20 1.36 ± 0.23 N.D N.D 1.18 ± 0.10 0.51 ± 0.02 0.33 ± 0.01 40 ± 1 
30 1.27 ± 0.09 N.D N.D 2.41 ± 0.16 0.43 ± 0.04 0.33 ± 0.07 42 ± 5 
60 1.01 ± 0.13 N.D N.D 3.86 ± 0.78 0.31 ± 0.04 0.24 ± 0.03 44 ± 4 
90 0.85 ± 0.13 N.D N.D 5.87 ± 1.15 0.24 ± 0.01 0.17 ± 0.09 37 ± 15 
120 0.65 ± 0.14 N.D N.D 6.89 ± 1.47 0.16 ± 0.02 0.13 ± 0.03 45 ± 10 
Time Recovery       
(min) (%)       
10 104       
20 103       
30 103       
60 99       
90 95       
120 90       
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Table 3.4. Kinetic parameters (min-1) estimated from compartmental 
pharmacokinetic modeling analysis  
TGZ (10 µM) was incubated in day 4 rat SCH as described under Materials and 
Methods. Parameter estimates were generated by nonlinear regression of the mean 
TGZ, TS, TG and TQ data in the medium, hepatocytes and bile based on the 
equations described in Materials and Methods according to the model scheme 
depicted in Figure 3.1.  
Parameters Estimates (min-1) CV% 
Kuptake, TGZ 0.007 2 
Kuptake, TS 0.005 39 
Kuptake, TG 0.001 384 
Kf, TS 0.382 11 
Kf, TG 0.061 12 
Kf, TQ 0.001 19 
Kother 0.064 25 
Kefflux, TS 0.031 15 
Kefflux, TG 0.16 29 
Kbile, TS 0.023 17 
Kbile, TG 0.061 44 
Kflux, TS 0.17 22 
Kflux, TG 0.094 55 
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Table 3.5. Evaluation of the sensitivity of cell and medium accumulation to detect 
changes in biliary excretion of TS or TG utilizing data from Monte Carlo simulations.  
Monte Carlo simulations were performed by modulating the rate constant for biliary 
excretion of TS or TG by 3 different scenarios [experimentally-determined parameter 
estimates; 2-fold increase; 2-fold decrease]. The relative power to detect a 
statistically significant difference in medium vs. cell was calculated as the ratio of the 
number of observations (sample size) necessary to detect a statistically significant 
difference in TS or TG accumulation in medium to the number of observations 
necessary for accumulation in hepatocytes.  
  Time 
Number of Observations to 
Detect a Statistically 
Significant Difference 
Relative 
Power 
  (min) (Ncell) (Nmedium) (NMedium/NCell) 
TG 
10 20 47 2.4 
20 14 19 1.4 
30 14 108 7.7 
60 15 662 44.1 
90 15 1265 84.3 
120 27 7271 269.3 
TS 
10 27 144 5.3 
20 9 28 3.1 
30 6 13 2.2 
60 4 18 4.5 
90 4 33 8.3 
120 5 51 10.2 
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Figure 3.1. Model scheme depicting the mass (X) of TGZ, TGZ sulfate (TS), TGZ 
glucuronide (TG), and TGZ quinone (TQ) in the medium (M), hepatocytes (C), and 
bile (B) of rat SCH. Kuptake, Kefflux and  Kbile represent first-order rate constants for 
uptake, basolateral efflux and biliary excretion, respectively. Kf, TS, Kf, TG and Kf, TQ 
represent first-order rate constants for formation of TS, TG and TQ, respectively; 
Kflux, TS and Kflux, TG represent first-order rate constant for flux of TS and TG from the 
bile canaliculi into the incubation medium, respectively. Dotted line represents flux 
from bile canaliculi to medium that occurs during incubation after the 20-min 
timepoint.  
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Figure 3.2. Accumulation of TGZ, TS, and TG in rat SCH.  Rat SCH were treated for 
10 min with 5 µM TGZ, TS, or TG and accumulation (pmol/mg protein) was 
measured in cells + bile (solid bars) and in cells (open bars). Values represent the 
mean of triplicate determinations from n=1 experiment (TGZ) or mean ± SEM of 
triplicate determinations in n=3 experiments (TS and TG).  
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Figure 3.3. Mass vs. time profiles of TGZ (●), TS (○), TG (▼) and TQ (∆) in the 
medium initially containing 10 µM TGZ in day 4 rat SCH (Mean ± S.E.M.; n=3 livers 
in triplicate). Dashed lines represent the best fit of the pharmacokinetic model 
derived from the scheme depicted in Figure 3.1 to the data. 
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Figure 3.4. Mass vs. time profiles of TGZ (●), TS (○) and TG (▼) in the hepatocytes 
in day 4 rat SCH; incubation medium initially contained 10 µM TGZ (Mean ± S.E.M.; 
n=3 livers in triplicate). Dashed lines represent the best fit of the pharmacokinetic 
model derived from the scheme depicted in Figure 3.1 to the data. 
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Figure 3.5. Mass vs. time profiles of TS (○) and TG (▼) in the bile canaliculi of day 4 
rat SCH; incubation medium initially contained 10 µM TGZ (Mean ± S.E.M.; n=3 
livers in triplicate). Dashed lines represent the best fit of the pharmacokinetic model 
derived from the scheme depicted in Figure 3.1 to the data. 
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Figure 3.6. Monte Carlo simulations were performed to examine the impact of 
modulation of TS or TG biliary excretion on the disposition of TS or TG in 
hepatocytes (A and C, respectively) and medium (B and D, respectively). The rate 
constant for biliary excretion of TS (Kbile,TS) or TG (Kbile,TG) was modulated by 5 
different scenarios [experimentally-determined parameter estimates (black); 2-fold 
increase
 
(red); 10-fold increase (green); 2-fold decrease (yellow); 10-fold decrease 
(blue)]. 
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CHAPTER 4 
 
Modulation of Trabectedin (ET-743) Hepatobiliary Disposition by Multidrug 
Resistance-Associated Proteins (Mrps) May Prevent Hepatotoxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter has been published in Toxicology and Applied Pharmacology 
(228(1):17-23, 2008) and is presented in the style of that journal. 
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ABSTRACT 
Trabectedin is a promising anticancer agent, but dose-limiting hepatotoxicity 
was observed during phase I/II clinical trials. Dexamethasone (DEX) has been 
shown to significantly reduce trabectedin-mediated hepatotoxicity. The current study 
was designed to assess the capability of sandwich-cultured primary rat hepatocytes 
(SCRH) to predict the hepato-protective effect of DEX against trabectedin-mediated 
cytotoxicity. The role of multidrug resistance-associated protein 2 (Mrp2; Abcc2) in 
trabectedin hepatic disposition also was examined. In SCRH from wild-type Wistar 
rats, cytotoxicity was observed after 24-hr continuous exposure to trabectedin.  
SCRH pretreated with additional DEX (1 µM) exhibited a 2-3-fold decrease in toxicity 
at 100 nM and 1000 nM trabectedin. Unexpectedly, toxicity in SCRH from Mrp2-
deficient (TR-) compared to wild-type Wistar rats was markedly reduced. Depletion of 
glutathione from SCRH using buthionine sulfoximine (BSO) mitigated trabectedin 
toxicity associated with 100 nM and 1000 nM trabectedin. Western blot analysis 
demonstrated increased levels of CYP3A1/2 and Mrp2 in SCRH pretreated with 
DEX; interestingly, Mrp4 expression was increased in SCRH after BSO exposure.  
Trabectedin biliary recovery in isolated perfused livers from TR- rats was decreased 
by ~75% compared to wild-type livers. In conclusion, SCRH represent a useful in 
vitro model to predict the hepatotoxicity of trabectedin observed in vivo. The 
protection by DEX against trabectedin-mediated cytotoxicity may be attributed, in 
part, to enhanced Mrp2 biliary excretion and increased metabolism by CYP3A1/2.  
Decreased trabectedin toxicity in SCRH from TR- rats, and in SCRH pretreated with 
BSO, may be due to increased basolateral excretion of trabectedin by Mrp3 and/or 
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Mrp4. 
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INTRODUCTION 
Trabectedin (Ecteinascidin 743, YondelisTM) is a DNA alkylating agent 
extracted from the marine tunicate Ecteinascidia turbinate that exhibits potent 
antineoplastic activity against a variety of tumor cells at nanomolar concentrations 
(Izbicka et al., 1998).  Trabectedin is currently under phase II/III evaluation in 
advanced gastrointestinal stromal tumors, pretreated soft tissue sarcoma, ovarian 
cancer and breast cancer (Laverdiere et al., 2003; Robey et al., 2004; Yovine et al., 
2004; Zelek et al., 2006).   
Trabectedin is metabolized primarily by CYP 3A4; 2C9, 2C19, 2D6 and 2E1, 
and to a lesser extent conjugated by the phase II enzymes uridine 
diphosphoglucuronosyl transferase (UGT) and glutathione-S-transferase (GST)  
(Allen et al., 2002; Brandon et al., 2006).  Extensive metabolism of trabectedin was 
demonstrated in a mass balance study conducted in patients with advanced cancer 
(Beumer et al., 2007b).  Following i.v. [14C]trabectedin administration to patients, 
~55.5% and ~5.9% of the dose was recovered in feces and urine, respectively, 
suggesting that trabectedin and its metabolites undergo biliary excretion (Beumer et 
al., 2005a).  However, the involvement of transport proteins in hepatobiliary 
disposition of trabectedin remains to be elucidated. 
During phase I/II clinical trials, the most prevalent adverse effect associated 
with trabectedin treatment was dose-limiting hepatotoxicity secondary to increases 
in blood alkaline phosphatase and/or bilirubin levels (Delaloge et al., 2001; 
Taamma et al., 2001; Lee et al., 2005a).  An in vitro cytotoxicity study using HepG2 
cells showed increased trabectedin-mediated toxicity after 1-hr preincubation with 
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inhibitors of cytochrome P450 (CYP) enzymes involved in trabectedin metabolism; 
CYP inducers and phase II enzyme inhibitors did not significantly affect 
trabectedin-mediated toxicity, suggesting that trabectedin metabolites may be less 
toxic compared to the parent compound (Brandon et al., 2005).  Pretreatment of 
female Fisher rats with DEX has been shown to ameliorate the hepatotoxic effects 
of trabectedin while coadministration of DEX with trabectedin did not reduce 
toxicity (Donald et al., 2003).  Consistent with the protective effect of DEX on 
trabectedin-mediated toxicity in rats, DEX premedication markedly reduced 
trabectedin-mediated hepatotoxicity in patients with advanced sarcoma (Grosso et 
al., 2006).  However, this hepato-protective effect of DEX could not be mimicked in 
vitro using primary rat hepatocytes cultured on a fibronectin matrix (Donald et al., 
2004).  
Significant induction of Mrp2 mRNA and protein by DEX treatment has been 
reported in primary rat and mouse hepatocytes (Kast et al., 2002; Luttringer et al., 
2002; Turncliff et al., 2004).  Mrp2, a transport protein localized on the hepatic 
canalicular plasma membrane, is responsible for the biliary excretion of organic 
anions as well as numerous drugs including pravastatin, vincristine and etoposide 
(Cui et al., 1999; Kawabe et al., 1999; Konig et al., 1999a; Sasaki et al., 2002).  
Animals with hereditary conjugated hyperbilirubinemia [Mrp2-deficient rats (TR-) 
and Eisai hyperbilirubinemic rats (EHBR)] have been used extensively to examine 
the substrate specificity and in vivo function of Mrp2 (Westley et al., 2006; Zamek-
Gliszczynski et al., 2006a).  Patients with Dubin-Johnson syndrome lack MRP2 
and hence suffer from hereditary conjugated hyperbilirubinemia (Paulusma et al., 
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1997).  In the absence of Mrp2/MRP2, rats and humans exhibit increased 
expression of basolateral Mrp3/MRP3 as a compensatory mechanism that enables 
the excretion of Mrp2/MRP2 substrates into the systemic circulation, thus avoiding 
excessive accumulation of organic anions in the hepatocyte (Kiuchi et al., 1998; 
Hirohashi et al., 1999; Johnson et al., 2006; Nies and Keppler, 2007).  
Drug-induced liver injury has emerged as the most common reason for the 
withdrawal of Food and Drug Administration-approved drugs from the market 
(Abboud and Kaplowitz, 2007; FDA, 2007).  Covalent adduct formation, 
immunotoxicity, and disruption of cellular bioenergetics have been considered 
previously as mechanisms underlying hepatotoxicity, but more recent data suggest 
that hepatic transport proteins may be an important site of toxic interactions 
(Fattinger et al., 2001; Funk et al., 2001a; Leslie et al., 2007).  The objective of this 
study was to evaluate the capability of sandwich-cultured primary rat hepatocytes 
(SCRH), which more closely mimic the metabolic and transport capabilities of the 
intact liver, to predict the hepato-protective effect of DEX against trabectedin-
mediated hepatotoxicity.  An additional objective was to examine the role of Mrp2 in 
trabectedin hepatobiliary disposition.  
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MATERIALS AND METHODS 
Materials. Trabectedin (Ecteinascidin 743, YondelisTM, NSC 648766) was supplied 
by the National Cancer Institute, Developmental Therapeutics Program Repository 
(http://dtp.nci.nih.gov/branches/dscb/repo_open.html) and was prepared as a 10 mM 
stock solution in DMSO.  DEX and BSO were purchased from Sigma Chemical Co. 
(St. Louis, MO).  Dulbecco’s modified Eagle’s medium (DMEM), human recombinant 
insulin, modified essential media non-essential amino acids, L-glutamine, penicillin 
and streptomycin were purchased from GIBCO (Invitrogen Corporation, Grand 
Island, NY).  ITS+ (insulin, transferin, and selenium) was purchased from BD 
Biosciences (Bedford, MA).  
Animals. Male wild-type Wistar rats (220-300 g; Charles River Laboratories, Raleigh, 
NC) and male TR- Wistar rats (220-300 g; in-house breeding colony originally 
obtained from Dr. Mary Vore, University of Kentucky, Lexington, KY) were used for 
hepatocyte isolation and as liver donors for isolated perfused liver experiments. Male 
wild-type Wistar rats (>400 g) were used as blood donors for isolated perfused liver 
experiments.  Rats were anesthetized with ketamine/xylazine (60/12 mg/kg 
intraperitoneally) before surgical manipulation. The Institutional Animal Care and 
Use Committee of the University of North Carolina at Chapel Hill approved all 
procedures. 
Hepatocyte Isolation and Culture. Hepatocytes were isolated from male Wistar or 
TR- rats (220-300 g) by a modification of the two-step collagenase digestion method 
as described previously (Liu et al., 1998).  Hepatocyte viability was >85% as 
determined by trypan blue exclusion.  Hepatocytes were plated at a density of 
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~1.5×106 cells/well in 6-well plates coated with 0.1 ml of rat tail collagen Type I 
solution (1.5 mg/ml, pH 7.4) in 1.5 ml of plating medium (phenol red-free DMEM 
containing 5% fetal bovine serum, 0.1 mM MEM nonessential amino acids, 2 mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 4 µg/ml human recombinant 
insulin and 1 µM DEX), and allowed to attach for 2-3 hr at 37 ˚C in a humidified 
incubator with 95%O2/5%CO2.  After attachment, medium was replaced to remove 
dead/unattached cells.  To achieve a sandwich configuration, medium was aspirated 
and cells were overlaid with 0.1 ml of rat tail collagen Type I solution (1.5 mg/ml, pH 
7.4) at 24 hr (day 1).  Collagen was allowed to gel for 1 hr in a 37 ˚C humidified 
incubator 95%O2/5% CO2, and then culture medium was added (1.5 ml/well; phenol 
red-free DMEM supplemented with 0.1 mM MEM nonessential amino acids, 2 mM L-
glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.1% ITS+ and 0.1 µM DEX).  
Subsequently, the culture medium was changed daily until the conduct of 
experiments.   
DEX and BSO Pretreatment in SCRH. From day 2 to day4, additional DEX (1 µM) 
or BSO (500 µM) was added to the culture medium containing 0.1 µM DEX.  On day 
3, SCRH were incubated for 24 hr in culture medium containing a range of 
trabectedin concentrations (1-1000 nM) to compare trabectedin-mediated 
cytotoxicity between SCRH pretreated with vehicle (0.1 µM DEX) and additional 
DEX (1 µM) or BSO (500 µM).  DEX and trabectedin were prepared in DMSO, and 
BSO was solubilized in water.  Stock solutions were diluted in culture medium for 
treatment.  The final concentration of DMSO was <0.2% and had no effect on 
untreated controls.    
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Determination of Cell Viability Using LDH Release. LDH leakage into the culture 
medium was measured at the end of the 24 hr exposure using the Cytotoxicity 
Detection kit (Roche, Indianapolis, IN) according to the manufacturer’s instructions.  
The degree of LDH release was expressed as a percentage of the maximum cellular 
LDH release, which was measured by adding 2% Triton X-100 to SCRH. 
blank100-X Triton
blanksample
LDHLDH
LDHLDH
control) of (%ty Cytotoxici
−
−
=  
Western Blot Analysis of Mrp2, 3, 4 and CYP3A1/2 Proteins. On day 4, the 
medium was removed and cells were washed twice with ice-cold phosphate-buffered 
saline (PBS).  Subsequently, cells were lysed with 400 µl of lysis buffer [1 mM EDTA, 
1% sodium dodecyl sulfate (SDS), pH 8, with Complete protease inhibitor cocktail 
tablets (Roche Diagnostics, Mannheim, Germany)] in each well of a 6-well plate.  
Lysates were stored at -20 ˚C until western blot analysis.  The whole cell lysates 
were thawed on ice and protein concentrations were determined using the BCA 
protein assay (Pierce, Rockford, IL).  Protein samples (25 µg/well) were separated 
by SDS-polyacrylamide gel electrophoresis, and electrotransferred to polyvinylidene 
difluoride (PVDF) membranes (Millipore, Billerica, MA).  Blots were blocked with Tris-
buffered saline with 0.1% Tween 20 (TBS-T) containing 5% nonfat dry milk for 1 hr at 
room temperature.  Subsequently, the membrane was incubated with appropriate 
primary antibodies for 2 hr at room temperature or over-night at 4 ˚C and then rinsed 
three times at 10-min intervals with TBS-T.  Mrp2, 3 and 4 were detected using 
monoclonal antibodies M2III-6, M3II-9 and M4I-10, respectively, at a 1:1000 dilution 
(Alexis Biochemicals, San Diego, CA).  CYP3A1/2 protein expression was 
determined with a polyclonal antibody against rat CYP3A1/2 at a 1:1500 dilution 
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(Xenotech, Kansas City, KS).  Protein loading was normalized to β-actin expression 
using a β-actin antibody at a dilution of 1:5000 (C4; Chemicon, San Fransisco, CA).  
Immunoreactive protein bands were detected by chemilumiscence using a Bio-Rad 
VersaDoc imaging system and densitometry analysis was achieved using the 
Quantity One software package v.4.1 (Bio-Rad Laboratories, Hercules, CA).  
Isolated Perfused Liver Study. Recirculating isolated perfused liver (IPL) studies 
were performed with male Wistar wild-type and TR- rat livers as described previously 
(Brouwer and Thurman, 1996).  Briefly, livers were perfused in situ with oxygenated 
Krebs-Henseleit bicarbonate buffer (pH 7.4) after cannulation of the bile duct and 
portal vein.  Livers were removed from the body cavity and placed into a humidified 
perfusion chamber at 37 ˚C.  Perfusion was continued with oxygenated buffer 
containing 20% (v/v) heparinized male rat blood at a flow rate of 20 ml/min.  Livers 
were allowed to equilibrate for 10-15 min prior to bolus administration of 24 nmol of 
trabectedin (preliminary recovery studies in the perfusion system without the liver 
indicated that the actual dose delivered to the IPL was decreased by 50% due to 
nonspecific binding/degradation in blood-containing perfusate).  Liver viability was 
assessed by monitoring portal pressure (<15 cm of H2O), observing gross 
morphology, and measuring bile flow in perfused livers from control and TR- rats 
(>0.8 and >0.3 µl/min/g liver, respectively).  Taurocholate (0.5 µmol/min, in saline) 
was infused to maintain bile flow.  Bile was collected in toto every 10 min, and the 
volume was determined gravimetrically (specific gravity 1.0).  Perfusate samples 
(0.5 ml) were immediately centrifuged following collection to obtain plasma for 
analysis.   
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Analytical Methods. Bile and perfusate samples were analyzed by liquid 
chromatography with detection by tandem mass spectrometry (Applied Biosystems 
API 4000 triple quadrupole with TurboIonSpray interface, MDS Sciex, Concord, ON, 
Canada).  Trabectedin and cimetidine (internal standard) were eluted from an 
Aquasil C18 column (dp=5µm, 2.1 x 50 mm, Thermo-Electron, Waltham, MA) using a 
mobile phase gradient (A: water with 0.1% formic acid, B: methanol with 0.1% formic 
acid); 0-2.5 min hold at 95% B, a linear gradient to 10% B from 2.5-3 min, 3-4 min 
hold at 10% B; flow rate was 0.75 mL/min (Shimadzu solvent delivery system, 
Columbia, MD).  Trabectedin and cimetidine were detected in positive ion mode 
using multiple reaction monitoring; trabectedin: 744.2  495.2 m/z, cimetidine: 250.9 
 156.9 m/z.  Trabectedin was quantified with calibration curves prepared in the 
appropriate matrix using analyte:internal standard (trabectedin:cimetidine) peak area 
ratios.  The lower limit of detection was 1 nM for all analytes and standard curves 
ranged from 1 to 1000 nM. 
Statistical Analysis. Statistical significance was assessed using two-way analysis of 
variance with Bonferroni’s post hoc test, except where the groups being compared 
had unequal variances, in which case log-transformed data were assessed.  SCRH 
data were presented as the mean ± S.E.M. when at least three sets of independent 
experiments were performed in triplicate.  In all cases, p < 0.05 was considered to 
be statistically significant.  
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RESULTS 
DEX effect on trabectedin-mediated cytotoxicity in SCRH from wild-type rats 
Trabectedin-mediated cytotoxicity was defined as LDH release, relative to a 
Triton X-100 treated control, from hepatocytes into the culture medium.  Following 2 
hr of trabectedin exposure, LDH release was not increased relative to untreated 
SCRH (data not shown).  However, cytotoxicity was observed after 24 hr of 
continuous trabectedin exposure to SCRH (Figure 4.1).  From day 2 to day 4, 
additional DEX (1 µM) was added to the culture medium containing 0.1 µM DEX to 
examine the effect of DEX on trabectedin-mediated cytotoxicity; SCRH were 
incubated with trabectedin for 24 hr starting on day 3. This pretreatment of SCRH 
with additional DEX (1 µM) decreased toxicity of trabectedin compared to vehicle-
pretreated SCRH (Figure 4.1).  
Trabectedin-mediated cytotoxicity in SCRH from TR- rats 
Primary hepatocytes from Mrp2-deficient TR- rats were utilized to examine the 
involvement of Mrp2 in trabectedin-mediated cytotoxicity at 0.1 µM DEX.  
Unexpectedly, cytotoxicity caused by exposure to 50 nM and 100 nM trabectedin in 
TR- SCRH was reduced compared to that in wild-type SCRH (Figure 4.2).   
BSO effect on trabectedin-mediated cytotoxicity in wild-type and TR- SCRH 
Elevated levels of glutathione in TR- compared to wild-type rat hepatocytes 
has been proposed as one mechanism that can protect the hepatocyte from drug-
induced hepatotoxicity (Lu et al., 1996).  To determine the effect of GSH depletion on 
trabectedin cytotoxicity, BSO (500 µM), an inhibitor of γ-glutamylcysteine synthetase 
which is the rate-liming step in GSH synthesis, was incubated for 24 hr prior to 
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trabectedin exposure in SCRH from wild-type and TR- rats (Griffith and Meister, 
1979).  Interestingly, toxicity in wild-type SCRH pretreated with BSO was reduced 
compared to vehicle-pretreated wild-type SCRH (Figure 4.3).  Trabectedin-mediated 
cytotoxicity in BSO-pretreated TR- SCRH was not different from vehicle-pretreated 
TR- SCRH (data not shown). 
Alteration of Mrp2, 3, 4 and CYP3A1/2 protein expression by DEX and BSO 
When SCRH were cultured with additional DEX (1 µM), the fold increase in 
expression of CYP3A1/2 and Mrp2 was 5.0 ± 2.5 and 2.5 ± 0.6, respectively, 
compared to vehicle, whereas the fold increase in protein expression of Mrp3 and 
Mrp4 was 1.2 ± 0.7 and 1.4 ± 0.4, respectively (Figure 4.4).  Interestingly, in BSO-
pretreated SCRH, the fold increase in Mrp4 expression was 3.1 ± 0.7 whereas the 
fold increase in Mrp2, Mrp3 and CYP3A1/2 protein expression was 1.5 ± 0.7, 1.9 ± 
0.4 and 1.2 ± 0.9, respectively.   
Hepatobiliary disposition of trabectedin in IPLs 
IPLs from wild-type and TR- rats were utilized to examine the involvement of 
Mrp2 in trabectedin hepatobiliary disposition.  Trabectedin concentrations in 
perfusate were not different between livers from wild-type and TR- rats; trabectedin 
was rapidly extracted by the liver and concentrations were negligible after 20 min 
(Figure 4.5.a).  Biliary recovery of trabectedin represented less than 3% of the dose 
in wild-type rat livers, consistent with extensive metabolism of trabectedin in rats as 
reported previously (Figure 4.5.b) (Allen et al., 2002).  Biliary recovery of trabectedin 
in IPLs from TR- rats was decreased by ~75% compared to wild-type IPLs. 
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DISCUSSION 
SCRH were selected to investigate the hepato-protective effect of DEX 
against trabectedin-mediated cytotoxicity because they maintain metabolic enzyme 
activity and develop functional bile canalicular networks with proper localization of 
hepatic transport proteins (Liu et al., 1998; LeCluyse et al., 1999; Liu et al., 1999a; 
Hoffmaster et al., 2004a).  Previous experiments in freshly isolated rat hepatocytes 
cultured in a conventional configuration were unable to replicate the hepato-
protective effect of DEX against trabectedin-mediated cytotoxicity when rats were 
pretreated orally with 20 mg/kg/day of DEX 24 hr prior to hepatocyte isolation 
(Donald et al., 2004).  When freshly isolated hepatocytes are cultured on a single 
collagen substratum (conventional configuration), hepatocytes do not form bile 
canalicular networks, do not re-establish cell polarity, and gradually lose expression 
of CYP enzymes (LeCluyse et al., 1996; George et al., 1997).  The loss of CYP 
expression over time in culture of human hepatocytes varies for each isoform 
(George et al., 1997); mRNA levels of some P450s such as CYP1A2 and CYP2C9 
did not change over time in culture whereas CYP2E1 and CYP3A4 expression 
declined gradually over time in culture.  Therefore, induction of CYP3A protein by 
DEX prior to hepatocyte isolation may be lost during culture in a conventional 
configuration.  In contrast, incubation of SCRH with additional DEX (1 µM) increased 
CYP3A1/2 protein levels compared to vehicle-treated SCRH (Figure 4.4) and may 
provide hepato-protection from trabectedin-mediated cytotoxicity. 
Vectorial transport studies in polarized cell monolayers examining cellular 
accumulation of [14C] trabectedin in the absence and presence of P-gp inhibitors 
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indicated that trabectedin is a substrate for P-gp (Beumer et al., 2007a).  However, 
P-gp was only able to confer resistance to trabectedin when expressed at very high 
levels, suggesting that the intrinsic clearance of P-gp for trabectedin is low.  Even 
though trabectedin seems to be more toxic than its metabolites based on previous 
cytotoxicity studies (Brandon et al., 2005), limited information is available on the 
interaction of other hepatic transport proteins with trabectedin. 
The present studies are the first to demonstrate the involvement of Mrp2 in 
the biliary excretion of trabectedin in whole rat livers. Although the biliary excretion of 
unchanged trabectedin was low as a percentage of the total dose, the biliary 
excretion of trabectedin in IPLs from TR- rats was decreased ~75% compared to 
wild-type IPLs (Figure 4.5.b).  As shown in Figure 4.4, induction of Mrp2 protein 
expression by additional DEX (1µM) in SCRH may provide hepato-protection from 
trabectedin-mediated cytotoxicity by increasing the biliary excretion of parent 
compound and/or derived metabolites.  
Interestingly, TR- SCRH were more resistant to trabectedin-mediated 
cytotoxicity relative to wild-type controls, despite the increased potential for 
trabectedin accumulation in TR- hepatocytes due to impaired biliary excretion.  This 
observation could be explained by modulation of the expression/activity of hepatic 
basolateral efflux transport proteins and metabolic enzymes in TR- rats.  Mrp2-
deficient rats are well-known to exhibit higher Mrp3 expression (Hirohashi et al., 
1998; Ogawa et al., 2000; Johnson et al., 2006).  Mrp3 mediates hepatic basolateral 
efflux of substrates from hepatocytes to the blood, and is thought to compensate for 
impaired biliary excretion of organic anions during Mrp2 deficiency (Hirohashi et al., 
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2000; Xiong et al., 2000).  In addition, the expression and activity of several phase I 
and II metabolic enzymes that may be involved in trabectedin detoxification are 
modulated in TR- rats.  For example, the total P450 content and activity of CYP1A1/2 
and CYP2B1/2 were significantly higher in TR- compared to wild-type rats, although 
testosterone 6β-hydroxylation mediated by CYP3A1/2 was lower in TR- compared to 
wild-type rats (Newton et al., 2005; Silva et al., 2005).  TR- rats exhibit up-regulated 
UGT1a (Johnson et al., 2006).  Since Mrp2 plays an important role in GSH biliary 
excretion, impaired function of Mrp2 in TR- rats has been attributed to higher 
hepatocellular concentrations of GSH relative to wild-type rats (Lu et al., 1996).  The 
important role of GSH in detoxification of the reactive metabolite of acetaminophen, 
N-acetyl-p-benzoquinoneimine, was demonstrated recently in TR- rats (Silva et al., 
2005); TR- rats were more resistant to acetaminophen hepatotoxicity compared to 
wild-type rats, but this protection against acetaminophen hepatotoxicity in TR- rats 
was completely reversed by BSO treatment.  Previous studies in cultured rat 
hepatocytes have documented that 200 µM BSO reduced GSH levels by 50% after 5 
hr (Sinbandhit-Tricot et al., 2003). Interestingly, in the present study, pretreatment of 
SCRH with BSO (500 µM) for 48 hr decreased trabectedin–mediated cytotoxicity 
relative to vehicle-pretreated SCRH.    
A novel finding in the current study was induction of Mrp4 in SCRH 
associated with BSO treatment.  MRP4 is a basolateral protein involved in the 
transport of xenobiotics and endogenous substrates such as cyclic nucleotides 
(cAMP and cGMP) and bile acids (van Aubel et al., 2002; Reid et al., 2003b; Rius et 
al., 2003; Tian et al., 2006).  MRP4 mediates the efflux of GSH across the 
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basolateral membrane of hepatocytes into blood by co-transport with monoanionic 
bile acids (Rius et al., 2003).   BSO may play a role as a GSH-depleting agent not 
only by inhibiting synthesis, but also by enhancing hepatic efflux of GSH out of the 
hepatocyte by increasing the expression of Mrp4.  Whether upregulation of Mrp4 by 
BSO is a direct effect, or an indirect response associated with oxidative stress due to 
GSH depletion, requires further investigation.  MRP4 mRNA and protein expression 
were significantly up-regulated in liver samples from patients with cholestasis, 
indicating a potential role of MRP4 in protecting the liver by decreasing the 
intracellular accumulation of detergent-like bile acids (Gradhand et al., 2007).  
Hence, the protective role of BSO in trabectedin-mediated cytotoxicity may be due to 
increased efflux of trabectedin or toxic metabolites by Mrp4, although the affinity of 
trabectedin for Mrp4 is unknown.   
In conclusion, the hepato-protective effect of DEX on trabectedin toxicity may 
be due to increased metabolism by CYP3A1/2 as well as enhanced biliary excretion 
by Mrp2.  Although the interaction of trabectedin and/or derived metabolites with 
basolateral transport proteins such as Mrp3 and 4 remains to be elucidated, the 
unexpected attenuation of trabectedin toxicity in SCRH from TR- rats, and in SCRH 
pretreated with BSO, may be associated with increased basolateral excretion of 
trabectedin /metabolites by Mrp3 and/or Mrp4. 
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Figure 4.1. Effect of DEX on trabectedin-mediated cytotoxicity in SCRH isolated 
from wild-type Wistar rats.  Cytotoxicity was determined by measuring LDH release 
into the culture medium after 24 hr trabectedin (1-1000 nM) exposure.  Each bar 
represents the mean ± S.E.M. (n=3) for samples from vehicle- (0.1 µM DEX; solid 
bars) or additional DEX (1 µM; white bars); *, p < 0.05.   
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Figure 4.2. Trabectedin-mediated cytotoxicity in SCRH from wild-type and TR- rats.  
Cytotoxicity was determined by measuring LDH release into the culture medium 
after 24 hr trabectedin (1 - 100 nM) exposure.  Each bar represents the mean ± 
S.E.M. (n=3) for samples from wild-type (solid bars) or TR- (white bars) SCRH; *, p < 
0.05. 
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Figure 4.3. Effect of BSO on trabectedin-mediated cytotoxicity.  Cytotoxicity was 
determined by measuring LDH release into the culture medium after 24 hr 
trabectedin (50, 100 and 1000 nM) exposure.  BSO (500 µM) was added to the 
culture medium 24 h prior to trabectedin exposure.  Each bar represents the mean ± 
S.E.M. (n=3) for samples from vehicle- (solid bars) or BSO-pretreated (white bars) 
SCRH; *, p < 0.05. 
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Figure 4.4. Representative Western blot from whole cell lysates for  Mrp2, 3, 4 and 
CYP3A1/2  in SCRH pretreated with vehicle (0.1 µM DEX), additional DEX (1 µM) or 
BSO (500 µM) (25 µg protein/well; n=3). 
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Figure 4.5. Trabectedin perfusate concentrations (A) and cumulative biliary 
excretion (B) in isolated perfused livers from wild-type (solid circle) and TR- (white 
triangle) rats.  Data are presented as mean ± S.D., n= 3/group. 
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CHAPTER 5 
 
Interactions Between Sulindac, Sulindac Sulfone, Sulindac Sulfide and  
Hepatic Transport Proteins 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter will be submitted to the Journal of Pharmacology and Experimental 
Therapeutics 
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ABSTRACT 
Sulindac, a nonsteroidal anti-inflammatory drug (NSAID) used clinically to 
relieve symptoms of rheumatoid arthritis and osteoarthritis, is associated with a 
higher incidence of hepatotoxicity compared to other NSAIDS. The role of hepatic 
transport proteins in sulindac-mediated hepatotoxicity remains to be evaluated. 
Accordingly, model substrates for hepatic transport proteins [[3H]taurocholate (TC), 
[3H]estradiol 17-β-glucuronide (E217G), nitrofurantoin (NF)] were utilized in rat and 
human sandwich-cultured hepatocytes (SCH) and suspended hepatocytes to 
determine whether sulindac and/or sulindac metabolites (S-sulfone and S-sulfide) 
interfere with hepatic transport protein activity. In rat SCH, compared to control, S-
sulfone and S-sulfide (100 µM) decreased TC biliary excretion index (BEI) by 42% 
and 55%, respectively, but had no effect on E217G BEI; in contrast, 
sulindac/metabolites (100 µM) decreased both TC and E217G in vitro biliary 
clearance (Clbiliary) by 38-83% and 81-97%, respectively, consistent with impaired 
uptake of TC and E217G and impaired excretion of TC. In suspended rat 
hepatocytes, S-sulfone and S-sulfide inhibited Na+-dependent TC initial uptake (IC50 
of 25.6±10.7 and 12.7±5.3 µM, respectively) and Na+-independent E217G initial 
uptake (IC50 of 12.6±5.1 and 6.5±1.2 µM, respectively). In rat SCH, compared to 
control, sulindac, S-sulfone and S-sulfide (100 µM) decreased NF BEI and Clbiliary by 
30-57%. In suspended human hepatocytes, S-sulfone and S-sulfide inhibited Na+-
dependent TC initial uptake (IC50 of 42.2 and 3.1 µM, respectively). In conclusion, 
inhibition of multiple hepatic transport proteins (Na+/taurocholate cotransporting 
protein, organic anion transporting polypeptides, bile salt export pump, breast cancer 
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resistance protein) by sulindac/metabolites may play a role in clinically significant 
drug interactions and/or liver injury.  
 144
INTRODUCTION 
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the 
relief of signs and symptoms of arthritic conditions, including osteoarthritis and 
rheumatoid arthritis. Sulindac is reduced by the aldehyde oxidase system to sulindac 
sulfide (S-sulfide) (Figure 5.1), which has analgesic and anti-inflammatory properties.  
S-sulfide is converted by flavin-containing monooxygenase 3 back to sulindac and to 
sulindac sulfone (S-sulfone), which has been recognized as a promising 
antiproliferative agent in colon cancer (Tatsumi et al., 1983; Davies and Watson, 
1997; Hamman et al., 2000). Among NSAIDs, sulindac has been associated most 
consistently with hepatotoxicity (Aithal and Day, 2007), particularly with cholestatic 
hepatitis, and to a lesser extent with hepatocellular damage (Tarazi et al., 1993). 
Despite the high incidence of liver injury, the mechanism(s) underlying sulindac-
mediated hepatotoxicity remain(s) to be elucidated. 
Inhibition of hepatic transport proteins has been proposed as one mechanism 
of drug-induced liver injury (DILI). Inhibition of the canalicular bile salt export pump in 
rats (Bsep; ABCB11) by hepatotoxic drugs such as troglitazone and bosentan may 
lead to elevated hepatic concentrations of detergent-like bile acids, which can 
disrupt cellular function (Fattinger et al., 2001; Funk et al., 2001a). Several hepatic 
transport proteins other than Bsep also are involved in bile acid transport, acting in 
concert to maintain homeostasis of bile acids. In humans, conjugated and 
unconjugated bile acids are taken up primarily by Na+-dependent taurocholate co-
transporting polypeptide (NTCP; SLC10A1) with high affinity, as well as by Na+-
independent organic anion transporting polypeptides (OATPs; SLCOs). Once taken 
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up by the hepatocytes, bile acids are excreted into the canalicular lumen primarily by 
the bile salt export pump (BSEP). Alternatively, bile acids can be excreted into 
sinusoidal blood by basolateral hepatic transport proteins such as the multidrug 
resistance-associated protein (MRP; ABCC) 3, MRP4 and the organic solute 
transporter (OST) α/β (Kosters and Karpen, 2008). 
The involvement of hepatic transport proteins in DILI and some drug 
interactions has been established (Smith et al., 2005b; Pauli-Magnus and Meier, 
2006). Furthermore, interactions between sulindac and hepatic transport proteins 
have been demonstrated. Sulindac inhibited organic anion transporter (OAT) 1-
mediated [14C]para-aminohippurate uptake (IC50 ~36 µM) and OAT3-mediated 
[3H]estrone sulfate uptake (IC50 ~3 µM) in stably transfected cells; sulindac also was 
the most potent inhibitor among tested NSAIDs of organic cation transporter (OCT) 1 
and 2 in stably transfected cells (Khamdang et al., 2002). Sulindac also inhibited 
[3H]methotrexate transport in MRP2- and MRP4-overexpressing membrane vesicles, 
with IC50 values of ~38 µM and ~2 µM, respectively (El-Sheikh et al., 2006); MRP2 
functions to excrete compounds from the hepatocyte into bile. Finally, S-sulfide was 
shown to be a potent inhibitor of MRP4-mediated leukotriene B4 and C4 transport in 
MRP4-overexpressing membrane vesicles (Rius et al., 2008).  
Sulindac is metabolized extensively by the liver in rats as well as in humans, 
and plasma concentrations of sulindac metabolites are sustained due to extensive 
enterohepatic recycling (Dujovne et al., 1983). In rats, S-sulfone is the major 
metabolite in the plasma. After intravenous administration of sulindac (10 mg/kg) in 
rats, the plasma area under the concentration-time curve (AUC) for S-sulfone was 
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~2.5-fold higher than that of sulindac, whereas the AUC
 
for S-sulfide was only ~40% 
that of sulindac (Duggan et al., 1978); Clbiliary of sulindac and S-sulfone were 
comparable, whereas S-sulfide Clbiliary was only 40% of that of sulindac. In humans, 
after oral administration of sulindac, peak plasma total concentrations (Cmax) were 
achieved after 1 h for sulindac (10-34 µM), and after 2-4 h for S-sulfone (4-19 µM) 
and S-sulfide (3-33 µM) (Davies and Watson, 1997); the apparent Clbiliary of sulindac 
and S-sulfone, measured by an occludable T-tube that was placed in the common 
bile duct of patients following elective gallbladder surgery, was ~25-fold and ~18-fold 
greater, respectively, than that of S-sulfide (Dobrinska et al., 1983). Several groups 
have reported a proportional relationship between S-sulfide concentrations and the 
incidence of hepatotoxicity, emphasizing the potential for metabolites, in addition to 
the parent drug to cause hepatotoxicity (Duggan et al., 1978; Laffi et al., 1986).  
The aim of the present study was to examine the interactions between 
hepatic transport proteins and sulindac, S-sulfone and S-sulfide. First, interactions 
between sulindac/metabolites and the model substrates [3H]taurocholate (TC; 
substrate for Ntcp/Oatp/Bsep), [3H]estradiol 17-β-glucuronide (E217G; substrate for 
Oatp/Mrp2) and nitrofurantoin (NF; substrate for breast cancer resistance protein 
(Bcrp, a canalicular efflux transport protein) were examined in rat sandwich-cultured 
hepatocytes (SCH). Second, the inhibitory potency (IC50) of sulindac metabolites on 
Na+-dependent TC initial uptake and Na+-independent E217G initial uptake was 
examined in freshly-isolated rat hepatocytes. Third, the impact of 
sulindac/metabolites on the hepatobiliary disposition of TC was examined in human 
SCH, and suspended human hepatocytes were used to determine the IC50 of 
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sulindac metabolites on Na+-dependent TC initial uptake. Results suggested that 
inhibition of multiple transport proteins by sulindac/metabolites could play a role in 
sulindac-mediated liver injury.  
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MATERIALS AND METHODS 
Chemicals and Reagents. [3H]TC, [3H]E217G and [14C]inulin were purchased from 
PerkinElmer Life and Analytical Sciences (Boston, MA). Dulbecco’s modified Eagle’s 
medium (DMEM) and MEM non-essential amino acids were purchased from 
Invitrogen (Carlsbad, CA). BioCoatTM culture plates, MatrigelTM extracellular matrix, 
and insulin/transferrin/selenium culture supplement (ITSTM) were purchased from BD 
Biosciences Discovery Labware (Bedford, MA). NF, TC, E217G, sulindac, S-sulfone, 
S-sulfide, penicillin-streptomycin solution, dexamethasone, Hanks’ Balanced Salt 
Solutions (HBSS), HBSS modified (HBSS without Ca2+ and Mg+) and Triton X-100 
were purchased from Sigma-Aldrich, Inc (St. Louis, MO). All other chemicals and 
reagents were of analytical grade and were readily available from commercial 
sources.  
Culture of Primary Rat and Human Hepatocytes in a Sandwich Configuration. 
Primary rat hepatocytes were cultured as described previously (Marion et al., 2007). 
Briefly, hepatocytes were seeded at a density of 1.75×106 cells/well onto 6-well 
BioCoatTM plates. Approximately 24 hours later, hepatocytes were overlaid with 2 mL 
of 0.25 mg/mL BD MatrigelTM basement membrane matrix in DMEM containing 1% 
(v/v) ITS+TM, 0.1 µM dexamethasone, 2 mM L-glutamine, 1% (v/v) MEM non-
essential amino acids, 100 units penicillin G sodium/mL and 100 µg streptomycin 
sulfate/mL. CellzDirect (Durham, NC) kindly donated human hepatocytes cultured in 
6-well plates, seeded at a density of 1.5×106 cells/well, and overlaid with Matrigel™. 
Hepatocytes were cultured for 4 days (rat) or 7-8 days (human) to allow extensive 
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formation of canalicular networks between cells before experimentation; medium 
was changed daily.  
Transport Studies using Rat and Human Sandwich-Cultured Hepatocytes 
(SCH). The method to determine substrate accumulation in SCH has been 
described previously (Liu et al., 1999e). Briefly, SCH were washed twice with 2 ml of 
warm HBSS containing Ca2+ (standard; cells+bile) or Ca2+-free (cells), followed by 
incubation in the same buffer for 10 min at 37˚C. Subsequently, cells were incubated 
at 37˚C for 10 min with 1.5 mL  standard HBSS containing NF (5 µM), [3H]TC (1 µM; 
100 nCi/mL), or [3H]E217G (1 µM; 100 nCi/mL) in the presence of sulindac or its 
metabolites (0-100 µM). After 10 min, cells were washed 3 times with ice-cold 
standard HBSS. Cells were lysed either with 1 mL of methanol/water (70/30; v/v) 
(NF studies) or 0.5% (v/v) Triton X-100 in phosphate-buffered saline (TC and E217G 
studies), and plates were shaken for at least 20 min. Samples of cells+bile and cells 
were quantified by HPLC-MS/MS for NF, and by liquid scintillation spectroscopy 
(Packard Tricarb, Packard Corp., Meriden, CT) for [3H]TC or [3H]E217G, and 
transport function was normalized to the protein content of the hepatocytes using a 
BCA protein assay (Pierce, Rockford, IL). The biliary excretion index (BEI; %) and in 
vitro biliary clearance (Clbiliary; mL/min/kg) were calculated using B-CLEAR® 
technology (Qualyst, Inc., Raleigh, NC) based on the following equations: 
medium
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where AUCmedium represents the area under the substrate concentration-time curve, 
which was determined by multiplying the initial substrate concentration in the 
incubation medium by the incubation time (10 min). Clbiliary values were converted to 
milliliter per minute per kilogram based on previously reported values for liver weight 
(200 mg/g liver weight for rats; 160 mg/g liver weight for humans) and protein 
content in liver tissue (40 g/kg body weight for rats; 25.7 g/kg body weight for 
humans) (Davies and Morris, 1993; Wilson et al., 2003). 
HPLC/MS/MS Analysis of NF. NF accumulation in cells+bile and cells were 
quantified by HPLC/MS/MS as described previously (Yue et al., 2008). Briefly, 
samples obtained from rat SCH were deproteinated with 1 mL of methanol/water 
(70/30, v/v), and sonicated for 20 sec. After the removal of protein by centrifugation 
at 4°C (12000 g) for 3 min, the supernatant (20 µL) was mixed with 100 µL methanol 
and water (3.8:1) containing internal standard (ethyl warfarin, 10 mM). A Shimadzu 
solvent delivery system (Columbia, MD) and a Leap HTC Pal thermostatted 
autosampler (Carrboro, NC) connected to an Applied Biosystems API 4000 triple 
quadruple mass spectrometer with a Turbo Spray ion source (Applied Biosystems, 
Foster City, CA) were used for analysis. Tuning, operation, integration and data 
analysis were performed in negative ionization mode using multiple reaction 
monitoring (Analyst software v.1.4.1, Applied Biosystems). NF and internal standard 
were eluted from an Aquasil C18 column (50 × 2.1 mm, dp = 5 µm; Thermo Electron 
Corporation, San Jose, CA) with 20 µL injection volume at a flow rate of 0.75 mL/min. 
Initial gradient conditions (100% 10 mM ammonium acetate aqueous solution) were 
held for 0.75 min. From 0.75 to 1.39 min, the mobile phase composition increased 
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linearly to 40% methanol, and the eluent was directed to the mass spectrometer. At 
3.3 min, the methanol composition was increased to 90%. The flow was held at 90% 
methanol until 4 min. At 4 min, the column was equilibrated with 100% 10 mM 
ammonium acetate aqueous solution. The total run time, including equilibration, was 
5 min per injection. Eight-point calibration curves (2-1000 nM) were constructed 
based on peak area ratios of analyte to internal standard (ethyl warfarin) using the 
following transitions: 236.8  151.8 (NF) and 320.8  160.9 (ethyl warfarin). All 
points on the curves back-calculated to within ± 15% of the nominal value. 
Transport Studies using Suspended Primary Rat and Human Hepatocytes.  
[3H]TC and [3H]E217G initial uptake was determined in freshly-isolated hepatocytes 
as described previously (Leslie et al., 2007). Briefly, hepatocytes were washed twice 
with ice-cold standard HBSS modified with 10 mM Tris and 5 mM glucose (Na+-
containing condition) or Na+-free choline buffer (10 mM Tris, 5 mM glucose, 5.4 mM 
KCl, 1.8 mM CaCl2, 0.9 mM MgSO4, 10 mM HEPES, and 137 mM choline). 
Hepatocytes were suspended at 1×106 cells/mL in the same buffer, placed on ice, 
and used immediately in experiments. Hepatocytes (2 mL) in 16 × 100 mm test 
tubes were incubated at 37˚C in an orbital shaking water bath for 3 min. Vehicle 
control (0.1 % DMSO), S-sulfone or S-sulfide (0.5–100 µM) was added, followed by 
[3H]TC (1 µM; 60 nCi/mL) or [3H]E217G (1 µM; 60 nCi/mL). At 30 sec (TC) or 90 sec 
(E217G), samples (200 µL) were placed into 0.4-mL polyethylene tubes on top of a 
layer of silicone oil:mineral oil (82:18, v/v; 100 µL) and a bottom layer of 3 M KOH 
(50 µL), and immediately centrifuged. Radioactivity in the cell pellet and supernatant 
was quantified by liquid scintillation counting. The adherent fluid volume was 
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determined by the incubation of cells with [14C]inulin. At the end of each experiment, 
an aliquot (10 µl) of suspended cells was used to determine protein concentrations 
by the BCA protein assay. 
Determination of Inhibitory Potency of Sulindac Metabolites on Na+-dependent 
[3H]TC Uptake or Na+-independent [3H]E217G Uptake. The data obtained from 
substrate transport studies ([3H]TC and [3H]E217G) in suspended hepatocytes were 
plotted against the inhibitor concentration (S-sulfone and S-sulfide). Based on 
standard model selection criteria including residual distribution, Akaike’s information 
criterion and visual inspection, the sigmoidal inhibitory Emax model was selected to 
estimate the concentration for 50% inhibition of uptake (IC50) using WinNonlin 5.0.1 
(Pharsight, Mountain View, CA). 
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where E is the rate of substrate uptake, Emax is maximum rate of substrate uptake, C 
is the inhibitor concentration, and r is the curve shape factor.  
Statistical Analysis. Data are expressed as mean and the associated S.E.M. 
Statistical differences were determined using one-way analysis of variance with 
Bonferroni’s post hoc test using SigmaStat 2.03 (Aspire Software International 
Ashburn, VA). Differences were considered significant at p < 0.05.  
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RESULTS 
Effect of Sulindac and Metabolites on TC Hepatobiliary Disposition in Rat SCH.  
 [3H]TC was used as a model substrate to examine the impact of sulindac and 
metabolites on hepatic uptake and biliary excretion of bile acids in rat SCH (Figure 
5.2A-C). The accumulation of TC (1 µM, 100 nCi/mL, 10 min) in cells+bile in the 
presence of 100 µM S-sulfide was significantly decreased compared to vehicle 
control. TC BEI in the presence of 1 and 10 µM sulindac, S-sulfone and S-sulfide 
was not statistically different from those values in vehicle control. TC BEI was 
decreased significantly by 100 µM S-sulfone (42% decrease) and S-sulfide (55% 
decrease), but TC BEI in the presence of 100 µM sulindac was not different from 
those values in vehicle control. Sulindac (10 µM; 53% decrease), S-sulfone (100 µM; 
76% decrease) and S-sulfide (100 µM; 84% decrease) significantly inhibited TC 
Clbiliary. 
Effect of Sulindac and Metabolites on E217G Hepatobiliary Disposition in Rat 
SCH.  
[3H]E217G was used as a model substrate to examine the impact of sulindac 
and metabolites on Oatp-mediated uptake and Mrp2-mediated biliary excretion in rat 
SCH (Figure 5.3A-C). Accumulation of E217G (1 µM, 100 nCi/mL, 10 min) in 
cells+bile and in cells was decreased significantly in the presence of sulindac (100 
µM), S-sulfone (10 and 100 µM) and S-sulfide (10 and 100 µM). E217G BEI was not 
affected by sulindac, S-sulfone or S-sulfide (1-100 µM), whereas E217G Clbiliary was 
decreased significantly by S-sulfone (1, 10 and 100 µM) and S-sulfide (100 µM), but 
not by sulindac. 
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Effect of Sulindac and Metabolites on NF Hepatobiliary Disposition in Rat SCH.  
 NF, a specific Bcrp substrate in rat SCH (Yue, 2008), was used as a model 
substrate to examine the impact of sulindac and metabolites on Bcrp-mediated 
biliary excretion in rat SCH (Figure 5.4). NF accumulation (5 µM, 10 min) in 
cells+bile was not significantly different in the presence of 100 µM sulindac, S-
sulfone or S-sulfide, but cellular accumulation was increased significantly in the 
presence of S-sulfide. NF BEI was decreased by 30%, 39% and 57% in the 
presence of 100 µM sulindac, S-sulfone and S-sulfide, respectively, compared to 
vehicle control. Clbiliary of NF was decreased, with more potent inhibition by S-sulfide 
(50% decrease), followed by sulindac (33% decrease) and S-sulfone (33% 
decrease).  
Influence of S-sulfone and S-sulfide on Na+-dependent Initial Uptake of TC and 
Na+-independent Initial Uptake of E217G in Suspended Rat Hepatocytes.  
To further examine the mechanisms of inhibition of hepatic transport proteins 
by sulindac metabolites, the inhibitory potency of S-sulfone and S-sulfide on the 
initial uptake of TC and E217G in the absence or presence of Na+ was determined in 
suspended rat hepatocytes. Initial uptake was determined at 30 sec for TC (1 µM, 60 
nCi/mL) based on preliminary studies (data not shown). E217G initial uptake (1 µM, 
60 nCi/mL, 90 sec) was determined under Na+-free conditions to exclude Na+-
dependent E217G uptake, based on previously published data demonstrating that 
E217G uptake was partially dependent on sodium (Brock and Vore, 1984). The IC50 
values for inhibition of Na+-dependent TC initial uptake by S-sulfone and S-sulfide 
were 25.6±10.7 µM (Figure 5.5A) and 12.7±5.3 µM (Figure 5.5B), respectively. The 
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IC50 values for inhibition of Na+-independent E217G initial uptake by S-sulfone and 
S-sulfide were 12.6±5.1 µM (Figure 5.6A) and 6.5±1.2 µM (Figure 5.6B), respectively.  
Effect of Sulindac and Metabolites on TC Hepatobiliary Disposition in Human 
SCH.  
In human SCH, [3H]TC accumulation in cells+bile and cells (1 µM, 100 nCi/mL, 
10 min) in the presence of 10 and 100 µM sulindac and S-sulfone was comparable 
to vehicle control, but S-sulfide at 10 and 100 µM inhibited TC accumulation by 52% 
and 87%, respectively (Figure 5.7). TC BEI was not decreased by sulindac, S-
sulfone or S-sulfide, but the Clbiliary of TC was decreased by 50% and 88% with 10 
and 100 µM S-sulfide, respectively. 
Influence of S-sulfone and S-sulfide on Na+-dependent TC Initial Uptake in 
Suspended Human Hepatocytes.  
The initial uptake of [3H]TC (1 µM, 60 nCi/mL) in suspended human 
hepatocytes was determined at 30 sec based on previously published data 
demonstrating that TC uptake was linear for at least 2 min in freshly-isolated human 
hepatocytes (Shitara et al., 2003). The IC50 for inhibition of Na+-dependent TC initial 
uptake by S-sulfone and S-sulfide were 42.2 µM (Figure 5.8A) and 3.1 µM (Figure 
5.8B), respectively.   
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DISCUSSION 
Among the NSAIDs, sulindac has been associated with the highest incidence 
of DILI, which may involve interference with hepatic transport protein function. As 
such, the present study was designed to examine interactions between 
sulindac/metabolites and hepatic transport proteins using TC, E217G and NF as 
model substrates for Ntcp-/Bsep-, Oatp-/Mrp2- and Bcrp-mediated transport, 
respectively, in primary rat and human hepatocytes. BEI and Clbiliary from SCH were 
used as indices of hepatobiliary disposition of each model substrate; BEI is a 
measure of net canalicular efflux, whereas Clbiliary encompasses both uptake and 
efflux. 
Both the BEI and Clbiliary of TC in rat SCH were decreased significantly by S-
sulfone and S-sulfide (100 µM) (Figure 5.2A-C). Moreover, both metabolites inhibited 
Na+-dependent TC initial uptake in suspended rat hepatocytes (IC50 of 26 and 13 µM, 
respectively). Collectively, these data indicate that S-sulfone and S-sulfide inhibit 
Ntcp and Bsep. The balance between bile acid uptake and excretion in hepatocytes 
may be influence the occurrence of DILI. Indeed, the preferential inhibition of rat 
Ntcp rather than human NTCP by bosentan has been proposed as a plausible 
mechanism for protection of the rat against bosentan-mediated hepatotoxicity by 
preventing the further uptake of bile acids from blood when hepatocyte bile acid 
concentrations are increased due to bosentan-mediated Bsep/BSEP inhibition 
(Leslie et al., 2007).  
In rats, E217G is taken up by multiple Oatps, whereas biliary excretion of 
E217G is governed by Mrp2.  The decreased hepatocellular accumulation of E217G 
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in the presence of S-sulfone and S-sulfide in rat SCH, combined with the inhibition of 
E217G Clbiliary  but not BEI, suggested that sulindac metabolites inhibited Oatp-
mediated uptake but not Mrp2-mediated biliary excretion of E217G (Figure 5.3A-C). 
Subsequent investigations in suspended rat hepatocytes revealed that S-sulfone 
and S-sulfide were potent inhibitors (IC50 of 13 and 6.5 µM, respectively) of E217G 
initial uptake, consistent with inhibition of Oatp 1a1, 1a3, 1a4, 1a5 and 1b2.  
NF was chosen as a model substrate for Bcrp-mediated transport based on 
recent data demonstrating that NF is a specific Bcrp substrate in rat SCH (Yue et al., 
2008). Several clinical studies have reported that genetic polymorphisms in BCRP 
(ABCG2) can influence drug disposition. For example, the ABCG2 C421A 
polymorphism, which is associated with decreased protein expression and function 
in vitro (Imai et al., 2002), increased plasma concentrations of several BCRP 
substrates, including rosuvastatin, diflomotecan, and sulfasalazine (Morisaki et al., 
2005; Zhang et al., 2006a; Yamasaki et al., 2008). In the present study, 
sulindac/metabolites significantly decreased NF BEI and Clbiliary in rat SCH, 
consistent with inhibition of Bcrp (Figure 5.4). NF has been associated with 
hepatotoxicity; although cholestatic and mixed patterns of NF-mediated 
hepatotoxicity have been reported, hypersensitivity or immunologic injury were most 
common (Thiim and Friedman, 2003). NF-mediated oxidative stress via depletion of 
GSH or NADPH has been postulated as one mechanism for NF-mediated 
hepatotoxicity (Thiim and Friedman, 2003). Increased accumulation of NF in 
hepatocytes may occur in patients who have impaired BCRP activity (due to genetic 
variations or inhibitors), thus increasing the likelihood of NF-mediated hepatotoxicity. 
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Investigations are underway to determine whether sulindac and metabolites alter 
human BCRP-mediated transport.  
Due to the limited availability of human liver tissue combined with prominent 
roles of bile acid toxicity, only TC was tested further in human SCH to examine the 
effect of sulindac/metabolites on the hepatobiliary disposition of TC.  In human SCH, 
TC accumulation in cells+bile, and the TC Clbiliary, were markedly decreased by S-
sulfide without affecting TC BEI. These findings may reflect, at least in part, S-
sulfide-mediated inhibition of NTCP. The IC50 (3.1 µM) of Na+-dependent TC initial 
uptake by S-sulfide determined in human hepatocyte suspensions, which do not 
contain serum, was near the unbound plasma concentration range of S-sulfide 
(~0.14-1.5 µM) based on reported Cmax values of 3-33 µM and an unbound fraction 
(fu) of 4.6% after oral administration of a therapeutic dose of sulindac (Davies and 
Watson, 1997). However, the IC50 (42.2 µM) of Na+-dependent TC initial uptake by 
S-sulfone was ~100-fold greater than the unbound plasma concentration range 
(~0.1-0.4 µM) of S-sulfone (Cmax, 4-19 µM; fu, 2.1%). Although the IC50 for inhibition 
of Na+-dependent TC initial uptake by S-sulfide and S-sulfone was higher than 
unbound plasma concentrations, it is probable that initial inhibitor concentrations are 
higher than unbound plasma concentrations in the portal vein when sulindac is 
administered orally, since hepatic blood flow consists of ~85% the portal venous 
blood, which contains drug absorbed directly from the gastrointestinal tract (Ito et al., 
1998). In addition, it is plausible that the extensive enterohepatic recycling of 
sulindac and metabolites may result in prolonged inhibition of hepatic transport 
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proteins due to much higher concentrations in the portal circulation (Dujovne et al., 
1983).   
 The FDA has recommended an in vivo evaluation of drug interactions when 
the estimated [I]/Ki ratio is greater than 0.1, where [I] represents the mean steady-
state Cmax value for total drug (bound plus unbound) following administration of the 
highest proposed clinical dose (Huang et al., 2008). In theory, the IC50 values 
determined in the present study would be identical to Ki values, regardless of the 
mechanism of inhibition, based on previous data demonstrating the relationships 
between the Ki and IC50 values (Cheng and Prusoff, 1973); that is, the Ki value is 
equal to the IC50 value under conditions of either noncompetitive or uncompetitive 
inhibition, whereas under competitive inhibition conditions, the IC50 value will be 
identical to Ki(1+S/Km), where S is the substrate concentration and Km is an 
approximate measure of the affinity of the substrate for the enzyme. Because the TC 
concentration (1 µM) used for the IC50 determination in the present study was lower 
than the previously reported Km for the uptake of TC in rat (18 µM) and human 
hepatocytes (4.8 µM), the Ki values would be equal to or less than the IC50 value 
(Kouzuki et al., 1998; Shitara et al., 2003). With this assumption, the [I]/Ki ratio 
determined using data from human hepatocytes ranged from 0.9-10.6 for S-sulfide, 
and from 0.1-0.4 for S-sulfone, based on Cmax values of 3-33 µM and 4-19 µM, 
respectively. These findings suggest that S-sulfide and S-sulfone may interact with 
NTCP-mediated transport of drugs and/or bile acids in humans (Davies and Watson, 
1997). 
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In conclusion, the present studies demonstrated that hepatic transport 
proteins (Ntcp/NTCP, Oatps, Bsep, Bcrp) are inhibited by sulindac and metabolites. 
Considering the important role of Ntcp/NTCP, Oatp and Bsep in hepatic uptake and 
excretion of bile acids in the liver, impaired hepatic transport of bile acids by 
sulindac/metabolites may disturb bile acid homeostasis, resulting in sulindac-
mediated liver injury. Based on the present study demonstrating inhibition of multiple 
transport proteins by sulindac and metabolites, the possibility of drug-xenobiotic 
interactions should be considered when sulindac is coadministered with other 
drugs/xenobiotics, warranting careful monitoring for liver injury.  
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Figure 5.1. Chemical Structures of Sulindac, Sulindac Sulfone (S-sulfone) and 
Sulindac Sulfide (S-sulfide). 
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Figure 5.2. Effect of Sulindac and Metabolites on Hepatobiliary Disposition of TC in 
Rat SCH. Accumulation of [3H]TC (1 µM, 100 nCi/mL, 10 min) in cells+bile (solid 
bars) and cells (white bars) was measured in the presence of increasing 
concentrations (1-100 µM) of sulindac (A), S-sulfone (B) or S-sulfide (C) in rat SCH. 
BEI and in vitro Clbiliary of TC were calculated as described in Materials and Methods. 
Data are presented as the mean ± S.E.M (n=3-4 livers in triplicate); *, statistically 
different from vehicle control (CTL) by one-way ANOVA with Bonferroni’s post-hoc 
test. 
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Figure 5.3. Effect of Sulindac and Metabolites on Hepatobiliary Disposition of 
E217G in Rat SCH. Accumulation of [3H]E217G (1 µM, 100 nCi/mL, 10 min) in 
cells+bile (solid bars) and cells (white bars) was measured in the presence of 
increasing concentrations (1-100 µM) of sulindac (A), S-sulfone (B) or S-sulfide (C) 
in rat SCH. BEI and in vitro Clbiliary of E217G were calculated as described in 
Materials and Methods. Data are presented as the mean ± S.E.M (n=3-4 livers in 
triplicate); *, statistically different from vehicle control (CTL) by one-way ANOVA with 
Bonferroni’s post-hoc test.  
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Figure 5.4. Effect of Sulindac and Metabolites on Hepatobiliary Disposition of NF in 
Rat SCH. Accumulation of NF (5 µM, 10 min) in cells+bile (solid bars) and cells 
(white bars) was measured in the presence of 100 µM sulindac, S-sulfone or S-
sulfide in rat SCH. BEI and in vitro Clbiliary of NF were calculated as described in the 
Materials and Methods. Data are presented as the mean ± S.E.M (n=3 livers in 
triplicate); *, statistically different from vehicle control (CTL) by one-way ANOVA with 
Bonferroni’s post-hoc test. 
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Figure 5.5. Inhibition of Na+-dependent TC Initial Uptake in Suspended Rat 
Hepatocytes by S-sulfone (A) and S-sulfide (B). Na+-dependent [3H]TC initial uptake 
(1 µM, 60 nCi/ml, 30 sec) was determined by subtracting [3H]TC uptake in Na+-free 
buffer from [3H]TC uptake in Na+-containing buffer in the presence of increasing 
concentrations of S-sulfone (0.5-100 µM) and S-sulfide (0.5-100 µM). Symbols and 
error bars represent the mean ± S.E.M. of n=3 livers in duplicate. The dotted curve 
represents the best fit of the sigmoidal inhibitory Emax model to the data using 
WinNonlin; the curve shape factor (r) was estimated as 0.4±0.1 and 0.8±0.2 for S-
sulfone and S-sulfide, respectively. 
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Figure 5.6. Inhibition of Na+-independent E217G Initial Uptake in Suspended Rat 
Hepatocytes by S-sulfone (A) and S-sulfide (B). Na+-independent [3H]E217G initial 
uptake (1 µM, 60 nCi/ml, 90 sec) was determined in Na+-free buffer in the presence 
of increasing concentrations of S-sulfone (0.5-100 µM) and S-sulfide (0.5-100 µM). 
Symbols and error bars represent the mean ± S.E.M. of n=3 livers in duplicate. The 
dotted curve represents the best fit of the sigmoidal inhibitory Emax model to the data 
using WinNonlin; the curve shape factor (r) was estimated as 0.8±0.2 and 1±0.2 for 
S-sulfone and S-sulfide, respectively. 
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Figure 5.7. Effect of Sulindac and Metabolites on Hepatobiliary Disposition of TC in 
Human SCH. Accumulation of [3H]TC (1 µM, 100 nCi/mL, 10 min) in cells+bile (solid 
bars) and cells (white bars) was measured in the presence of 10 and 100 µM 
sulindac, S-sulfone or S-sulfide in human SCH. BEI and in vitro Clbiliary of TC were 
calculated as described in Materials and Methods. Bars and error bars denote mean 
± one-half of the range from n=2 livers in duplicate.  
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Figure 5.8. Inhibition of Na+-dependent TC Initial Uptake in Suspended Human 
Hepatocytes by S-sulfone (A) and S-sulfide (B). Na+-dependent [3H]TC initial uptake 
(1 µM, 60 nCi/ml, 30 sec) was determined by subtracting [3H]TC uptake in Na+-free 
buffer from those values in Na+-containing buffer in the presence of increasing 
concentrations of S-sulfone (1-300 µM) and S-sulfide (0.1-100 µM). Open and 
closed circles denote individual data from n=2 livers in duplicate. The dotted curve 
represents the best fit of the sigmoidal inhibitory Emax model to the data using 
WinNonlin; the curve shape factor (r) was estimated as 0.6 and 0.9 for S-sulfone and 
S-sulfide, respectively. 
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CHAPTER 6 
 
Summary and Future Directions 
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The objective of this dissertation research was to examine the role of hepatic 
transport proteins in drug disposition and drug-induced liver injury. Although a 
number of studies have focused on elucidating the transport mechanisms 
responsible for hepatic uptake and biliary excretion of drugs, the effect of one or 
more transport protein(s) on overall drug disposition and drug-induced liver injury 
has not been fully characterized. To address these questions, a series of 
experiments was designed using a multi-experimental approach.  
Sandwich-cultured hepatocytes (SCH) have been used instead of primary 
hepatocytes cultured in monolayer to examine the hepatobiliary disposition of 
substrates because SCH exhibit polarized architecture, form extensive canalicular 
networks over time in culture, and maintain function of metabolic enzymes and 
transport proteins. The maintenance of tight junction integrity in the presence of Ca2+ 
enables substrate accumulation in the canalicular spaces. Biliary clearance data 
estimated in rat and human SCH have been correlated with in vivo biliary clearance 
for several therapeutic compounds (Liu et al., 1999a; Ghibellini et al., 2007b; Abe et 
al., 2008). However, the use of SCH is limited when determining the contribution of a 
specific transport protein to overall drug hepatobiliary disposition because specific 
inhibitors or probe substrates for individual transport proteins have not been 
identified. Alternatively, membrane vesicles overexpressing a single transport 
protein can be used to determine substrate specificity or affinity for transport proteins.  
Isolated liver perfusion is an established technique. This approach enables careful 
and comprehensive assessment of hepatic disposition of drugs and metabolites by 
examining the rate of appearance of substrate in bile and in the fluid perfusing the 
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liver vasculature. In mice, this technique presents a number of technical challenges 
due to the small size of the liver. In recent years, our laboratory has modified 
successfully the technique in rats for use in mice (Nezasa et al., 2006). 
The underlying hypothesis of this doctoral dissertation research was that 
multiple transport proteins are involved in drug disposition and drug-induced liver 
injury. This hypothesis was examined by a series of experiments described below: 
 
1. Elucidate the mechanism of differences in the hepatobiliary disposition of 
acetaminophen and metabolites in male and female mice (Chapter 2). In situ 
mouse liver perfusion using male and female wild-type and Bcrp-knockout 
mice was performed to test the hypothesis that the biliary excretion of phase 
II conjugates was influenced by higher Bcrp expression in male mouse livers 
than female mouse livers. Acetaminophen and phase II metabolites (i.e, 
acetaminophen sulfate and glucuronide) were chosen based on previous 
findings demonstrating that Bcrp plays an important role in the biliary 
excretion of these conjugates in mice. Comprehensive pharmacokinetic 
models were developed to describe the hepatobiliary disposition of 
acetaminophen and metabolites in mouse livers.  
 
2. Assess the utility of an integrated in vitro approach [SCH and 
modeling/simulation] to predict alterations in drug hepatobiliary disposition 
(Chapter 3). These experiments tested the hypothesis that rat and human 
SCH can be used to mimic the in vivo disposition of troglitazone (TGZ) and 
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generated metabolites in rats and humans. Additionally, pharmacokinetic 
modeling and Monte Carlo simulation approaches coupled with data from 
SCH were utilized to examine the consequences of altered biliary excretion, 
which might be due to drug interactions or disease states, on hepatic 
exposure in hypothetical “populations” of hepatocytes.   
 
3. Examine the potential role of hepatic transport proteins in drug-induced 
liver injury (Chapters 4 and 5).  Trabectedin (a promising anticancer agent) 
and sulindac (a non-steroidal anti-inflammatory drug) were chosen based on 
previously published findings regarding the incidence of liver injury mediated 
by these drugs in humans.  
1) Dexamethasone (DEX) decreased liver injury mediated by trabectedin in 
rats and humans, but this was not mimicked in rat hepatocytes cultured on a 
fibronectin matrix. The hypothesis underlying this aim (Chapter 4) was that 
Mrp2 and CYP3A1/2 played a role in the hepato-protective effect of DEX 
against trabectedin-mediated hepatotoxicity. Trabectedin-mediated 
cytotoxicity was examined in SCH. The role of Mrp2 in biliary excretion of 
trabectedin was evaluated in isolated perfused livers from wild-type and 
Mrp2-deficient TR- rats.  
2) The hypothesis underlying this aim (Chapter 5) was that the interaction of 
sulindac as well as its metabolites with hepatic transport proteins altered the 
hepatobiliary disposition of bile acids and other endogenous or exogenous 
compounds, and these interactions played a role in sulindac-mediated liver 
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injury. Probe substrates including nitrofurantoin (NF), taurocholate (TC), and 
estradiol-17β-glucuronide (E217G) were used to examine the interaction 
between sulindac/metabolites and Bcrp-, Ntcp/Oatp/Bsep-, Oatp/Mrp2-
mediated transport, respectively, in rat or human SCH, and in suspended 
hepatocytes.  
 
Mechanism of differences in the hepatobiliary disposition of phase II 
conjugates in male and female mice (Chapter 2). 
 Sex-related variations in pharmacokinetics have been considered as a 
potential determinant for the clinical effectiveness of therapeutic agents by affecting 
ADME (absorption, disposition, metabolism and elimination). Emerging evidence 
suggests that sex-related variations in the expression and activity of drug transport 
proteins may contribute to differences in therapeutic response or toxicity.  
BCRP is highly expressed in the liver and mediates the excretion of a wide 
variety of drugs and environmental toxicants into bile, as well as specific metabolites 
(e.g., sulfate and glucuronide conjugates) formed in the liver. Interestingly, it has 
been reported that BCRP protein expression in liver is sex-dependent in mice and 
humans (Merino et al., 2005b). Furthermore, several anticancer drugs that are 
known BCRP substrates (e.g., topotecan, methotrexate, and doxorubicin) exhibit 
sex-dependent disposition in humans. Only a limited number of studies have 
explored relationships between BCRP and sex-related treatment efficacy; the 
specific role of BCRP in this therapeutically-important phenomenon has not been 
elucidated.    
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In situ mouse liver perfusion was applied to four different groups of mice; 
male and female wild-type and Bcrp-deficient mice (C57BL/6) were used to compare 
the perfusate disposition and biliary excretion of acetaminophen sulfate (AS) and 
acetaminophen glucuronide (AG) in the presence of differential BCRP expression 
(i.e, higher in males than in females). Male and female Bcrp-deficient mice, obtained 
through collaboration with Eli Lilly and Co., provided a unique opportunity to 
ascertain whether mechanisms other than Bcrp expression modulate hepatic 
disposition of acetaminophen metabolites between male and female mice. AG and 
AS biliary excretion in female wild-type mice was 3- and 2.5-fold lower, respectively, 
compared to male wild-type mice, reflecting male-predominant Bcrp expression. In 
Bcrp-deficient mice, sex-dependent differences in AG biliary excretion were not 
observed, indicating that Bcrp was likely responsible for the sex difference in wild-
type mice. Unexpectedly, excretion of AG and AS into the perfusate was also sex-
dependent; basolateral excretion of AG was higher in male wild-type mouse livers 
while AS basolateral excretion was higher in female wild-type mouse livers.  
Pharmacokinetic modeling was used to describe the disposition of 
acetaminophen, AG and AS in perfused mouse livers. The AG biliary excretion rate 
constant (Kbile,AG) was ~7-fold higher in male wild-type mouse livers, but was similar 
between male and female Bcrp-deficient mouse livers.  Likewise, the rate constant 
for AS biliary excretion (Kbile,AS) in male livers was ~2.5-fold higher than in female 
wild-type mouse livers. Sex-dependent differences in metabolite formation rate 
constants were observed for AG (~2-fold higher in males) and AS (~2-4-fold higher 
in females). The basolateral excretion rate constant of AS (Kperf,AS), but not AG 
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(Kperf,AG), differed based on sex; the AS basolateral excretion rate constant was ~2-
fold higher in females, potentially due to higher Mrp4 expression in female livers.  
Overall, these results demonstrated that sex-dependent differences in the 
hepatic disposition of AG and AS were due, in part, to sex-related BCRP expression. 
Other factors relating to formation of conjugates as well as conjugate transport from 
the liver into blood likely played a role in disposition of AG and AS. Sex-related 
differences in BCRP expression may cause clinically significant alterations in the 
disposition of drugs that are BCRP substrates. These exciting results provide a new 
framework for investigations directed towards elaborating the mechanisms 
underlying sex-related differences in drug disposition and drug interactions resulting 
in altered drug response and/or toxicity associated with therapeutic agents and 
environmental chemicals. 
An integrated in vitro approach [SCH and modeling/simulation] to predict 
alterations in hepatobiliary drug disposition (Chapter 3). 
Troglitazone (Rezulin; TGZ), an anti-diabetic and anti-inflammatory drug, 
was withdrawn from the market in 2000 due to severe hepatotoxicity. Inhibition of 
BSEP by TGZ and TGZ-sulfate (TS) has been hypothesized to be responsible for 
the cholestatic effect; BSEP was inhibited more potently by TS than by TGZ, 
demonstrating the importance of metabolite-mediated hepatotoxicity in addition to 
that of the parent drug. Unfortunately, preclinical toxicological studies failed to 
predict this hepatotoxicity (Smith, 2003). 
The aim of this study was to evaluate the capability of an in vitro model, rat 
and human SCH, to mimic the in vivo metabolism and hepatobiliary disposition of 
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TGZ in rats and humans. Consistent with the in vivo metabolism of TGZ, TGZ was 
extensively metabolized to TS and to a lesser extent to TG and TGZ-quinone (TQ) in 
rat and human SCH.  Moreover, TS was the predominant metabolite in medium and 
hepatocytes in both rat and human SCH. 
A secondary objective of this specific aim was to examine the impact of 
impaired biliary excretion on the hepatobiliary disposition of TS and TG using data 
from SCH coupled with pharmacokinetic modeling and Monte Carlo simulations. 
Parameters governing the hepatobiliary disposition of TGZ and its metabolites in 
SCH were estimated by compartmental pharmacokinetic modeling. Subsequently, 
Monte Carlo simulations were performed by utilizing parameter estimates and 
variance associated with nonlinear least-squares regression and uncontrolled error 
(e.g., experimental or analytical error; 15%) to examine the impact of altered biliary 
excretion on accumulation of TS and TG in hepatocytes and medium. In a 
hypothetical “population” of hepatocytes, cellular accumulation of substrate 
[representative of liver] was highly sensitive to altered biliary transport, but changes 
in biliary excretion exhibited only a modest effect on substrate in medium 
[representative of blood]. Data from Monte Carlo simulations at each time point were 
utilized to estimate the number of observations necessary to detect a statistically 
significant difference in TS or TG accumulation in hepatocytes and medium when 
the rate constant for biliary excretion of TS or TG was modulated [2-fold increase or 
decrease from experimentally-determined parameter estimates]. The number of 
observations required to detect a statistically significant difference for TS and TG 
was less in hepatocytes than in medium at all time points, supporting the hypothesis 
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that cellular accumulation of these substrates is more sensitive to changes in altered 
biliary excretion than accumulation in medium. In clinical studies, plasma 
concentrations are typically used to examine the effect of altered hepatic transport 
function (e.g., drug interactions in biliary excretion, polymorphisms of canalicular 
transport proteins). However, Monte Carlo simulations suggest that plasma 
concentrations may not always reflect changes in hepatic exposure when biliary 
excretion pathways are modulated. Previous findings have  demonstrated that 
BCRP plays an important role in TS biliary excretion in humans (Enokizono et al., 
2007). Simulations suggest that TS concentrations in the liver would be higher in 
subjects with less functional BCRP (due to drug-drug interactions, disease state 
alterations, and/or polymorphisms), resulting in more potent BSEP inhibition, thereby 
increasing the susceptibility of some patients to TS-mediated cholestatic effects.  
The potential role of hepatic transport proteins in drug-induced liver injury. 
 Drug-induced liver injury has been the most common reason for the 
withdrawal of approved drugs from the market. Although drug-induced liver injury 
has been attributed to many factors including covalent adduct formation, 
immunotoxicity, and impaired bioenergetics, accumulating evidence suggests that 
inhibition of hepatic transport proteins by a drug and/or derived metabolite may 
mediate liver injury. Many studies have focused on interactions with BSEP because 
inhibition of BSEP results in accumulation of detergent-like bile acids in the liver 
which may lead to hepatic injury. However, when drugs or metabolites are 
intrinsically hepatotoxic, impaired function of one or more transport proteins other 
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than BSEP which are responsible for hepatobiliary disposition of a drug or its 
metabolites can also contribute to drug-induced liver injury.  
1) Trabectedin (Chapter 4) 
 Liver injury mediated by trabectedin (ET-743), a promising anticancer agent, 
has been the most common side effect during phase I/II clinical trials (Beumer et al., 
2005b). Interestingly, pretreatment with DEX in rats and humans markedly 
decreased ET-743-mediated hepatotoxicity, which was attributed to DEX-mediated 
CYP3A4 induction. However, the protection by DEX against trabectedin-mediated 
hepatotoxicty could not be mimicked in primary rat hepatocytes cultured on a 
fibronectin matrix.  The objective of this specific aim was to examine whether SCH 
could predict the hepatoprotective effect of DEX against trabectedin-mediated 
hepatotoxicity, and to further examine the involvement of Mrp2 in ET-743 biliary 
excretion using isolated perfused rat livers (IPL).  
 Pretreatment with DEX in wild-type rat SCH significantly decreased 
trabectedin-mediated cytotoxicity compared to vehicle control. In addition to inducing 
CYP3A1/2, DEX also induces Mrp2.  To investigate the involvement of Mrp2, 
trabectedin-mediated cytotoxicity was compared between wild-type and Mrp2-
deficient TR- rats. Surprisingly, trabectedin-mediated cytotoxicity was less extensive 
in TR- than wild-type rat SCH. One possible explanation for this unexpected finding 
was that TR- rat hepatocytes were protected from trabectedin-mediated 
hepatotoxicity because of a higher level of glutathione in these hepatocytes due to 
impaired Mrp2-mediated excretion. To examine this hypothesis, trabectedin-
mediated cytotoxicity was examined in wild-type rat SCH pretreated with buthionine 
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sulfoximine (BSO), a glutathione depleting agent. Trabectedin-mediated cytotoxicity 
was significantly decreased in BSO-pretreated compared to vehicle-pretreated SCH. 
Consistent with previous findings (Turncliff et al., 2004), immunoblot analysis 
demonstrated that Mrp2 and CYP3A1/2 protein expression in rat SCH was 
increased by DEX pretreatment. Interestingly, BSO pretreatment markedly increased 
expression of Mrp4 and to a lesser extent Mrp2 and Mrp3 compared to vehicle 
control. To examine the involvement of Mrp2 in trabectedin hepatobiliary disposition, 
IPL studies were performed in wild-type and TR- rats. Trabectedin biliary excretion in 
IPLs from TR- rats was decreased by ~75% compared to wild-type IPLs, suggesting 
that Mrp2 plays a significant role in trabectedin biliary excretion.  
 Collectively, the hepatoprotection that DEX provides in trabectedin-mediated 
hepatotoxicity may be due to the combined effect of increased metabolism by 
CYP3A1/2 and enhanced biliary excretion by Mrp2.  Increased expression of 
basolateral transport proteins such as Mrp3 and/or Mrp4 due to BSO-pretreatment in 
TR- rat SCH may be one mechanism underlying the unexpected attenuation of 
trabectedin-mediated hepatotoxicity. 
2) Sulindac, sulindac sulfone and sulindac sulfide (Chapter 5) 
 Sulindac is converted to two major metabolites; sulindac sulfide (S-sulfide) 
has anti-inflammatory activity and sulindac sulfone (S-sulfone) has been recognized 
recently as a chemopreventive agent in colon cancer. After oral administration of 
sulindac, plasma concentrations of sulindac and its metabolites were comparable in 
humans (Davies and Watson, 1997). Among other NSAIDS, sulindac was 
associated most consistently with hepatotoxicity (Aithal and Day, 2007), but the 
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mechanism(s) of sulindac-mediated hepatotoxicity are not fully characterized. It has 
been shown that S-sulfide concentrations in plasma correlated in a linear manner 
with the incidence of hepatotoxicity, suggesting that S-sulfide may be involved in 
sulindac-mediated hepatotoxicity (Duggan et al., 1978; Laffi et al., 1986). The 
potential role of transport proteins in drug-induced liver injury has been hypothesized 
recently and some studies have demonstrated the interaction between sulindac and 
transport proteins (e.g., MRP2, MRP4, OAT1, OAT3, and OCT3) (Khamdang et al., 
2002; El-Sheikh et al., 2006). However, only limited information about the interaction 
between sulindac metabolites and hepatic transport proteins is available (e.g., S-
sulfide-mediated MRP4 inhibition) (Rius et al., 2008). Therefore, the aim of this study 
was to determine the interaction of hepatic transport proteins with sulindac as well 
as its metabolites using nitrofurantoin (NF), taurocholate (TC) and estradiol-17β-
glucuronide (E217G) as probe substrates for Bcrp-, Ntcp/Oatp/Bsep- and 
Oatp/Mrp2-mediated transport.  
In rat SCH, the in vitro Clbiliary of NF was decreased significantly by 100 µM 
sulindac (33% decrease), S-sulfone (33% decrease) and S-sulfide (42% decrease) 
without affecting NF accumulation in the hepatocyte and bile compartments, 
suggesting that Bcrp-mediated transport was inhibited by sulindac and its 
metabolites. Sulindac (10 µM; 53% decrease), S-sulfone (100 µM; 76% decrease) 
and S-sulfide (100 µM; 84% decrease) significantly inhibited in vitro Clbiliary of TC; the 
biliary excretion index (BEI) of TC was inhibited significantly by 100 µM S-sulfone 
(43% decrease) and S-sulfide (55% decrease) but not by sulindac.  The BEI of 
E217G was not decreased in the presence of sulindac, S-sulfone and S-sulfide, but 
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in vitro Clbiliary of E217G was significantly decreased by S-sulfone and S-sulfide, 
suggesting more potent inhibition in the hepatic uptake process than biliary excretion. 
Suspended hepatocytes were selected as the model system to further characterize 
the inhibitory kinetics of sulindac metabolites on TC and E217G uptake, because it is 
easier to determine initial uptake rates using this system compared to SCH. In 
suspended rat hepatocytes, S-sulfone and S-sulfide inhibited Na+-dependent TC 
initial uptake (IC50 of 25.6±10.7 µM and 12.7±5.3 µM, respectively), and Na+-
independent E217G initial uptake (IC50 of 12.6±5.1 µM and 6.5±1.2 µM, respectively). 
In addition, S-sulfide markedly decreased TC accumulation in the hepatocytes and 
bile compartments as well as in vitro TC Clbiliary, but did not affect TC BEI in human 
SCH. The IC50 of S-sulfide (3.1 µM) on Na+-dependent TC uptake determined in 
suspended human hepatocytes was ~14-fold lower than for S-sulfone (42.2 µM).   
Collectively, studies conducted to address this specific aim revealed that 
hepatic transport proteins (Ntcp/NTCP, Oatp, Bsep or Bcrp) are inhibited by sulindac 
and its metabolites. Considering the important role of Ntcp/NTCP, Oatp and Bsep in 
hepatic uptake and excretion of bile acids in the liver, impaired hepatic transport of 
bile acids by sulindac and its metabolites may disturb bile acid homeostasis, 
resulting in sulindac-mediated hepatotoxicity. Although the contribution of BCRP to 
bile acid transport is minor, inhibition of BCRP-mediated transport by sulindac and 
its metabolites may result in increased hepatic accumulation of potentially toxic 
metabolites such as S-sulfide or other co-administered drugs. Several studies with 
sulindac alone or combined with other drugs (e.g., lovastatin, celecoxib, doxetaxel, 
carboplatin, and vinorelbine) have been conducted recently to examine the 
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therapeutic effect of sulindac as an antiproliferative agent for colon cancer (Jones et 
al., 2005; Hoang et al., 2006; Xiao and Yang, 2008).  Based on the present study 
demonstrating inhibition of multiple transport proteins by sulindac and its metabolites, 
the possibility of  drug-drug interactions should be examined carefully when sulindac 
is coadministered with other drugs, and careful monitoring for hepatotoxicity would 
be warranted.  
 
Future directions 
This dissertation research has prompted a number of proposed future studies 
regarding the impact of sex-dependent transport protein expression on overall drug 
pharmacokinetics, the utility of pharmacokinetic modeling and simulation coupled 
with SCH to examine the impact of transport modulation on drug disposition, and 
assessing multiple types of interactions between compounds and transport proteins. 
These topics are detailed below.  
 
Sex differences in drug transport 
Discrepancies in drug metabolism between sexes are currently thought to 
play a role in determining sex-differences in pharmacokinetic parameters. For 
example, significant sex-differences in some key CYP450 enzymes have been 
demonstrated.  A recent study analyzed 38 data sets containing the clearance 
values of 10 xenobiotics which were CYP3A [but not P-glycoprotein (P-gp)] 
substrates in healthy young male and female subjects; the overall mean of weighted-
normalized clearance values was significantly different between males and females 
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(Greenblatt and von Moltke, 2008).  Although some animal and human data suggest 
sex differences in expression of transport proteins, evidence for sex-dependent 
pharmacokinetic differences in relation to transport proteins in humans are less 
apparent. For example, despite higher P-gp expression in livers of men compared to 
women, phenotyping with fexofenadine did not demonstrate sex differences in 
clearance (Schuetz et al., 1995; Kim et al., 2001).  
There are several potential reasons to explain the less apparent transporter-
mediated pharmacokinetic differences in male and female subjects. First, the 
overlapping substrate specificity among hepatic transport proteins may be a 
confounding factor in assessing sex-dependent differences in drug transport. For 
example, multiple transport mechanisms such as BSEP and MRP4 are involved in 
the hepatobiliary disposition of fexofenadine which was used in P-gp phenotyping 
(Matsushima et al., 2008). Although higher P-gp expression in male subjects results 
in decreased biliary excretion of fexofenadine in the liver, BSEP-mediated biliary 
excretion and/or MRP3-mediated basolateral excretion of fexofenadine could 
completely offset the impact of differences in P-gp expression. Second, tissue-
specific sex-dependent expression of transport proteins can be another confounding 
factor. Sex-dependent hepatic Bcrp/BCRP expression in mice and humans was not 
observed in rats (Merino et al., 2005b), but Bcrp expression in the kidney was higher 
in male rats (Tanaka et al., 2005).  Although this finding may suggest apparent 
species differences in sex-dependent expression of transport proteins, it also 
suggests that differential mechanisms may be involved in the tissue-specific 
regulation of transport proteins. Therefore, sex-dependent expression of transport 
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proteins in one organ may not change the overall pharmacokinetics due to equal 
expression of the same transport protein in other organs between males and 
females.  
Overall, it is still challenging to examine the possible influence of sex on 
transporter-mediated drug disposition due to the apparent complexity of transport 
mechanisms as mentioned above. It is plausible that transporter-dependent sex 
differences in drug disposition between males and females may influence 
therapeutic outcome and/or toxicological response if a drug is targeting one specific 
organ for its therapeutic efficacy (e.g., statins).  Data regarding sex-dependent 
differences in transport proteins in clearance organs (e.g., liver, kidney) can be 
incorporated in physiologically-based pharmacokinetic modeling to predict the 
impact of sex-dependent transport functions on the overall drug disposition. 
 
Pharmacokinetic modeling and simulation coupled with data from SCH 
 The utility of SCH as an in vitro model to examine phase I and II metabolism 
and hepatic transport mechanisms has been established (Chapter 3, (Liu et al., 
1999c; Hoffmaster et al., 2005; Turncliff et al., 2006; Ghibellini et al., 2007a). 
Pharmacokinetic modeling has been employed to describe the hepatobiliary 
disposition of model substrates, and subsequent simulation studies utilizing 
parameter estimates from pharmacokinetic modeling have been performed to further 
examine the impact of altered function of one or more hepatic transport proteins on 
overall hepatobiliary disposition (Chandra et al., 2005; Hoffmaster et al., 2005; 
Turncliff et al., 2006; Ghibellini et al., 2008). However, these simulations did not 
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incorporate uncertainty associated with parameter estimates or 
experimental/analytical error, thereby resulting in a less reliable prediction of the true 
phenomenon. A Monte Carlo simulation is a stochastic method using random 
numbers and probability to analyze the behavior of a complex system that involves 
uncertainty and to determine how random variation or error influences the sensitivity, 
performance, or reliability of a model (Rubinstein, 2008). Recently, Monte Carlo 
simulations have been applied to the design and execution of clinical trials, and to 
evaluating methods to predict drug-drug interactions (Kato et al., 2003; Michelson et 
al., 2006).  Monte Carlo simulations using data from rat SCH were employed to 
predict the impact of altered biliary excretion on the hepatobiliary disposition of TS 
and TG in a hypothetical “population” of hepatocytes, and to examine the impact of a 
first-order leakage process of TS and TG from the bile canaliculi of SCH into the 
incubation medium on the accumulation of TS and TG in hepatocytes and medium.  
Interestingly, pharmacokinetic modeling revealed the presence of a first-order 
leakage process for TS and TG from bile canaliculi to the incubation medium in SCH 
after 20 min of incubation. The mechanism(s) responsible for this leakage process in 
SCH have not been characterized. In future studies, it would be beneficial to 
examine the hepatobiliary disposition of drugs which undergo enterohepatic 
recycling as the parent drug, or without deconjugation, [e.g., rosuvastatin, TS (Kawai 
et al., 2000; Nezasa et al., 2002)] because it may reflect a fundamental physiological 
process of bile excretion in vivo and subsequent reuptake into the liver after 
intestinal absorption. On the other hand, when the time-course data with more than 
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a 20-min incubation time in SCH is used to predict in vivo drug biliary clearance, the 
leakage process in SCH may result in underestimation of biliary clearance.  
As shown in Chapters 4 and 5, the SCH system is a useful in vitro model to 
examine the potential role of transport proteins in the hepatobiliary disposition of a 
drug that is associated with liver injury due to its intrinsically toxic properties, or its 
interaction with hepatic transport proteins.  However, elucidating the role of hepatic 
transport proteins in the hepatobiliary disposition of hepatotoxic drugs does not 
answer the important question of how impaired hepatic transport mechanisms result 
in hepatotoxicity. Although increased accumulation of detergent-like bile acids in the 
liver due to drug/metabolite-mediated BSEP inhibition has been proposed as one 
mechanism for liver injury associated with some hepatotoxic drugs, the role of other 
transport proteins in drug-induced hepatotoxicity remains to be determined.  
In order to answer these questions, SCH can be used to measure the activity 
of alanine aminotransferase (ALT) and alkaline phosphatase (ALP) along with the 
accumulation of drugs/metabolites in medium, hepatocytes, and bile at 
predetermined time points. Pharmacokinetic modeling can be constructed to explain 
the flux of drug/metabolites in SCH.  Changes in the activity of ALT and ALP due to 
drug exposure can be linked to pharmacokinetic parameters as toxicodynamic 
responses when developing an integrated pharmacokinetic/toxicodynamic model.  
This approach may provide a mechanistic understanding of the role of hepatic 
transport proteins in drug-mediated hepatotoxicity.   
Several clinical studies have demonstrated that genetic polymorphisms in 
BCRP (ABCG2) can influence drug disposition. For example, the ABCG2 C421A 
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polymorphism, which is associated with decreased protein expression and function 
in vitro (Imai et al., 2002), increased plasma concentrations of several BCRP 
substrates such as rosuvastatin, diflomotecan, and sulfasalazine (Morisaki et al., 
2005; Zhang et al., 2006a; Yamasaki et al., 2008). However, the ABCG2 C421A 
polymorphism had no effect on the plasma pharmacokinetics of NF, which was 
tested as a potential clinical probe substrate to assess BCRP activity in humans 
(Adkison et al., 2008).  Hepatobiliary disposition of the BCRP substrates, whose 
pharmacokinetics were examined in subjects, can be assessed in human SCH.  
Pharmacokinetic modeling/simulation of the data from human SCH can be utilized to 
test whether the impact of hypothetical changes in the biliary excretion pathway on 
hepatobiliary disposition of BCRP substrates is consistent with previously reported in 
vivo findings in humans. SCH with partial and/or complete BCRP knockdown using 
RNAi, which has been recently optimized for Bcrp knockdown in rat SCH (Yue, 
2008), can be used to confirm the reliability of predicting the consequences of 
altered biliary excretion.  
 
Interaction between compounds and hepatic transport proteins 
 The results of this dissertation research demonstrate that compounds interact 
with transport proteins in multiple ways. For example, BSO increased protein 
expression of Mrp4 in rat SCH (Chapter 4).  BSO inhibits γ-glutamylcysteine 
synthetase, the rate-limiting step in GSH synthesis (Griffith and Meister, 1979), and 
has been used as a glutathione (GSH)-depleting agent. Considering that GSH is 
excreted with monoanionic bile acids by Mrp4 (Rius et al., 2003), increased Mrp4 
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expression by BSO may augment GSH depletion in hepatocytes. Interestingly, 
Aleksunes et al. demonstrated that the transcription factor NFE2-related factor 2 
(Nrf2) was involved in the upregulation of Mrp3 and Mrp4 as one mechanism of 
neutralizing oxidative stress during acetaminophen hepatotoxicity (Aleksunes et al., 
2008). Therefore, BSO-mediated upregulation of Mrp4 may be mediated by an 
indirect response associated with oxidative stress due to GSH depletion. 
 Pharmacokinetic modeling of the hepatobiliary disposition of acetaminophen 
and metabolites in mouse livers (Chapter 2) required an intervening compartment 
between the sites of conjugate formation and excretion into bile to describe the 
prolonged biliary excretion of AG and AS during the washout phase.  These data 
suggest the presence of a discrete compartment with cytosolic localization and 
functional Bcrp activity that explains the unidirectional flux of AG and AS prior to 
biliary excretion. This hypothesis may be supported by a recent study demonstrating 
subcellular localization of BCRP in folate-deprived MCF cells as a process of cellular 
adaptation to folate deprivation. (Ifergan et al., 2005). Additionally, the presence of 
functional P-gp in the Golgi and the mitochondrial membrane has been reported in 
doxorubicin-resistant K562 leukemia cells (Munteanu et al., 2006).  Intracellular 
sequestration of substrates mediated by transport proteins, which are functionally 
expressed in cytosolic organelles, may affect overall hepatobiliary disposition of 
substrates, and further studies are warranted.  
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Summary 
This dissertation work furthered our understanding of the role of hepatic 
transport proteins in drug disposition and drug-induced liver injury using several 
model compounds. First, the hepatobiliary disposition of AS and AG was influenced 
by sex-dependent Bcrp expression in mice. Clinically-significant sex-dependent 
disposition of drugs/metabolites that are BCRP substrates is plausible due to male-
predominant BCRP expression in humans. Second, the similarity of TGZ metabolism 
and disposition in rat and human SCH with those in rats and humans in vivo further 
established the utility of the SCH model as an in vitro tool to predict in vivo 
disposition in rats and humans. In addition, pharmacokinetic modeling and 
simulation coupled with data obtained from the SCH model predicted likely 
alterations in drug/metabolite hepatobiliary disposition in humans.  Third, the 
potential involvement of transport proteins other than BSEP in drug-induced liver 
injury was proposed for trabectedin (Mrps) and sulindac/metabolites (Ntcp, Oatp or 
Bcrp).  
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APPENDIX 1 
 
GF120918 (Elacridar) Inhibits Multidrug Resistance- 
Associated Protein 3 (MRP3)- and MRP4-Mediated Transport. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This Chapter will be submitted to Drug Metabolism and Disposition as Short 
Communication. 
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ABSTRACT 
GF120918 (GW918) has been used extensively as a potent and selective 
inhibitor of P-glycoprotein-(P-gp; MDR1) and breast cancer resistance protein-
(BCRP; ABCG2) mediated transport. Interestingly, pharmacokinetic modeling of 
data generated in our laboratory supports a potential interaction between GW918 
and hepatic basolateral efflux proteins. The inhibition, by GW918, of both biliary 
and basolateral excretion routes may cause unexpected hepatic accumulation of 
drugs. The aim of the present study was to examine the interaction between 
GW918 and hepatic basolateral efflux transport proteins, specifically MRP3 and 
MRP4. Effects of GW918 (P-gp/BCRP inhibitor) and MK571 (MRP inhibitor; 
positive control) on MRP3- and MRP4-mediated transport were examined in 
inside-out HEK293 membrane vesicles overexpressing MRP3 or MRP4 using two 
model substrates (Estradiol-17-β-glucuronide, E217G and methotrexate, MTX). In 
the presence of physiologic concentration of reduced glutathione (GSH, 3 mM), 
MK571 (18 µM) significantly inhibited MRP3- and MRP4-mediated E217G and 
MTX transport. Interestingly, GW918 (18 µM) significantly inhibited MRP3-
mediated E217G transport, and MRP4-mediated E217G (30%) and MTX (60%) 
transport when GSH was coadministered. In conclusion, GW918, which previously 
was designated as a specific canalicular transport inhibitor, also inhibits MRP3- 
and MRP4-mediated hepatic basolateral transport.   
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INTRODUCTION 
GW918 (GF120918 ; elacridar; N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-
isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine 
carboxamide) has been used extensively as a potent and selective inhibitor for P-
glycoprotein (P-gp; MDR1) and breast cancer resistance protein (BCRP; ABCG2) 
in vitro as well as in vivo.  For example, the systemic exposure of topotean was 
increased 10-fold in mice in the presence of GW918 (Jonker et al., 2000); the 
apparent oral bioavailability of topotecan combined with GW918 was improved 
from 40% to 97.1% in patients (Kruijtzer et al., 2002). Recently, a phase I clinical 
study was conducted to determine an optimal oral dosing schedule for 
coadministration of topotecan and GW918 (Kuppens et al., 2007). 
Although GW918 has been designated as a canalicular transport inhibitor, 
pharmacokinetic modeling of in vitro/in vivo data generated in our laboratory 
indicated that GW918 inhibits a hepatic basolateral efflux process. However, the 
exact mechanism of an interaction between GW918 and hepatic basolateral 
export proteins remains to be elucidated.  Dual inhibition of biliary and basolateral 
excretion by GW918 may cause unexpected hepatic accumulation of drugs, 
thereby impacting drug efficacy and/or toxicity.   
A previous study suggested GW918-mediated inhibition of  basolateral 
transport of [D-Pen2, D-Pen5]-enkephalin (DPDPE), an opioid peptide, in isolated 
perfused rat liver experiments (Hoffmaster et al., 2004b). In this study, GW918 
decreased steady-state perfusate concentrations of DPDPE due to increased 
perfusate clearance (Hoffmaster et al., 2004b).  These unexpected findings, 
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particularly in Mrp2-deficient TR- rat livers where DPDPE biliary clearance was 
decreased, could be explained by the increased liver/perfusate partitioning and 
inhibition of hepatic basolateral efflux of DPDPE in the presence of GW918. 
Furthermore, Tian et al. also observed a significant decrease in the rate constant 
representing basolateral efflux of spiramycin by GW918 in isolated perfused 
mouse livers (Tian et al., 2007). An interaction between GW918 and MRP4 was 
proposed by Lee et al. who examined the role of Bcrp in brain disposition of 
mitoxantrone and dehydroepiandrosterone sulfate (DHEAS) in mice (Lee et al., 
2005b).  The brain uptake of [3H]DHEAS and [3H]mitoxantrone in Bcrp-deficient 
mice was comparable with that in wild-type and P-gp-deficient mice, indicating a 
minor role of Bcrp and P-gp in the active efflux transport of these substrates at the 
blood brain barrier (BBB).  Interestingly, the inhibitory effect of GW918 on the 
brain disposition of [3H]DHEAS and [3H]mitoxantrone was still observed in P-gp-
deficient mice, suggesting a possible contribution of one or more GW918-sensitive 
efflux transporters that are distinct from Bcrp and/or P-gp at the BBB. Based on 
the abundant expression of MRP4 mRNA at the BBB, it was proposed that MRP4 
plays a role in efflux of DHEAS and mitoxantrone at the BBB, and that GW918 
may affect the brain uptake of these substrates by inhibiting MRP4.  
This study was aimed to identify interactions between GW918 and hepatic 
basolateral transport proteins MRP3 and MRP4.  Estradiol 17-β-glucuronide 
(E217G) and methotrexate (MTX) were selected as model substrates for MRP3 
and MRP4 since the kinetics of both compounds have been characterized 
previously in MRP3- and MRP4-overexpressing membrane vesicles; E217G is 
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transported with moderate affinity and low capacity for MRP3 [Km = 25.6 µM; Vmax 
= 75.6 pmol/mg protein/min] and for MRP4 [Km = 30.3 µM; Vmax = 102 pmol/mg 
protein/min] (Zeng et al., 2000; Chen et al., 2001); MTX is transported with low 
affinity and high capacity for MRP3 [Km = 776 µM; Vmax = 288 pmol/mg 
protein/min] and for MRP4 [Km = 220 µM; Vmax = 240 pmol/mg protein/min] (Zeng 
et al., 2000; Chen et al., 2002) .   
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MATERIALS AND METHODS 
Chemicals. Estradiol-17-β-glucuronide (E217G), rifampicin, AMP, ATP, pyruvic 
acid and gentamicin sulfate were purchased from Sigma Chemical Co (St. Louis, 
MO, USA); creatine phosphate and creatine kinase were purchased from Roche 
Diagnostics (Indianapolis, IN, USA), and MK571 was purchased from Cayman 
Chemical Co (Ann Arbor, MI, USA). [3H]E217G (46.9 Ci/mmol; purity>97%) were 
purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). 
[3H]Methotrexate, disodium salt (MTX; 24 mCi/mmol; purity>99%) was purchased 
from Moravek Biochemicals (Brea, CA). All other chemicals and reagents were of 
analytical grade and readily available from commercial sources. 
Transient Transfection of HEK293 Cells with MRP3 or MRP4. The 
pcDNA3.1(+)/MRP3 was kindly provided by Dr. Susan Cole, Queen’s University, 
Ontario, Canada.  Recombinant pcDNA3.1/Hygro plasmids containing human 
MRP4 cDNA were kindly provided by Dr. Dietrich Keppler, German Cancer 
Research Center, Heidelberg, Germany. HEK293 cells were cultured in T-150 
flasks with DMEM (high glucose with phenol red containing 10% FBS). After cell-
counting with trypan blue in 1:10 dilutions, 4.6 × 106 cells in serum-free DMEM 
were seeded in T-150 flasks. After 24-h of cell seeding, HEK293 cells were 
transiently transfected using FuGENE 6 kit (Roche Molecular Biochemicals, Laval, 
PQ, Canada) per the manufacturer’s instructions.  Briefly, 46.77 µl of Fugene 
reagent was diluted with 1553 µl of serum free DMEM without antibiotics and 
incubated for 5 min at room temperature per transfection. DNA was added to the 
mixture of serum free medium and Fugene reagent and incubated for 45 min at 
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room temperature.  After incubation, the total mixture was added directly to the T-
150 flask.  Incubation was continued until cells were confluent (~60-72 hr). 
Membrane Vesicle Preparation. MRP3- or MRP4-overexpressing membrane 
vesicles were prepared as described previously (Leslie et al., 2001).  Transfected 
HEK293 cells were homogenized in buffer (250 mM sucrose/50 mM Tris, 0.25 mM 
CaCl2, and EDTA-free protease inhibitor, pH 7.4).  Cells were disrupted by N2 
cavitation (200 PSI, 5 min).  The exploded cell suspension was mixed with 0.5 M 
EDTA and centrifuged at 1900 rpm for 10 min at 4˚C to remove nuclei.  The 
supernatant was layered onto 10-12 ml of 35% (w/w) sucrose/1 mM EDTA/50 mM 
Tris, pH 7.4 in high speed centrifuge tubes.  After centrifugation at 100,000g at 
4˚C for 1 hr using SW28 rotor (Beckman), the interface was placed in a 25 mM 
sucrose/50 mM Tris, pH 7.4 buffer solution and centrifuged at 100,000g at 4˚C for 
30 min.  The pellets were resuspended with 250 mM sucrose/50 mM Tris, pH 7.4 
and centrifuged at 100,000g at 4˚C for 30 min.  The membranes were washed 
with buffer (250 mM sucrose, 50 mM Tris, pH 7.4) and resuspended by passing 
them through a 27-gauge needle (10-20 times) to make the suspension 
homogeneous and aid in vesicle formation.  The membranes were aliquoted and 
stored at – 80˚C until use.   
Western Blot Analysis. Overexpression of MRP3 and MRP4 in membrane 
vesicles was confirmed by Western blot analysis. After determination of protein 
concentration using the BCA protein assay reagent kit (Pierce Biotechnology, Inc., 
Rockford, IL), samples were diluted to a final protein concentration of 2 µg/10 µl 
with 4X NuPAGE sample buffer, dithiothreitol (DTT; 10% final sample volume) and 
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water.  Samples were loaded onto a NuPAGE 4-12% 10-well SDS polyacrylamide 
gel and separated by electrophoresis in a NOVEX Minicell II blot with NuPAGE 
running buffer at 180 V until the marker reached the bottom of the gel (~2 hr). 
Proteins in the SDS polyacrylamide gel were transferred onto a PVDF membrane 
at 30V for 90 min with  NuPAGE transfer buffer. Following transfer, the membrane 
was incubated in 5%  nonfat dry milk solution in Tris-buffered saline (TBS) with 
0.1% (v:v) Tween-20 for 30-60 min at room temperature.  After blocking, the 
membrane was incubated with anti-MRP3 antibody (M3II-9; Alexis Biochemicals) 
and anti-MRP4 antibody (M4I-10; Alexis Biochemicals) for 2 hr at room 
temperature or over-night at 4˚C and rinsed three times at 10 min intervals.  
Subsequently, the membrane was incubated with 15 mL horseradish peroxidase-
linked secondary antibodies, and rinsed three times. MRP3 and MRP4 in 
membranes were treated with SuperSignal West Dura (Pierce Biotechnology) and 
detected with a VersaDoc 1000 molecular imager (Bio-Rad Laboratories, Hercules, 
CA).  
Membrane Vesicle Transport Studies. Uptake of [3H]E217G and [3H]MTX into 
membrane vesicles was performed by a rapid filtration method as described 
previously (Leslie et al., 2001).  Membrane vesicles (5 µg of protein per time point) 
were pre-warmed for 1 min at 37˚C and added to Tris/sucrose (TS) buffer, 
supplemented with an ATP-regeneration mixture (4 mM ATP or AMP, 10 mM 
MgCl2, 10 mM creatine phosphate and 100 µg/ml creatine kinase) in a final 
volume of 40 µl. The reaction mixture was incubated with [3H]E217G or [3H]MTX 
at 37˚C in the presence of 10 mM DTT or 3 mM GSH solubilized in 10 mM DTT.  
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Initial uptake for E217G and MTX was determined at 1.5 min and 5 min, 
respectively, based on previously published studies (Zeng et al., 2000; Chen et al., 
2001; Chen et al., 2002).  At designated times, 800 µl of ice-cold TS buffer was 
added to the sample mixture.  Diluted samples were filtered through Type A/E 
glass fiber filters (Pall Life Sciences, East Hills, NY) by a rapid filtration method 
and washed twice with TS buffer. Radioactivity associated with the filters was 
measured by liquid scintillation counting.  In control experiments, ATP was 
substituted with AMP.  Net ATP-dependent transport was calculated by 
subtracting uptake measured in the presence of AMP from uptake measured in 
the presence of ATP.  Measurements were corrected for the amount of ligand 
bound to the filters (usually <2% of total radioactivity). To evaluate the inhibitory 
effects of GW918 or MK571 (18 µM) on [3H]E217G and [3H]MTX uptake mediated 
by MRP3 and MRP4, GW918 or MK571 was added into the reaction mixture, and 
then the transport assay was performed as described previously. MK571 was 
utilized as a positive control to ensure functional inhibition of MRP3- and MRP4-
mediated uptake. GW918 and MK571 were dissolved in dimethyl sulfoxide 
(DMSO) and diluted with incubation medium. The final DMSO content was less 
than 0.1 % in the reaction mixture. In all transport assays, the same concentration 
of DMSO was used as a control.  
Data Analysis. All data are expressed as mean ± SE unless otherwise indicated. 
The effect of GW918 and MK571 on MRP3- and MRP4-mediated uptake was 
assessed using a one-way analysis of variance followed by Bonferroni’s post hoc 
test. Differences were considered to be statistically significant when p < 0.05  
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RESULTS  
Western blot analysis confirmed overexpression of MRP3 and MRP4 in 
membrane vesicles (Figure A.1).  To examine functional activity of MRP3- or 
MRP4-overexpressing membrane vesicles, [3H]E217G was used as a model 
substrate at initial concentrations of 5 µM.  At the 0.5-min time point, ATP-
dependent [3H]E217G uptake was markedly higher in MRP3- and MRP4-
membrane vesicles with 56.7 ± 15.3 pmol/mg protein and 29.8 ± 6.1 pmol/mg 
protein, respectively, compared to 7.4 ± 4.5 pmol/mg protein in control (CTL) 
membrane vesicles prepared from nontransfected HEK293 cells (Figure A.2).  
ATP-dependent MRP3-mediated [3H]E217G uptake rate in the absence of 
GSH was ~26% stimulated by GW918, compared to CTL (Figure A.3.A). In MRP4-
overexpressing membrane vesicles, uptake of [3H]E217G in the absence of GSH 
was ~30% decreased in the presence of GW918, compared to in the absence of 
GW918 (Figure A.3.B). MK571 (18 µM), a known inhibitor of MRPs, was used as a 
positive control to ensure functional inhibition of MRP-mediated [3H]E217G uptake.  
MK571 inhibited ~47% of MRP3-mediated [3H]E217G uptake while transport of 
MRP4-mediated [3H]E217G uptake was completely inhibited in the presence of 
MK571 in the absence of GSH (Figure A.3.A and A.3.B).  
MTX was employed as a substrate with low affinity and high capacity for 
MRP3 and MRP4 to examine the interaction between GW918 and basolateral 
transport proteins. In MRP3-overexpressing membrane vesicles, ATP-dependent 
MRP3-mediated [3H]MTX uptake in the absence of GSH was not affected by 
GW918 (Figure A.3.C). Transport of MRP4-mediated [3H]MTX uptake in the 
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absence of GSH was ~15% decreased by GW918  (Figure A.3.D). The degree of 
inhibition of [3H]MTX uptake by MK571 was comparable between values obtained 
in MRP3-overexpressing membrane vesicles (75% inhibition) and those in MRP4-
overexpressing membrane vesicles (82% inhibition). 
The effect of GSH on MRP3- and MRP4-mediated [3H]E217G and [3H]MTX 
uptake was examined in the presence of GW918 or MK571 because previous 
reports indicated that GSH is necessary for MRP4-mediated transport of some 
substrates (Rius et al., 2003; Rius et al., 2008). DTT (10 mM) was added to the 
reaction mixture as a vehicle control since GSH was solubilized in DTT. ATP-
dependent MRP3- and MRP4-mediated [3H]E217G and MRP3-mediated [3H]MTX 
uptake was comparable in the absence or presence of GSH, but MRP4-mediated 
[3H]MTX uptake was significantly decreased In the presence of GSH, compared to 
DTT control (Figure A. 4.A-D).  
ATP-dependent MRP3-mediated [3H]E217G uptake in the presence of 
GSH was not affected by GW918 (Figure A.4.A). In MRP4-overexpressing 
membrane vesicles, transport of [3H]E217G in the presence of GSH was ~30% 
decreased by GW918, compared to without GW918 (Figure A.4.B). MRP3-
mediated [3H]E217G uptake and MRP4-mediated [3H]E217G uptake was inhibited 
~50% and ~100% when MK571 and GSH were included in the incubation medium 
(Figure A.4.A and A.4.B).  
In MRP3-overexpressing membrane vesicles, ATP-dependent [3H]MTX 
uptake in the presence of GSH was significantly decreased (15%) by GW918, 
compared to without GW918 (Figure A.4.C). Transport of MRP4-mediated 
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[3H]MTX uptake in the presence of GSH was ~60% decreased by GW918  (Figure 
A.4.D). The degree of inhibition of [3H]MTX uptake by MK571 in the presence of 
GSH was comparable (~90% inhibition) between values obtained in MRP3-
overexpressing membrane vesicles and those in MRP4-overexpressing 
membrane vesicles (Figure A.4.C and A.4.C). 
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DISCUSSION 
The present study demonstrated that GW918 inhibited MRP3-mediated 
[3H]MTX transport (~15% inhibition) and MRP4-mediated transport of [3H]E217G 
(~30% inhibition) and [3H]MTX (~60% inhibition) when GSH was present. In 
contrast, GW918 did not inhibit MRP3-mediated [3H]E217G transport. Compound-
specific GW918 inhibition of MRP3-mediated transport may be due to different 
affinities of the substrate for MRP3; E217G represents a substrate with moderate 
affinity and MTX a substrate with low affinity.   
GW918-mediated inhibition of MRP4 transport may cause organ-specific 
differences in drug disposition, depending on the localization of MRP4 throughout 
the body. Considering the sinusoidal localization of MRP4 in the liver, GW918-
mediated inhibition of MRP4 transport coupled with inhibition of canalicular 
transport proteins including P-gp and BCRP, may increase hepatic accumulation 
of drug, thus causing unexpected hepatic toxicity or compromised therapeutic 
efficacy.  In contrast to the liver, MRP4 along with P-gp and BCRP are expressed 
on the apical domain in the kidney and brain. Therefore, inhibition of MRP4 
transport by GW918 may result in more potent inhibition of drug efflux in the 
kidney and brain than expected.  
While the bile salt export pump (BSEP) is the major canalicular bile salt 
transport proteins in hepatocytes, MRP4, but not MRP3, plays an important role in 
hepatic basolateral efflux of bile acids in the presence of GSH (Zeng et al., 2000; 
Byrne et al., 2002; Rius et al., 2003). Interestingly, affinities of bile acids for MRP4 
in the presence of GSH were comparable to those obtained for BSEP, 
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emphasizing the importance of MRP4 as an alternate route of bile acid excretion 
from hepatocytes into blood (Byrne et al., 2002; Rius et al., 2003). Up-regulation 
of MRP4 under cholestatic conditions has been observed in mice and rats, as well 
as in BSEP-deficient patients suffering from progressive familial intrahepatic 
cholestasis 2 (PFIC2) (Schuetz et al., 2001; Denk et al., 2004; Keitel et al., 2005). 
Therefore, up-regulation of MRP4 under cholestatic conditions has been 
recognized as a protective mechanism against hepatotoxicity by preventing 
accumulation of bile acids in hepatocytes through MRP4-mediated basolateral 
efflux of bile acids. Considering the hepatoprotective role of MRP4, GW918-
mediated inhibition of MRP4 transport may predispose the hepatocyte to toxicity 
when canalicular excretion of bile acids also is impaired due to disease states or 
drug interactions.   
In conclusion, the present study demonstrated that GW918 significantly 
inhibited MRP4-mediated transport in the presence of GSH in inside-out 
membrane vesicles. GW918 also impaired MRP3-mediated transport, but the 
extent of inhibition was less than for MRP4. Although GW918 has been used 
extensively as a P-gp and BCRP inhibitor, the potential inhibition of other hepatic 
basolateral transport proteins such as MRP4 and MRP3 may confound data 
interpretation when this inhibitor is employed. 
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Figure A.1. Representative western blot of MRP3 (A) and MRP4 (B) in MRP3- 
and MRP4- overexpressing membrane vesicle preparations.  Membrane vesicles 
were prepared from HEK293 cells transiently transfected with MRP3 or MRP4 
cDNA. Equal amounts of protein (7 µg/lane) were used for immunoblot (n=3).   
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Figure A.2. Functional activity of MRP3- or MRP4-overexpressing membrane 
vesicles. Membrane vesicles were incubated with 5 µM of [3H]E217G for 0.5 min 
at 37˚C. Net ATP-dependent transport was calculated by subtracting uptake 
measured in the presence of AMP from uptake measured in the presence of ATP 
(mean ± SD from a single experiment in triplicate).   
CTL MRP3 MRP4
AT
P 
de
pe
n
de
n
t E
21
7G
 
u
pt
a
ke
 
(pm
o
l/m
g 
pr
o
te
in
/0
.
5 
m
in
)
0
20
40
60
80
 218
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.3. Inhibitory effect of GW918 and MK571 on MRP3- and MRP4-
mediated [3H]E217G and [3H]MTX uptake in the absence of GSH. Membrane 
vesicles overexpressing MRP3 (A) or MRP4 (B) were incubated with 0.5 µM of 
[3H]E217G for 1.5 min at 37˚C in the presence or absence of 18 µM GW918 or 
MK571 (mean ± S.E; n=3 in triplicate). Membrane vesicles overexpressing MRP3 
(C) or MRP4 (D) were incubated with 10 µM of [3H]MTX for 5 min at 37˚C in the 
presence or absence of 18 µM GW918 or MK571 (mean ± SD from a single 
experiment in triplicate). Net ATP-dependent uptake was calculated by subtracting 
values in the presence of 4 mM AMP from those in the presence of 4 mM ATP.  
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Figure A.4. Inhibitory effect of GW918 and MK571 on MRP3- and MRP4-
mediated [3H]E217G and [3H]MTX uptake in the presence of GSH (3 mM). 
Membrane vesicles overexpressing MRP3 (A) or MRP4 (B) were incubated with 
0.5 µM of [3H]E217G for 1.5 min at 37˚C in the presence or absence of 18 µM 
GW918 or MK571 (mean ± SD from a single experiment in triplicate). Membrane 
vesicles overexpressing MRP3 (C) or MRP4 (D) were incubated with 10 µM of 
[3H]MTX for 5 min at 37˚C in the presence or absence of 18 µM GW918 or MK571 
(mean ± SD from a single experiment in triplicate). GSH (3 mM), which is 
solubilized in 10 mM DTT (vehicle control), was added into the reaction mixture.  
Net ATP-dependent uptake was calculated by subtracting values in the presence 
of 4 mM AMP from those in the presence of 4 mM ATP.  
 
CTL  CTL GW918 MK571
M
R
P3
-
m
e
di
a
te
d 
M
TX
 
u
pt
ak
e 
ra
te
(pm
ol
/m
g 
pr
o
te
in
/5
 
m
in
)
0
50
100
150
200
250
300
DTT GSH
CTL  CTL GW918 MK571M
R
P3
-
m
ed
ia
te
d 
E2
17
G
 
u
pt
a
ke
 
ra
te
(pm
o
l/m
g 
pr
ot
e
in
/1
.
5 
m
in
)
0
20
40
60
80
100
DTT GSH
CTL  CTL GW918 MK571M
R
P4
-
m
e
di
at
e
d 
E2
17
G
 
u
pt
a
ke
 
ra
te
(pm
o
l/m
g 
pr
ot
e
in
/1
.
5 
m
in
)
0
5
10
15
20
25
DTT GSH
CTL  CTL GW918 MK571
M
R
P4
-
m
e
di
a
te
d 
M
TX
 
u
pt
ak
e 
ra
te
(pm
o
l/m
g 
pr
ot
ei
n
/5
 
m
in
)
0
50
100
150
200
250
DTT GSH
A B 
C D 
* 
* 
* * 
  
 
APPENDIX 2 
 
Data Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 221
Figure 2.2. APAP concentrations (nM) in outflow perfusate from male wild-type (●) 
and Bcrp-deficient (○), and female wild-type (▼) and Bcrp-deficient (∆) mouse liver 
perfusions. Livers were perfused with Krebs-Henseleit buffer containing 500 nM 
APAP for 40 min followed by an additional 30-min infusion with drug-free buffer (n = 
3-4/group).  
  Wild-type mice Bcrp-deficient mice 
Time  
(min) Male Female Male Female 
0 0 0 0 0 
10 334 ± 48 297 ± 32 324 ± 20 354 ± 53 
20 372 ± 19 332 ± 116 333 ± 29 412 ± 8 
30 343 ± 18 379 ± 63 349 ± 29  406 ± 11 
35 356 ± 23 358 ± 41 336 ± 39 376 ± 39 
40 332 ± 28 357 ± 49 355 ± 14 384 ± 32 
40.3 338 ± 88 345 ± 34 321 ± 49 346 ± 91 
42 229 ± 87 206 ± 20 153 ± 10 188 ± 40 
46 57 ± 41 22 ± 26 22 ± 25 37 ± 33 
50 0 0 0 0 
60 0 0 0 0 
70 0 0 0 0 
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Figure 2.3. Cumulative biliary excretion and basolateral excretion of AG (A and B, 
respectively; nmol/g liver) in male and female wild-type and Bcrp-deficient perfused 
mouse livers through 70 min as described in Figure 2.2 legend (n = 3-4/group; p < 
0.05).  
AG Wild-type mice Bcrp-deficient mice 
(nmol/g liver) Male Female Male Female 
Cumulative Biliary Excretion  1.02 ± 0.40 0.42 ± 0.19 0.32 ± 0.02 0.22 ± 0.08 
Cumulative Basolateral Excretion 19.06 ± 2.09 12.47 ± 1.58 18.42 ± 1.92 12.35 ± 2.19 
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Figure 2.4. Cumulative biliary excretion and basolateral excretion of AS (A and B, 
respectively; nmol/g liver) in male and female wild-type and Bcrp-deficient perfused 
mouse livers through 70 min as described in Figure 2.2 legend (n = 3-4/group; 
N.D.:not detected; p < 0.05).  
AS Wild-type mice Bcrp-deficient mice 
(nmol/g liver) Male Female Male Female 
Cumulative Biliary Excretion  0.14 ± 0.05 0.07 ± 0.03 0 0 
Cumulative Basolateral Excretion 1.02 ± 0.31 3.37 ± 0.73 1.09 ± 0.50 2.91 ± 0.96 
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Figure. 2.6. Representative outflow perfusate rate (pmol/min/g liver) of AG (●) and 
AS (■), and biliary excretion rate (pmol/min/g liver) of AG (○) and AS (□) in male and 
female wild-type (solid symbols) and Bcrp-deficient (open symbols) mouse livers 
(N/A, not available; N/D, not detectable). 
Male Wild-type Mouse Liver 
  
Outflow Perfusate Rate 
(pmol/min/g liver) 
  
Biliary Excretion Rate 
(pmol/min/g liver) 
Observed Predicted Observed Predicted 
Time 
(min) AG AS AG AS 
Time 
(min) AG AS AG AS 
0 0 0 0 0 0 0 0 0 0 
5 296.87 6.40 218.09 26.50 5 0 0 0.40 0.38 
15 599.62 44.05 545.92 40.24 15 2.02 2.71 3.99 2.04 
25 579.43 35.71 644.76 40.67 25 8.44 3.52 9.23 3.13 
37.5 619.80 50.54 676.33 40.68 35 16.21 3.02 14.91 3.73 
44 566.82 19.16 516.10 19.03 45 28.44 5.54 20.26 3.68 
48 315.37 0.00 326.50 5.35 55 25.28 1.95 22.39 2.20 
55 145.49 0.00 137.90 0.43 65 14.40 1.51 22.83 1.21 
65 62.91 0.00 39.74 0.01      
 
Female Wild-type Mouse Liver 
  
Outflow Perfusate Rate 
(pmol/min/g liver) 
  
Biliary Excretion Rate 
(pmol/min/g liver) 
Observed Predicted Observed Predicted 
Time 
(min) AG AS AG AS 
Time 
(min) AG AS AG AS 
0 0 0 0 0 0 0 0 0 0 
5 220.34 68.75 222.76 102.62 5 0 0 0.24 0.31 
15 464.22 111.48 443.40 123.24 15 1.47 1.57 1.99 1.31 
25 460.86 119.32 476.05 123.33 25 3.92 1.84 4.21 1.89 
37.5 501.22 125.00 480.90 123.33 35 6.61 1.69 6.48 2.21 
44 259.86 28.52 307.03 33.37 45 10.13 1.66 8.51 2.07 
48 116.06 0 148.33 4.44 55 11.79 1.27 9.02 1.17 
55 30.36 0 37.94 0.09 65 6.05 0 9.03 0.64 
65 21.78 0 5.30 0      
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Male Bcrp-deficient Mouse Liver 
  
Outflow Perfusate Rate 
(pmol/min/g liver) 
  
Biliary Excretion Rate 
(pmol/min/g liver) 
Observed Predicted Observed Predicted 
Time 
(min) AG AS AG AS 
Time 
(min) AG AS AG AS 
0 0 0 0 0 0 0 N/D 0 N/A 
5 294.34 1.44 279.21 11.45 5 0.00 N/D 0.36 N/A 
15 516.36 19.87 483.85 19.27 15 1.57 N/D 2.55 N/A 
25 486.93 20.31 499.94 19.80 25 3.83 N/D 4.84 N/A 
37.5 451.61 16.67 501.13 19.83 35 7.34 N/D 6.85 N/A 
44 295.18 13.69 278.11 10.65 45 6.84 N/D 8.22 N/A 
48 65.85 0 106.70 3.87 55 8.90 N/D 7.52 N/A 
55 37.09 0 17.32 0.56 65 3.86 N/D 6.53 N/A 
65 0 0 1.24 0.03      
 
 
 
Female Bcrp-deficient Mouse Liver 
  
Outflow Perfusate Rate 
(pmol/min/g liver) 
  
Biliary Excretion Rate 
(pmol/min/g liver) 
Observed Predicted Observed Predicted 
Time 
(min) AG AS AG AS 
Time 
(min) AG AS AG AS 
0 0 0 0 0 0 0 N/D 0 N/A 
5 16.31 41.36 89.67 67.67 5 0 N/D 0.10 N/A 
15 146.33 80.18 275.19 85.18 15 1.13 N/D 1.06 N/A 
25 428.06 126.21 374.86 85.31 25 2.98 N/D 2.62 N/A 
37.5 488.61 91.74 435.64 85.31 35 4.31 N/D 4.40 N/A 
44 374.24 26.83 386.06 27.01 45 7.00 N/D 6.10 N/A 
48 338.91 0.00 303.41 4.42 55 8.67 N/D 6.86 N/A 
55 181.65 0.00 193.53 0.13 65 3.97 N/D 6.90 N/A 
65 49.53 0.00 101.36 0.00      
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Figure 3.2. Accumulation of TGZ, TS, and TG in rat SCH.  Rat SCH were treated for 
10 min with 5 µM TGZ, TS, or TG and accumulation (pmol/mg protein) was 
measured in cells + bile (solid bars) and in cells (open bars). Values represent the 
mean of triplicate determinations from n=1 experiment (TGZ) or mean ± SEM of 
triplicate determinations in n=3 experiments (TS and TG).  
Accumulation (pmol/mg protein) 
  Cells + Bile Cells 
TGZ 1577 1560.2 
TS 2274.8 ± 547.9 1939.3 ± 461.5 
TG 907.8 ± 247.0 605.4 ± 171.2 
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Figure 3.3. Mass vs. time profiles of TGZ (●), TS (○), TG (▼) and TQ (∆) in the 
medium initially containing 10 µM TGZ in day 4 rat SCH (Mean ± S.E.M.; n=3 livers 
in triplicate). Dashed lines represent the best fit of the pharmacokinetic model 
derived from the scheme depicted in Figure 3.1 to the data. 
Accumulation in Medium (pmol/well) 
  Observed Predicted 
Time  
(min) TGZ TS TG TQ TGZ TS TG TQ 
10 14141±1394 72±10 29±2 150±11 13773 80 45 115 
20 12956±513 446±88 178±14 204±35 12646 324 139 166 
30 12165±552 922±85 361±24 190±13 11612 977 278 184 
60 9533±748 2782±302 579±117 151±19 8989 2849 622 170 
90 7035±461 4489±397 881±172 128±19 6958 4488 887 135 
120 5294±431 5670±404 1034±221 98±21 5386 5794 1092 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 228
Figure 3.4. Mass vs. time profiles of TGZ (●), TS (○) and TG (▼) in the hepatocytes 
in day 4 rat SCH; incubation medium initially contained 10 µM TGZ (Mean ± S.E.M.; 
n=3 livers in triplicate). Dashed lines represent the best fit of the pharmacokinetic 
model derived from the scheme depicted in Figure 3.1 to the data. 
Accumulation in Hepatocytes (pmol/well) 
  Observed Predicted 
Time  
(min) TGZ TS TG TGZ TS TG 
10 226 ± 49 819 ± 179 59 ± 5 233 582 53 
20 296 ± 34 1072 ± 264 76 ± 7 217 1013 61 
30 235 ± 14 1187 ± 333 64 ± 15 199 1229 58 
60 206 ± 58 1378 ± 276 46 ± 6 154 1360 47 
90 110 ± 38 1296 ± 280 37 ± 11 119 1285 38 
120 45 ± 17 1182 ± 243 24 ± 3 92 1197 31 
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Figure 3.5. Mass vs. time profiles of TS (○) and TG (▼) in the bile canaliculi of day 4 
rat SCH; incubation medium initially contained 10 µM TGZ (Mean ± S.E.M.; n=3 
livers in triplicate). Dashed lines represent the best fit of the pharmacokinetic model 
derived from the scheme depicted in Figure 3.1 to the data. 
Accumulation in Bile (pmol/well) 
  Observed Predicted 
Time  
(min) TS TG TS TG 
10 138 ± 70 28 ± 2 60 17 
20 234 ± 22 50 ± 2 247 53 
30 202 ± 40 49 ± 10 172 44 
60 174 ± 68 36 ± 4 182 33 
90 191 ± 51 26 ± 13 174 26 
120 112 ± 18 20 ± 5 162 22 
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Figure 4.1. Effect of DEX on trabectedin-mediated cytotoxicity in SCRH isolated 
from wild-type (WT) Wistar rats.  Cytotoxicity was determined by measuring LDH 
release into the culture medium after 24 hr trabectedin (1 - 1000 nM) exposure.  
Each bar represents the mean ± S.E.M. (n=3) for samples from vehicle- (0.1 µM 
DEX; solid bars) or additional DEX (1 µM ; white bars); *, p < 0.05.   
Trabectedin Concentration 
(nM) 
Vehicle-treated WT SCRH  
(0.1 µM DEX) 
DEX-treated WT SCRH 
(1 µM DEX) 
1 0.1 ± 0.1 0.1± 0.1 
10 1.3 ± 0.8 0.1 ± 0.3 
50 18.9 ± 4.6 5.1 ± 1.1 
100 21.5 ± 4.1 6.9 ± 0.8 
1000 25.7 ± 3.2 11.6 ± 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 231
Figure 4.2. Trabectedin-mediated cytotoxicity in SCRH from WT and TR- rats.  
Cytotoxicity was determined by measuring LDH release into the culture medium 
after 24 hr trabectedin (1 - 100 nM) exposure.  Each bar represents the mean ± 
S.E.M. (n=3) for samples from wild-type (solid bars) or TR- (white bars) SCRH; *, p < 
0.05. 
Trabectedin Concentration 
(nM) 
WT SCRH  
(0.1 µM DEX) 
TR- SCRH 
(0.1 µM DEX) 
1 0.4 ± 0.2 0.2 ± 0.2 
10 0.9 ± 0.4 0.6 ± 0.6 
50 23.0 ± 1.7 7.5 ± 3.5 
100 28.3 ± 0.7 10.2 ± 0.2 
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Figure 4.3. Effect of BSO on trabectedin-mediated cytotoxicity.  Cytotoxicity was 
determined by measuring LDH release into the culture medium after 24 hr 
trabectedin (50, 100, and 1000 nM) exposure.  BSO (500 µM) was added to the 
culture medium 24 h prior to trabectedin exposure.  Each bar represents the mean ± 
S.E.M. (n=3) for samples from vehicle- (solid bars) or BSO-pretreated (white bars) 
SCRH; *, p < 0.05. 
Trabectedin Concentration 
(nM) Vehicle-treated WT SCRH  
BSO-treated WT SCRH 
(500 µM BSO) 
50 18.9 ± 4.6 3.8 ± 1.9 
100 21.5 ± 4.1 7.8 ± 2.1 
1000 25.7 ± 3.2 13.4 ± 2.0 
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Figure 4.5. Trabectedin perfusate concentrations (Figure 4.5.a) and cumulative 
biliary excretion (Figure 4.5.b) in isolated perfused livers from WT (solid circle) and 
TR- (white triangle) rats.  Data are presented as mean ± S.D., n= 3/group. 
Perfusate Concentrations (nM) 
Time  
(min) WT Rat Livers TR
- Rat Livers 
5 35.1 ±  1.2 38.2 ± 11.5 
10 7.3 ± 6.4 13.9 ± 3.2 
20 0.5 ± 0.8 2.2 ± 2.0 
30 0 0.2 ± 0.3 
40 0 0 
50 0 0 
60 0 0 
70 0 0 
80 0 0 
90 0 0 
 
Cumulative Biliary Excretion (% of dose) 
Time  
(min) WT Rat Livers TR
-
 Rat Livers 
5 0.08 ±  0.09 0 
10 0.84 ± 0.54 0.08 ± 0.10 
20 1.79 ± 0.84 0.37 ± 0.29 
30 2.13 ± 0.96 0.49 ± 0.37 
40 2.26 ± 1.00 0.53 ± 0.39 
50 2.31 ± 1.01 0.54 ± 0.41 
60 2.34 ± 1.02 0.56 ± 0.41 
70 2.36 ±  1.01 0.56 ± 0.42 
80 2.38 ±  1.00 0.56 ± 0.42 
90 2.39 ±  0.99 0.57 ± 0.42 
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Figure 5.2. Effect of Sulindac and Metabolites on Hepatobiliary Disposition of TC in 
Rat SCH. Accumulation of [3H]TC (1 µM, 100 nCi/mL, 10 min) in cells+bile (solid 
bars) and cells (white bars) was measured in the presence of increasing 
concentrations (1-100 µM) of sulindac (A), S-sulfone (B) or S-sulfide (C) in rat SCH. 
BEI and in vitro Clbiliary of TC were calculated as described in Materials and Methods. 
Data are presented as the mean ± S.E.M (n=3-4 livers in triplicate); *, statistically 
different from vehicle control (CTL) by one-way ANOVA with Bonferroni’s post-hoc 
test. 
TC accumulation (pmol/mg protein) in rat SCH 
    Cells+bile Cells 
  
Concentration 
(µM) Mean SEM Mean SEM 
Sulindac 
0 50.6 4.0 10.6 1.7 
1 41.6 3.5 9.0 2.3 
10 31.0 6.5 12.6 4.8 
100 35.5 4.1 11.0 3.2 
S-Sulfone 
0 67.2 13.6 11.2 1.4 
1 46.2 16.9 7.6 1.4 
10 33.5 7.1 8.2 2.2 
100 22.9 8.8 9.6 2.7 
S-Sulfide 
0 75.2 9.1 11.1 1.5 
1 50.4 8.3 10.8 2.1 
10 48.2 13.1 9.4 2.3 
100 17.6 7.7 8.1 1.8 
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Figure 5.3. Effect of sulindac and metabolites on hepatobiliary disposition of E217G 
in rat SCH. Accumulation of [3H]E217G (1 µM, 100 nCi/mL, 10 min) in cells+bile 
(solid bars) and cells (white bars) was measured in the presence of increasing 
concentrations (1-100 µM) of sulindac (A), S-sulfone (B) or S-sulfide (C) in rat SCH. 
BEI and in vitro Clbiliary of E217G were calculated as described in Materials and 
Methods. Data are presented as the mean ± S.E.M (n=3-4 livers in triplicate); *, 
statistically different from vehicle control (CTL) by one-way ANOVA with Bonferroni’s 
post-hoc test.  
E217G accumulation (pmol/mg protein) in rat SCH 
    Cells+bile Cells 
  
Concentration 
(µM) Mean SEM Mean SEM 
Sulindac 
0 143.2 24.0 116.4 14.9 
1 146.9 15.4 123.2 3.9 
10 110.2 9.9 101.4 12.4 
100 42.2 0.5 37.1 2.2 
S-Sulfone 
0 141.1 10.0 116.0 6.1 
1 120.0 6.7 107.9 7.8 
10 80.9 3.5 78.8 5.5 
100 30.9 3.2 26.7 2.9 
S-Sulfide 
0 141.1 10.0 116.0 6.1 
1 113.2 8.2 104.2 5.8 
10 71.9 8.6 59.3 4.9 
100 8.7 1.9 7.7 1.8 
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Figure 5.4. Effect of Sulindac and Metabolites on Hepatobiliary Disposition of NF in 
Rat SCH. Accumulation of NF (5 µM, 10 min) in cells+bile (solid bars) and cells 
(white bars) was measured in the presence of 100 µM sulindac, S-sulfone or S-
sulfide in rat SCH. BEI and in vitro Clbiliary of NF were calculated as described in the 
Materials and Methods. Data are presented as the mean ± S.E.M (n=3 livers in 
triplicate); *, statistically different from vehicle control (CTL) by one-way ANOVA with 
Bonferroni’s post-hoc test. 
NF accumulation (pmol/mg protein) in rat SCH 
    Cells+bile Cells 
  
Concentration 
(µM) Mean SEM Mean SEM 
CTL  58.4 4.9 20.9 1.1 
Sulindac 100 61.4 0.3 34.0 0.0 
S-Sulfone 100 59.7 1.4 36.5 0.6 
S-Sulfide 100 68.9 8.6 50.7 7.1 
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Figure 5.5. Inhibition of Na+-dependent TC initial uptake in suspended rat 
hepatocytes by S-sulfone (A) and S-sulfide (B). Na+-dependent [3H]TC initial uptake 
(1 µM, 60 nCi/ml, 30 sec) was determined by subtracting [3H]TC uptake in Na+-free 
buffer from [3H]TC uptake in Na+-containing buffer in the presence of increasing 
concentrations of S-sulfone (0.5-100 µM) and S-sulfide (0.5-100 µM). Symbols and 
error bars represent the means ± S.E.M. of n=3 livers in duplicate. The dotted curve 
represents the best fit of the sigmoidal inhibitory Emax model to the data using 
WinNonlin; the curve shape factor (r) was estimated as 0.4±0.1 and 0.8±0.2 for S-
sulfone and S-sulfide, respectively. 
  
S-Sulfone S-Sulfide 
  Observed Predicted Observed Predicted 
Concentration 
(µM) Mean SEM   Mean SEM 
  
0.5 72.4 21.2 82.8 89.5 22.1 93.0 
1 71.4 10.6 78.5 84.6 19.5 88.4 
5 68.7 17.1 65.8 69.9 22.2 67.8 
10 53.0 8.8 59.3 54.2 6.7 54.8 
30 51.3 19.3 48.4 43.0 15.4 33.5 
50 39.1 0.7 43.3 21.1 7.4 25.0 
75 47.6 0.0 39.4 13.3 0.0 19.5 
100 36.3 7.1 36.7 12.0 6.5 16.1 
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Figure 5.6. Inhibition of Na+-independent E217G unitial uptake in suspended rat 
hepatocytes by S-sulfone (A) and S-sulfide (B). Na+-independent [3H]E217G initial 
uptake (1 µM, 60 nCi/ml, 90 sec) was determined in Na+-free buffer in the presence 
of increasing concentrations of S-sulfone (0.5-100 µM) and S-sulfide (0.5-100 µM). 
Symbols and error bars represent the means ± S.E.M. of n=3 livers in duplicate. The 
dotted curve represents the best fit of the sigmoidal inhibitory Emax model to the data 
using WinNonlin; the curve shape factor (r) was estimated as 0.8±0.2 and 1±0.2 for 
S-sulfone and S-sulfide, respectively. 
  
S-Sulfone S-Sulfide 
  Observed Predicted Observed Predicted 
Concentration 
(µM) Mean SEM   Mean SEM 
  
0.5 103.3 0.0 93.0 93.1 0.0 93.0 
1 86.7 14.9 88.4 84.5 5.6 86.9 
5 66.4 20.3 67.8 56.7 13.3 56.5 
10 50.3 14.7 54.7 56.8 6.7 39.3 
30 34.0 6.2 33.4 16.0 5.5 17.6 
50 23.2 5.6 25.0 12.4 2.6 11.3 
75 16.3 0.0 19.4 5.5 0.0 7.8 
100 20.2 7.4 16.1 8.1 2.2 5.9 
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Figure 5.7. Effect of sulindac and metabolites on hepatobiliary disposition of TC in 
human SCH. Accumulation of [3H]TC (1 µM, 100 nCi/mL, 10 min) in cells+bile (solid 
bars) and cells (white bars) was measured in the presence of 10 and 100 µM 
sulindac, S-sulfone or S-sulfide in human SCH. BEI and in vitro Clbiliary of TC were 
calculated as described in Materials and Methods. Bars and error bars denote 
means ± one-half of the range from n=2 livers in duplicate.  
TC accumulation (pmol/mg protein) in human SCH 
    Cells+bile Cells 
  
Concentration 
(µM) Mean Range/2 Mean  Range/2 
CTL   255.1 61.2 108.0 49.5 
  
Sulindac 10 209.5 22.3 90.9 20.2 100 226.8 33.4 127.8 17.3 
S-Sulfone 10 190.6 21.0 88.7 20.9 100 215.9 24.7 103.7 8.3 
S-Sulfide 10 119.9 13.8 48.4 13.4 100 33.5 19.7 15.4 7.1 
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Figure 5.8. Inhibition of Na+-dependent TC initial uptake in suspended human 
hepatocytes by S-sulfone (A) and S-sulfide (B). Na+-dependent [3H]TC initial uptake 
(1 µM, 60 nCi/ml, 30 sec) was determined by subtracting [3H]TC uptake in Na+-free 
buffer from those values in Na+-containing buffer in the presence of increasing 
concentrations of S-sulfone (1-300 µM) and S-sulfide (0.1-100 µM). Open and 
closed circles denote individual data from n=2 livers in duplicate. The dotted curve 
represents the best fit of the sigmoidal inhibitory Emax model to the data using 
WinNonlin; the curve shape factor (r) was estimated as 0.6 and 0.9 for S-sulfone and 
S-sulfide, respectively. 
  S-Sulfone S-Sulfide 
Concentration 
(µM) 
Observed 
(n=1) 
Observed  
(n=2) Predicted 
Observed 
(n=1) 
Observed  
(n=2) Predicted 
0.1        95.1 96.1 
0.5   90.8        
1 95.8 87.7 90.7 55.6 87.6 74.2 
5 91.2 72.9 76.6 37.2 59.1 38.8 
10 69.9 74.8 71.9 16.6 37.6 24.9 
30 55.3   55.2 0.0 11.1 10.6 
50 55.3 47.8 47.1 0.0 6.2 6.8 
100 32.8 36.1 37.3 0.0 0.0 3.7 
300   19.7 23.2       
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Figure A.2. Functional activity of MRP3- or MRP4-overexpressing membrane 
vesicles. Membrane vesicles were incubated with 5 µM of [3H]E217G for 0.5 min 
at 37˚C. Net ATP-dependent transport was calculated by subtracting uptake 
measured in the presence of AMP from uptake measured in the presence of ATP 
(mean ± SD from a single experiment in triplicate).   
  E217G transport (pmol/mg protein/0.5 min) 
  Mean SD 
CTL 7.4 4.5 
 MRP3  56.7 15.3 
MRP4 29.8 6.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 242
Figure A.3. Inhibitory Effect of GW918 and MK571 on MRP3- and MRP4-
mediated [3H]E217G and [3H]MTX uptake in the absence of GSH. Membrane 
vesicles overexpressing MRP3 (A) or MRP4 (B) were incubated with 0.5 µM of 
[3H]E217G for 1.5 min at 37˚C in the presence or absence of 18 µM GW918 or 
MK571 (mean ± S.E; n=3 in triplicate). Membrane vesicles overexpressing MRP3 
(C) or MRP4 (D) were incubated with 10 µM of [3H]MTX for 5 min at 37˚C in the 
presence or absence of 18 µM GW918 or MK571 (mean ± SD from a single 
experiment in triplicate). Net ATP-dependent uptake was calculated by subtracting 
values in the presence of 4 mM AMP from those in the presence of 4 mM ATP.  
E217G transport (pmol/mg protein/1.5 min) 
  MRP3 MRP4 
  Mean SEM Mean SEM 
CTL 64.7 7.1 22.4 6.4 
GW918 81.4 9.3 15.9 4.8 
MK571 34.5 2.0 0.5 0.5 
MTX transport (pmol/mg protein/5 min) 
  MRP3 MRP4 
  Mean SD Mean SD 
CTL 128.1 36.6 78.6 15.6 
GW918 128.7 35.1 67.9 7.5 
MK571 32.2 25.1 14.0 15.4 
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Figure A.4. Inhibitory Effect of GW918 and MK571 on MRP3- and MRP4-
mediated [3H]E217G and [3H]MTX uptake in the presence of GSH (3 mM). 
Membrane vesicles overexpressing MRP3 (A) or MRP4 (B) were incubated with 
0.5 µM of [3H]E217G for 1.5 min at 37˚C in the presence or absence of 18 µM 
GW918 or MK571 (mean ± SD from a single experiment in triplicate). Membrane 
vesicles overexpressing MRP3 (C) or MRP4 (D) were incubated with 10 µM of 
[3H]MTX for 5 min at 37˚C in the presence or absence of 18 µM GW918 or MK571 
(mean ± SD from a single experiment in triplicate). GSH (3 mM), which is 
solubilized in 10 mM DTT (vehicle control), was added into the reaction mixture.  
Net ATP-dependent uptake was calculated by subtracting values in the presence 
of 4 mM AMP from those in the presence of 4 mM ATP.  
E217G transport (pmol/mg protein/1.5 min) 
  MRP3 MRP4 
  Mean SD Mean SD 
CTL (DTT) 71.4 6.9 20.8 2.2 
 CTL 69.4 9.5 20.7 2.8 
GW918 74.4 1.6 14.7 3.2 
MK571 32.9 3.3 0.0 0.4 
MTX transport (pmol/mg protein/5 min) 
  MRP3 MRP4 
  Mean SD Mean SD 
CTL (DTT) 234.3 7.6 221.2 10.4 
 CTL 237.4 15.7 184.4 4.2 
GW918 199.3 7.2 79.1 8.9 
MK571 18.4 2.2 26.5 2.0 
 
 
 
 
 
